hydrogen
sulfid
produc
endogen
varieti
enzym
involv
cystein
metabol
clinic
data
indic
endogen
level
hydrogen
sulfid
diminish
variou
form
cardiovascular
diseas
aim
current
studi
investig
effect
hydrogen
sulfid
supplement
cardiac
function
reperfus
clinic
relev
experiment
model
cardiopulmonari
bypass
twelv
anesthet
dog
underw
hypotherm
cardiopulmonari
bypass
minut
hypotherm
cardiac
arrest
reperfus
start
applic
either
salin
vehicl
control
n
sodium
sulfid
infus
mgkghour
n
biventricular
hemodynam
variabl
measur
combin
pressurevolumeconduct
cathet
coronari
pulmonari
blood
flow
vasodil
respons
acetylcholin
sodiumnitroprussid
pulmonari
function
also
determin
administr
sodium
sulfid
led
significantli
better
recoveri
left
right
ventricular
systol
function
p
minut
reperfus
coronari
blood
flow
also
significantli
higher
sodium
sulfidetr
group
p
sodium
sulfid
treatment
improv
coronari
blood
flow
preserv
acetylcholineinduc
increas
coronari
pulmonari
blood
p
myocardi
atp
level
markedli
improv
sulfidetr
group
thu
supplement
sulfid
improv
recoveri
myocardi
endotheli
function
energet
statu
hypotherm
cardiac
arrest
cardiopulmonari
bypass
benefici
effect
occur
without
detect
advers
hemodynam
cardiovascular
effect
sulfid
dose
use
current
studi
aim
current
studi
test
potenti
cytoprotect
antiinflammatori
effect
novel
biolog
mediat
hydrogen
sulfid
murin
model
murin
macrophag
grown
cultur
expos
cytotox
concentr
nitrosoglutathion
peroxynitrit
reactiv
speci
form
reaction
nitric
oxid
superoxid
pretreat
cell
sodium
sulfid
reduc
loss
cell
viabil
elicit
nitric
oxid
donor
compound
mm
peroxynitrit
mm
measur
mtt
method
sodium
sulfid
affect
cell
viabil
concentr
rang
test
mice
subject
bacteri
lipopolysaccharid
lp
mgkg
ip
treatment
anim
sodium
sulfid
mgkghour
hour
administ
alzet
minipump
reduc
lpsinduc
increas
plasma
level
respons
attenu
anim
pretreat
heme
oxygenas
inhibitor
tinprotoporphyrin
ix
mgkg
current
result
point
cytoprotect
antiinflammatori
effect
hydrogen
sulfid
cell
expos
nitros
stress
anim
subject
endotoxemia
epitheli
cell
apoptosi
similar
hypoxicinduc
factor
express
weaker
acut
acalcul
cholecyst
calcul
cholecyst
introduct
extracellular
releas
atp
import
modul
immun
respons
atp
plasma
concentr
increas
sepsi
play
critic
role
host
defens
promot
phenotyp
bacteri
clearanc
low
level
associ
phenotyp
consist
critic
ill
anergi
report
mm
atp
increas
lpsphastimul
secret
human
blood
higher
ratio
shift
immun
phenotyp
respons
studi
effect
atp
lpsstimul
secret
standard
exvivo
whole
human
blood
cultur
method
venou
blood
healthi
volunt
drawn
tube
contain
ng
lpsml
edi
gmbh
reutlingen
germani
incub
without
mm
atp
respect
hour
supern
separ
frozen
cytokin
level
analys
robot
workstat
epmot
eppendorf
ag
hamburg
germani
duplic
use
elisa
cytokin
kit
luminex
biosourc
int
camarillo
ca
usa
result
ad
atp
reduc
mean
concentr
lpsstimul
blood
pgml
pgml
p
consist
effect
atp
secret
studi
pgml
pgml
interestingli
three
subject
indianindonesian
origin
level
assay
detect
limit
mean
ratio
increas
remain
caucasian
subject
p
see
figur
conclus
result
suggest
immunosuppress
effect
extracellular
atp
evid
decreas
therefor
rel
shift
immun
respons
toward
phenotyp
although
may
repres
selfprotect
mechan
may
contribut
critic
ill
anergi
introduct
sepsisassoci
arteri
hypotens
may
complic
inadequ
system
region
oxygen
deliveri
result
lactic
acidosi
multipl
organ
failur
hypothes
exogen
administr
adrenomedullin
vasodilatori
peptid
hormon
antiinflammatori
properti
may
improv
oxygen
deliverydemand
relationship
therebi
limit
increas
arteri
lactat
concentr
ovin
endotoxemia
method
fourteen
adult
ewe
instrument
chronic
hemodynam
monitor
follow
hour
endotoxemia
salmonella
typhosa
endotoxin
ngkgmin
anim
receiv
either
continu
infus
increment
dose
ngkgmin
min
vehicl
normal
salin
n
result
endotoxin
infus
contribut
hypotensivehyperdynam
circul
character
decreas
mean
arteri
pressur
map
system
vascular
resist
index
well
increas
heart
rate
hr
cardiac
index
ci
arteri
lactat
concentr
infus
ngkgmin
increas
ci
vs
lmin
oxygen
deliveri
index
vs
mlminm
therebi
decreas
arteri
lactat
concentr
vs
mgdl
mean
pulmonari
arteri
pressur
vs
mmhg
p
vs
control
notic
control
group
howev
infus
ngkgmin
link
decreas
map
vs
mmhg
p
vs
control
conclus
despit
decreas
map
infus
revers
pulmonari
hypertens
improv
oxygen
supplydemand
relationship
dosedepend
manner
indic
reduc
arteri
lactat
concentr
howev
due
vasodilatori
properti
may
rational
combin
vasopressor
agent
correl
pulmonari
capillari
permeabl
diseas
sever
critic
ill
patient
introduct
previous
shown
protect
adult
vasculatur
plasma
leakag
wherea
vegf
destabil
vascular
endothelium
result
vascular
leakag
consequ
might
involv
pathophysiolog
acut
lung
injuri
ali
acut
respiratori
distress
syndrom
ard
sepsi
patient
hypothes
plasma
level
associ
pulmonari
capillari
protein
permeabl
lung
injuri
score
li
length
stay
icu
apach
ii
score
surviv
septic
patient
ali
ard
method
prospect
observ
studi
perform
icu
univers
hospit
patient
elect
cardiac
surgeri
major
vascular
surgeri
sepsi
trauma
plasma
level
vegf
measur
mobil
probe
system
use
measur
pulmonari
leak
index
pli
transvascular
transport
rate
transferrin
result
plasma
level
pli
significantli
higher
patient
sepsi
compar
patient
group
sepsi
group
posit
linear
correl
observ
plasma
level
length
stay
icu
r
p
index
diseas
sever
patient
togeth
posit
linear
correl
pli
r
p
li
r
p
apach
ii
score
r
p
furthermor
significantli
increas
nonsurvivor
plasma
level
differ
group
vegf
level
undetect
plasma
major
patient
conclus
result
suggest
mediat
pulmonari
capillari
permeabl
marker
diseas
sever
critic
ill
patient
furthermor
plasma
level
ratio
import
pulmonari
capillari
permeabl
diseas
sever
absolut
level
vegf
introduct
cardiac
dysfunct
featur
sepsi
order
gain
insight
fundament
mechan
phenotyp
gene
express
analysi
affymetrix
appli
serial
cardiac
biopsi
sham
n
e
coli
infect
pig
n
method
cardiac
sampl
taken
basal
hourli
infect
gene
analysi
end
experi
histopatholog
examin
gene
determin
differenti
regul
greater
less
twofold
chang
p
result
sham
pig
stabl
heart
rate
cardiac
output
co
core
temperatur
period
infect
pig
demonstr
earli
elev
co
ventricular
shorten
andor
eject
assess
echocardiographi
follow
develop
hypodynam
infect
anim
increas
number
gene
upregul
downregul
hour
figur
wherea
sham
infect
alter
fewer
gene
hour
compar
sham
vs
infect
anim
time
number
significantli
alter
gene
increas
time
basal
hour
post
infect
hematoxylineosinstain
section
histopatholog
assess
reveal
acut
inflamm
pericardium
myocardium
infect
pig
conclus
result
provid
biomark
mechanist
insight
pathogenesi
cardiac
dysfunct
septic
periton
may
also
help
identifi
alter
novel
gene
transcript
pathway
serv
new
target
diagnost
tool
therapeut
strategi
candid
gene
valid
quantit
pcr
associ
proxim
tubul
injuri
sever
vitro
anim
studi
alkalin
phosphatas
ap
found
effect
attenu
inflammatori
respons
dephosphoryl
lp
may
prevent
organ
damag
object
studi
investig
effect
ap
renal
ino
express
kidney
damag
patient
sever
sepsi
septic
shock
fifteen
patient
nine
malesix
femal
age
year
gramneg
bacteri
infect
two
four
sir
criteria
hour
acut
onset
endorgan
dysfunct
hour
includ
random
doubleblind
placebocontrol
phase
iia
studi
ratio
intraven
bolu
inject
ukg
bovin
intestin
ap
follow
mainten
dose
ukg
hour
arteri
blood
urin
collect
differ
time
point
analyz
stabl
metabolit
ino
mrna
determin
quantit
realtim
rtpcr
use
rna
isol
renal
cell
urin
urinari
excret
cytosol
glutathion
marker
proxim
tubul
damag
measur
use
elisa
data
depict
median
rang
metabolit
blood
significantli
differ
aptreat
n
placebotr
n
patient
howev
urinari
excret
metabolit
decreas
baselin
mmol
creatinin
p
hour
ap
administr
placebo
treatment
amount
urinari
metabolit
increas
mmol
creatinin
p
baselin
express
level
ino
renal
cell
induc
baselin
vs
healthi
subject
ap
administr
reduc
induct
figur
creatinin
clearanc
improv
patient
treat
ap
declin
placebotr
patient
first
hour
amount
urin
aptreat
patient
decreas
compar
increas
placebotr
patient
correl
urinari
metabolit
indic
noinduc
proxim
tubular
damag
conclus
septic
patient
infus
ap
result
attenu
upregul
ino
subsequ
reduc
product
kidney
associ
improv
renal
function
introduct
hypothermia
shown
attenu
ventilatorinduc
lung
injuri
vili
high
endinspiratori
lung
volum
model
vili
experiment
evid
suggest
moder
tidal
volum
may
certain
clinic
condit
induc
alveolar
instabl
lead
lung
injuri
recent
studi
also
suggest
insult
like
shock
surgeri
sensit
lung
injuri
prime
exagger
respons
second
stimulu
aim
studi
investig
whether
moder
hypothermia
attenu
low
lung
volum
injuri
low
peep
high
fio
moder
tidal
volum
ventil
anim
sensit
injuri
previou
anesthesia
surgeri
method
sixteen
male
adult
spraguedawley
rat
instrument
ether
anesthesia
vascular
cathet
previou
day
anesthet
tracheostom
connect
ventil
randomli
alloc
group
normothermia
group
n
n
hypothermia
group
h
n
hour
mechan
ventil
fio
respiratori
rate
tidal
volum
mlkg
peep
cmh
inspiratori
pressur
record
rat
sacrif
pv
curv
respiratori
system
construct
bronchoalveolar
lavag
aortic
blood
sampl
obtain
result
group
h
anim
exhibit
comparison
group
n
anim
lower
increas
peak
inspiratori
pressur
vs
mmhg
p
signific
shift
pv
curv
left
lower
total
protein
vs
p
tnf
vs
pgml
p
level
bal
sampl
conclus
moder
hypothermia
attenu
lung
injuri
low
peep
high
fio
moder
tidal
volum
ventil
anim
sensit
injuri
previou
anesthesia
surgeri
appar
thick
evalu
use
intravit
microscopi
compar
kda
dextran
distribut
marker
glx
permeabl
imperm
tracer
respect
intravit
microscopi
use
character
mesenteri
function
capillari
densiti
glycocalyx
extrem
sensit
free
radic
oxid
stress
evalu
oxid
dihydrorhodamin
dhr
microvascular
bed
concentr
heart
malondialdehyd
mda
plasma
carbonyl
protein
cp
result
lp
elicit
hour
later
profound
reduct
glx
layer
thick
increas
plasma
hyaluronan
level
lp
rat
decreas
capillari
continu
flow
signific
increas
intermitt
stop
flow
capillari
compar
control
pressor
respons
norepinephrin
greatli
reduc
indic
vascular
hyporeact
vivo
oxid
dhr
level
heart
mda
plasma
cp
increas
lpstreat
rat
interestingli
lp
rat
apc
reduc
plasma
hyaluronan
level
glx
destruct
accompani
major
improv
vasopressor
respons
function
capillari
densiti
apc
treatment
also
prevent
increas
biochem
vivo
microvascular
oxid
stress
marker
conclus
model
septic
shock
increas
plasma
hyluronan
level
reduct
endotheli
layer
thick
indic
glx
degrad
apc
prevent
vascular
oxid
stress
limit
glx
loss
glx
degrad
play
critic
role
septic
vasculatur
gener
free
radic
septic
shock
potenti
toxic
glx
function
introduct
mechan
ventil
may
induc
lung
injuri
patient
normal
lung
applic
peep
appear
protect
lung
injuri
associ
product
releas
inflammatori
mediat
mediat
identifi
patient
exhal
breath
condens
ebc
variou
lung
patholog
studi
identifi
ebc
inflammatori
marker
mechan
ventil
braininjur
subject
neither
acut
lung
injuri
ali
sepsi
method
patient
ventil
mlkg
tidal
volum
put
either
peep
zeep
n
cmh
peep
n
ebc
collect
use
rtube
devic
respiratori
research
inc
charlottesvil
va
us
first
third
fifth
day
mechan
ventil
ph
measur
appli
mix
effect
model
investig
potenti
relationship
ebc
marker
indic
lung
injuri
li
score
pao
fio
detect
patholog
lung
ct
ii
brain
injuri
icp
cpp
gc
serum
protein
pentoth
mannitol
administr
iii
endotheli
injuri
von
willebrand
factor
antigen
iv
system
inflamm
temperatur
leukocyt
count
neutrophil
count
blood
albumin
solubl
trigger
receptor
express
myeloid
cell
strem
crp
procalcitonin
pct
abovement
cytokin
serum
plasma
v
diseas
sever
apach
ii
score
hour
icu
trauma
score
presenc
sir
mean
arteri
pressur
result
signific
differ
ebc
measur
observ
two
group
except
timedepend
decreas
p
anova
peep
group
ebc
ph
show
signific
relationship
mix
effect
model
paramet
measur
ebc
cytokin
invers
relat
strem
level
addit
signific
relationship
obtain
individu
ebc
cytokin
pct
exist
sir
pentoth
administr
conclus
popul
mechan
ventil
braininjur
patient
ali
zeep
appli
peep
induc
detect
chang
lung
inflammatori
mediat
ebc
latter
appear
mostli
relat
marker
system
inflamm
especi
rather
indic
brain
endotheli
injuri
introduct
aim
studi
access
local
inflammatori
reactiv
measur
cytokin
respons
onset
mechan
aliard
subsequ
tissu
injuri
consid
associ
neutrophil
elastas
main
caus
aliard
consid
sepsi
aspir
pneumonia
japan
sivelestat
sodium
hydrat
elaspol
select
elastas
inhibitor
approv
aliard
accompani
sir
medicin
evalu
clinic
situat
studi
perform
retrospect
comparison
sivelestat
sodium
administr
two
group
patient
group
elaspol
consist
patient
male
femal
age
year
aliard
accompani
sir
treat
sivelestat
sodium
dose
mgkghour
hour
approv
drug
group
control
consist
patient
male
femal
age
year
aliard
accompani
sir
treat
icu
similar
condit
use
tradit
method
respiratori
control
prior
approv
sivelestat
sodium
apach
ii
score
group
elaspol
group
control
sofa
score
lung
injuri
score
respect
signific
differ
group
initi
peep
valu
group
elaspol
significantli
higher
group
control
cmh
pao
fio
ratio
mechan
ventil
manag
hour
begin
drug
administr
mmhg
group
elaspol
mmhg
group
control
ventilatorfre
day
group
elaspol
group
control
day
respect
valu
show
signific
differ
p
furthermor
surviv
rate
day
significantli
higher
group
elaspol
group
control
group
elaspol
group
control
p
result
suggest
sivelestat
sodium
hydrat
good
option
treatment
strategi
neutrophil
elastaseassoci
septic
aliard
accompani
sir
introduct
mani
patient
experi
surgic
stress
includ
burn
injuri
becom
suscept
sever
sepsi
septic
organ
dysfunct
includ
acut
lung
injuri
ali
remain
primari
contributor
morbid
mortal
burn
patient
proinflammatori
cytokin
includ
sever
chemokin
implic
process
pharmacolog
modul
steroid
inhibit
process
cytokin
synthesi
may
serv
effect
therapi
prevent
tissu
injuri
result
organ
dysfunct
includ
respiratori
failur
develop
murin
model
septic
ali
burn
insult
examin
effect
prolong
administr
moder
dose
steroid
method
male
balbc
mice
divid
three
group
group
serv
sham
burn
group
ii
iii
bsa
fullthick
burn
made
dorsum
ether
anesthesia
follow
adequ
fluid
resuscit
burn
injuri
mgkg
prednisolon
psl
group
iii
administ
subcutan
daili
day
day
mgkg
lipopolysaccharid
lp
inject
intraven
first
experi
observ
surviv
within
hour
lp
inject
group
n
second
experi
sacrif
anim
hour
lp
inject
obtain
plasma
lung
tissu
determin
level
macrophag
inflammatori
function
homologu
human
mice
sampl
n
sandwich
elisa
also
determin
gene
express
n
mrna
ratio
rtpcr
myeloperoxidas
activ
mpo
n
histopatholog
find
lung
tissu
surviv
product
cytokin
shown
tabl
histopatholog
find
group
iii
obvious
attenu
introduct
lethal
sepsi
occur
excess
inflammatori
respons
evolv
control
physiolog
antiinflammatori
mechan
vagu
nerv
stimul
show
improv
surviv
sepsi
howev
seem
feasibl
septic
patient
therefor
investig
effect
activ
cholinerg
antiinflammatori
pathway
pharmacolog
cholinesteras
inhibit
surviv
inflamm
septic
mous
model
method
investig
therapeut
effect
nicotin
physostigmin
perform
cecal
ligat
punctur
clp
femal
mice
group
n
substanc
administ
intraperiton
inject
control
group
receiv
volum
lpsfree
nacl
solvent
clp
perform
blind
ident
treatment
group
addit
surviv
experi
perform
measur
cytokin
plasma
electrophoret
mobil
shift
assay
emsa
periton
skin
liver
kidney
result
anim
treat
nicotin
physostigmin
surviv
significantli
better
control
mice
p
differ
treatment
group
dose
escal
physostigmin
superior
normal
dose
surviv
highdos
group
howev
still
significantli
better
control
group
proinflammatori
cytokin
level
significantli
reduc
anim
treat
physostigmin
p
cholinesteras
inhibit
physostigmin
clp
reduc
activ
peritoneum
kidney
liver
compar
control
shamoper
group
p
conclus
show
pharmacolog
cholinesteras
inhibit
physostigmin
improv
surviv
experiment
sepsi
probabl
activ
cholinerg
antiinflammatori
pathway
one
possibl
mechan
modul
pathway
therefor
cholinesteras
inhibit
may
import
implic
treatment
sepsi
introduct
highmobilitygroup
box
protein
highli
conserv
ubiquit
protein
present
nuclei
cytoplasm
nearli
cell
type
secret
extracellular
milieu
act
proinflammatori
cytokin
function
wide
studi
sepsi
inflamm
report
late
mediat
endotox
shock
known
abund
protein
present
nuclei
cytoplasm
involv
maintain
nucleosom
structur
regul
gene
transcript
moreov
elev
circul
level
also
describ
case
human
hemorrhag
shock
due
abdomin
aortic
aneurysm
without
evid
infect
howev
relationship
trauma
studi
except
report
rat
model
burn
studi
case
consist
trauma
patient
admit
emerg
room
ambul
soon
arriv
emerg
room
blood
sampl
collect
centrifug
store
serum
concentr
measur
elisa
compar
injuri
sever
score
lung
heat
shock
protein
express
glucosamin
vs
salin
follow
cecal
ligat
punctur
introduct
earli
aggress
fluid
administr
associ
improv
outcom
sepsi
approach
may
increas
risk
lung
edema
abdomin
compart
syndrom
capillari
permeabl
increas
aim
studi
test
two
differ
approach
volum
resuscit
septic
anim
method
thirti
pig
anaesthet
invas
monitor
system
region
flow
pressur
random
control
moder
volum
c
n
control
high
volum
ch
n
periton
moder
volum
p
n
periton
high
volum
ph
n
periton
induc
instil
gkg
autolog
faec
dissolv
glucos
solut
ventil
adjust
maintain
arteri
po
mmhg
group
ch
ph
receiv
mlkghour
ringer
solut
plu
mlkghour
he
wherea
group
c
p
receiv
mlkghour
ringer
solut
clinic
sign
hypovolaemia
present
addit
bolus
he
maxim
mlhour
given
anim
treat
observ
hour
death
result
cardiac
output
higher
group
ph
compar
group
p
mean
arteri
pressur
avail
onlin
http
oxygen
index
surviv
proport
similar
group
oxygen
index
pao
fio
decreas
group
group
ph
lowest
valu
hour
throughout
rest
experi
p
figur
surviv
lowest
group
ph
follow
group
p
anim
control
group
surviv
hour
figur
conclus
highvolum
administr
decreas
oxygen
surviv
periton
control
anim
highvolum
approach
may
gener
benefici
abdomin
sepsi
introduct
fluid
resuscit
necessari
sepsi
posit
fluid
balanc
may
increas
risk
mortal
test
hypothesi
volum
resuscit
strategi
may
modifi
liver
mitochondri
function
outcom
method
twentynin
anesthet
pig
receiv
hour
either
endotoxin
placebo
either
ringer
lactat
mlkghour
mlkghour
mlhour
he
system
region
hemodynam
measur
liver
mitochondri
state
state
oxygen
consumpt
determin
result
hepatosplanchn
oxygen
deliveri
similar
endotox
pig
high
mlminkg
vs
moder
volum
administr
mlminkg
hepatosplanchn
vo
lower
anim
high
mlminkg
vs
moder
volum
administr
mlminkg
p
endotoxin
highvolum
pig
exhibit
decreas
state
respir
complex
complex
ii
signific
comparison
control
highvolum
endotoxin
lowvolum
pig
figur
also
increas
mortal
rate
studi
period
vs
control
conclus
prolong
highvolum
resuscit
approach
endotoxemia
may
associ
impair
hepatosplanchn
oxygen
consumpt
liver
mitochondri
dysfunct
high
mortal
impact
aggress
prolong
volum
administr
hepatosplanchn
oxygen
mitochondri
function
human
sepsi
determin
multipl
studi
stress
import
contribut
activ
complement
patholog
reperfus
injuri
tissu
ischemia
use
intravit
microscopi
studi
explor
function
consequ
inhibit
classic
pathway
complement
activ
inhibitor
context
superior
mesenter
arteri
occlus
smao
reperfus
thirti
anesthet
spontan
breath
male
spraguedawley
rat
underw
smao
minut
follow
reperfus
hour
inhibitor
iukg
iukg
bodi
weight
salin
given
singl
bolu
reperfus
shamoper
anim
n
without
smao
serv
control
system
hemodynam
monitor
continu
arteri
blood
gase
analyz
intermitt
leukocyt
endotheli
interact
mesenter
microcircul
quantifi
interv
use
intravit
microscopi
ileal
lipidbind
protein
ilbp
level
measur
serum
sampl
elisa
end
experi
restor
microcirculatori
perfus
postcapillari
venul
baselin
level
dosedepend
manner
reduc
leukocyt
adhes
follow
smaoreperfus
similar
level
group
reperfus
furthermor
treatment
effici
prevent
metabol
acidosi
reduc
need
intraven
fluid
support
blood
pressur
furthermor
ilbp
level
decreas
dosedepend
manner
compar
level
shamoper
anim
end
experi
surviv
rate
control
iukg
iukg
salinetr
anim
set
mesenter
ischemia
given
bolu
infus
shortli
reperfus
effici
restor
microcirculatori
perfus
dosedepend
manner
reduc
local
system
inflammatori
respons
improv
outcom
ilbp
level
correl
well
function
consequ
mesenter
ischemiareperfus
treatment
end
experi
introduct
terlipressin
increasingli
use
treatment
sepsisassoci
hypotens
howev
terlipressin
may
reduc
cardiac
output
global
oxygen
suppli
method
perform
prospect
random
control
clinic
studi
determin
whether
dobutamin
may
counterbal
depress
cardiac
index
mixedven
oxygen
satur
result
sole
terlipressin
infus
enrol
septic
shock
patient
requir
high
dose
norepinephrin
maintain
mean
arteri
pressur
mmhg
patient
randomli
alloc
treat
either
mg
terlipressin
b
mg
terlipressin
follow
increment
dobutamin
dose
revers
anticip
reduct
mixedven
oxygen
satur
c
sole
norepinephrin
infus
control
n
result
data
right
heart
catheter
thermody
dilut
cathet
gastric
tonometri
well
organ
function
coagul
obtain
baselin
hour
terlipressin
without
dobutamin
infus
preserv
mean
arteri
pressur
threshold
valu
mmhg
allow
one
reduc
norepinephrin
dose
respect
vs
control
hour
p
terlipressinlink
decreas
mixedven
oxygen
satur
revers
dobutamin
hour
vs
p
statist
signific
differ
found
intragroup
group
term
differ
gastric
mucos
arteri
carbon
dioxid
partial
pressur
blood
clearanc
indocyanin
green
well
plasma
disappear
rate
indocyanin
green
conclus
catecholaminedepend
human
septic
shock
terlipressin
without
concomit
dobutamin
stabil
hemodynam
reduc
norepinephrin
requir
dobutamin
use
inotrop
agent
revers
depress
global
oxygen
transport
result
sole
terlipressin
infus
without
obviou
side
effect
thenar
muscl
sto
measur
nearinfrar
spectroscopi
inspectra
hutchinson
technolog
hutchinson
mn
usa
oral
mucos
tissu
oxygen
satur
microcirculatori
blood
flow
blood
flow
veloc
measur
depth
mm
laser
doppler
flowmetri
remiss
spectroscopi
system
c
result
see
tabl
vasopressin
infus
led
signific
decreas
oral
mucos
oxygen
satur
blood
flow
signific
decreas
flow
veloc
depth
mm
chang
thenar
tissu
perfus
detect
conclus
vasopressin
caus
deterior
oral
mucos
blood
flow
thenar
tissu
perfus
introduct
sepsi
alter
vascular
reactiv
studi
impact
periton
endotoxemia
hepat
superior
mesenter
arteri
contractil
materi
method
studi
fecal
periton
p
n
endotoxininfus
e
n
control
c
n
hour
abdomin
surgeri
eight
control
pig
without
surgeri
spa
system
region
hemodynam
exvivo
splanchnic
vascular
reactiv
norepinephrin
ne
tissu
bath
measur
cumul
doserespons
curv
ne
construct
tension
express
gram
result
co
increas
p
p
e
sma
flow
median
rang
decreas
c
mlkgmin
p
tabl
data
present
median
rang
p
e
vs
p
c
p
vs
c
p
e
p
vs
c
e
p
p
vs
c
splanchnic
vascular
respons
ne
heterogen
sepsi
sma
affect
may
modifi
blood
flow
distribut
high
ne
dose
use
mean
arteri
pressur
map
continu
intermitt
bolu
infus
terlipressin
endotexem
ewe
introduct
tissu
doppler
imag
tdi
novel
techniqu
measur
myocardi
veloc
peak
earli
diastol
mitral
annulu
veloc
offer
rel
preloadinsensit
measur
lv
relax
scant
data
regard
use
sepsi
endotoxemia
studi
sought
determin
effect
endotoxemia
upon
tdi
variabl
method
ethic
committe
approv
male
spraguedawley
rat
studi
anesthesia
induc
alfaxalon
maintain
isofluoran
mechan
ventil
perform
via
tracheostomi
rat
receiv
nacl
mlhour
via
carotid
line
immedi
baselin
assess
rat
receiv
mlkg
iv
infus
minut
studi
group
n
endotoxin
mgml
escherichia
coli
sigma
mo
usa
control
group
nacl
echocardiographi
perform
mhz
transduc
ge
healthcar
minut
hour
measur
includ
heart
rate
mean
arteri
pressur
map
femor
venou
pressur
lv
outflow
tract
diamet
flow
peak
veloc
v
peak
cardiac
output
co
peak
earli
diastol
mitral
inflow
e
peak
systol
mitral
annulu
veloc
result
signific
differ
mean
sd
weight
studi
g
control
g
p
hemodynam
variabl
v
peak
higher
studi
group
compar
control
vs
ms
p
studi
group
demonstr
lower
map
e
tabl
introduct
aim
retrospect
studi
evalu
hemodynam
neurohormon
effect
levosimendan
cardiac
patient
sepsisinduc
cardiac
dysfunct
septic
shock
character
profound
cardiovascular
alter
includ
myocardi
depress
levosimendan
recent
shown
improv
cardiac
function
septic
shock
method
fifteen
patient
myocardi
depress
relat
septic
shock
enrol
patient
sir
criteria
cultur
isol
one
pathogen
posit
procalcitonin
sbp
mmhg
unrespons
load
challeng
defin
myocardi
depress
reduc
svo
presenc
increas
brain
natriuret
peptid
secret
troponin
releas
systol
andor
diastol
dysfunct
transoesophag
echo
evalu
eject
fraction
mitral
annulu
tissu
doppler
imag
veloc
patient
receiv
levosimendan
infus
hour
combin
norepinephrin
result
data
obtain
evalu
averag
percentag
variat
start
infus
hour
infus
hour
hour
hour
hour
hour
levosimendan
significantli
increas
svo
eject
fraction
decreas
troponin
brain
natriuret
peptid
levosimendan
improv
diastol
function
increas
veloc
tissu
doppler
imag
hour
data
analys
fisher
f
test
introduct
sickeuthroid
syndrom
frequent
critic
ill
patient
cytokin
may
role
syndrom
involv
central
regul
hypothalamicpituitarythyroid
hpt
axi
ill
aim
studi
evalu
relationship
thyroid
function
septic
patient
materi
method
twentyfour
septic
patient
healthi
control
enrol
studi
mean
age
year
respect
hyperthyroid
hypothyroid
patient
exclud
free
triiodothyronin
free
thyroxin
tsh
measur
simultan
mean
tsh
valu
septic
patient
control
group
present
tabl
significantli
higher
septic
patient
pgml
vs
pgml
p
tsh
valu
significantli
low
septic
patient
significantli
strong
correl
septic
patient
tsh
r
p
correl
thyroid
indic
control
group
center
directli
admiss
network
hospit
final
step
present
project
differ
hospit
result
treat
children
waterhousefriderichsen
syndrom
network
three
attend
site
seven
transfer
tertiari
center
announc
time
eight
case
hour
primarili
consult
accomplish
routin
transport
team
tertiari
center
continu
treatment
site
afterward
center
patient
show
typic
sign
waterhousefriderichsen
syndrom
purpura
fulminan
sever
multiorgan
failur
patient
die
one
patient
necrosi
skin
exist
alreadi
admiss
other
restitut
ad
integrum
advers
effect
observ
pc
concentr
administr
conclus
network
system
standard
treatment
pc
work
without
sever
problem
surviv
rate
outcom
small
studi
group
excel
experi
allow
us
enlarg
system
diseas
introduct
neonat
infant
icu
high
risk
sever
infect
sepsi
often
easi
diagnos
sepsi
base
clinic
find
reliabl
biomark
need
prove
diagnosi
object
studi
valu
procalcitonin
pct
marker
verifi
diagnosi
enabl
start
deescal
abt
patient
clinic
sign
sepsi
method
three
hundr
seventyfour
patient
artifici
lung
ventil
two
pediatr
icu
two
russian
hospit
enrol
blood
sampl
pct
test
pct
lia
brahm
ag
germani
taken
suspicion
sepsi
exacerb
bacteri
infect
first
stage
januarydecemb
neonat
age
day
variou
perinat
patholog
studi
group
routin
abt
prescrib
blood
sampl
taken
store
pct
assess
second
stage
januarynovemb
infant
age
month
cardiac
surgeri
enrol
group
b
abt
adjust
base
pcttest
result
pct
ngml
indic
system
bacteri
inflamm
addit
clinic
sign
sepsi
indic
abt
carbapenem
data
shown
median
interquartil
rang
result
group
sepsi
diagnos
patient
pct
ngml
observ
case
includ
patient
clinic
diagnos
sepsi
patient
pct
ngml
mortal
rate
carbapenem
meropenem
imipenemcilastatin
administ
n
compar
differ
abt
n
although
patient
pct
ngml
n
abt
carbapenem
n
result
paradox
higher
mortal
compar
abt
scheme
n
vs
group
b
sepsi
defin
patient
pct
ngml
case
includ
patient
clinic
diagnos
sepsi
earli
abt
meropenem
combin
vancomycin
linezolid
allow
one
decreas
sepsisrel
mortal
patient
use
high
introduct
algorithm
p
conclus
earli
verif
sepsi
use
pct
combin
carbapenemsbas
abt
enabl
decreas
sepsisrel
mortal
critic
ill
infant
newborn
stay
icu
avail
onlin
http
introduct
aim
studi
investig
preval
endotoxemia
earli
elect
surgic
procedur
patient
admit
icu
univers
hospit
method
one
hundr
four
nonselect
patient
recruit
patient
exclud
admit
weekend
anoth
icu
chronic
dialysi
within
hour
admiss
function
data
collect
sever
score
apach
sofa
calcul
arteri
blood
sampl
also
taken
process
accord
spectral
diagnost
endotoxin
activ
ea
assay
method
allow
one
express
ea
function
patient
neutrophil
chemiluminesc
activ
scale
ea
level
approxim
equival
endotoxin
concentr
pgml
level
approxim
equival
lp
concentr
pgml
data
analys
accord
ea
rang
low
ea
intermedi
ea
high
ea
differ
rang
ea
assess
analysi
varianc
sigma
stat
spss
accept
p
signific
data
express
mean
sd
result
case
mix
patient
low
group
intermedi
group
high
group
age
year
significantli
differ
three
group
p
function
sever
score
significantli
differ
group
averag
valu
follow
wbc
nmm
p
hr
bpm
p
map
mmhg
p
lactat
mmoll
p
pao
fio
mmhg
p
apach
ii
score
p
sofa
score
p
interestingli
patient
higher
level
ea
character
longer
length
stay
icu
icu
length
stay
day
low
group
day
intermedi
group
day
high
group
p
conclus
rather
high
number
patient
admit
icu
follow
elect
surgeri
character
intermediatehigh
level
endotoxemia
assess
ea
assay
despit
rel
low
level
complex
admiss
high
level
ea
associ
longer
length
stay
object
evalu
septic
patient
plasma
level
solubl
form
seem
play
import
role
inflammatori
diseas
determin
whether
plasma
could
use
diagnost
prognost
marker
sepsi
surgic
icu
design
observ
clinic
studi
set
surgic
icu
univers
hospit
heidelberg
germani
patient
patient
admit
icu
period
clinic
evid
sever
sepsi
septic
shock
intervent
none
sixtysix
intens
care
patient
enrol
studi
within
first
hour
onset
sever
sepsi
septic
shock
twentyon
healthi
individu
serv
control
day
day
day
diagnosi
sever
sepsi
septic
shock
plasma
measur
elisa
plasma
concentr
healthi
control
differ
patient
sever
sepsi
septic
shock
day
pgml
vs
pgml
signific
day
pgml
vs
pgml
signific
day
pgml
vs
pgml
signific
survivor
defin
patient
surviv
least
day
differ
plasma
survivor
nonsurvivor
day
day
day
pgml
vs
pgml
pgml
vs
pgml
pgml
vs
pgml
signific
conclus
studi
includ
surgic
patient
sever
sepsi
septic
shock
plasma
elev
compar
healthi
control
furthermor
measur
plasma
allow
one
differ
survivor
nonsurvivor
suggest
role
diagnost
prognost
marker
sepsi
confirm
studi
plasmafre
dna
concentr
diagnost
tool
critic
ill
septic
patient
recent
evid
suggest
plasmafre
dna
concentr
potenti
use
prognost
marker
mani
clinic
situat
includ
sepsi
trauma
acut
stroke
howev
predict
valu
arguabl
hypothes
plasma
dna
increas
septic
patient
admit
icu
compar
nonsept
icu
patient
correl
diseas
sever
clinic
outcom
fortytwo
consecut
patient
septic
nonsept
admit
mix
icu
mechan
ventil
recruit
plasmafre
dna
concentr
measur
realtim
pcr
assay
gene
apach
ii
score
sofa
score
serum
creactiv
protein
crp
concentr
procalcitonin
pct
concentr
serum
lipid
concentr
clinic
outcom
icuhospit
day
mortal
assess
admiss
icu
assess
sampl
repeat
diagnosi
patient
chang
sepsi
sever
sepsi
septic
shock
final
plasma
sampl
collect
descript
statist
mannwhitney
u
kruskallw
spearman
test
receiv
oper
characterist
analysi
use
appropri
demograph
data
similar
icu
hospit
mortal
respect
mean
dna
concentr
admiss
significantli
higher
icu
patient
compar
healthi
subject
n
geml
versu
geml
p
septic
patient
compar
nonsept
patient
geml
versu
geml
p
furthermor
overal
icu
stay
increas
dna
concentr
associ
increas
sever
ill
note
howev
increas
statist
signific
septic
septic
shock
sampl
geml
versu
geml
p
area
curv
obtain
plasmafre
dna
concentr
distinguish
septic
nonsept
patient
admiss
sensit
specif
cutoff
geml
also
plasmafre
dna
concentr
found
higher
patient
die
icu
compar
patient
surviv
although
statist
signific
dna
concentr
demonstr
signific
correl
crp
p
r
pct
p
r
highdens
lipoprotein
p
r
concentr
conclus
plasma
dna
may
potenti
valuabl
tool
confirm
diagnosi
sepsi
admiss
icu
monitor
diseas
sever
introduct
inadequ
tissu
perfus
uncontrol
system
inflammatori
respons
associ
poor
outcom
critic
ill
surgic
patient
increas
concentr
unmeasur
anion
reflect
hypoperfus
magnitud
earli
inflammatori
respons
correl
strongli
mortal
aim
assess
relationship
factor
abil
combin
predict
outcom
method
prospect
studi
evalu
consecut
patient
admit
surgic
high
depend
unit
region
ethic
committe
approv
obtain
serum
electrolyt
albumin
phosphat
lactat
creactiv
protein
crp
measur
admiss
day
deriv
calcul
ion
gap
cig
use
simplifi
modif
stewartfigg
equat
result
base
previou
work
threshold
mmoll
cig
mgl
crp
use
categoris
patient
patient
crp
mgl
elev
cig
patient
crp
mgl
elev
cig
p
chisquar
test
patient
n
cig
mmoll
crp
mgl
mortal
wherea
n
cig
mmoll
crp
mgl
mortal
p
chisquar
test
tabl
crp
mgl
crp
mgl
cig
mmoll
cig
mmoll
inhospit
mortal
n
n
conclus
inflamm
potent
caus
oxid
stress
turn
result
endotheli
damag
increas
concentr
unmeasur
anion
combin
crp
cig
marker
inflamm
inadequ
tissu
perfus
respect
power
predictor
mortal
critic
ill
surgic
patient
creactiv
protein
predict
mortal
admiss
surgic
highdepend
unit
measur
admiss
day
day
evalu
respect
inhospit
mortal
result
crp
admiss
hdu
discrimin
survivor
nonsurvivor
p
analysi
varianc
crp
greater
mgl
correl
strongli
mortal
mortal
patient
crp
less
mgl
n
mortal
patient
crp
greater
mgl
n
p
chisquar
test
tabl
howev
signific
differ
crp
respect
mortal
day
day
p
respect
conclus
crp
admiss
surgic
hdu
power
predictor
mortal
p
correl
persist
initi
measur
data
suggest
earli
crp
measur
undertaken
critic
ill
surgic
patient
order
quantifi
ultim
magnitud
inflammatori
respons
associ
mortal
test
abil
biphas
aptt
waveform
diagnosi
sepsi
patient
present
emerg
depart
ed
system
inflammatori
respons
syndrom
sir
biphas
aptt
waveform
bpw
result
rapid
complex
vldl
creactiv
protein
aptt
test
demonstr
promis
earli
diagnost
test
sepsi
method
prospect
observ
studi
design
patient
present
ed
urban
univers
hospit
screen
sir
patient
sir
unrel
trauma
myocardi
infarct
elig
plasma
bpw
test
obtain
time
enrol
daili
day
admit
subject
primari
outcom
diagnosi
sepsi
relat
presenc
bpw
enrol
secondari
measur
mortal
relat
bpw
correl
posit
bpw
sepsi
bpw
statin
therapi
two
criteria
posit
test
light
transmitt
second
initi
slope
waveform
slope
use
two
independ
expert
made
final
diagnosi
result
screen
consecut
admiss
ed
identifi
elig
subject
enrol
particip
bpw
present
enrol
subject
subject
slope
fortysix
subject
eventu
develop
bpw
diagnos
sepsi
sensit
specif
sepsi
ci
ci
ci
ci
slope
posit
predict
valu
test
slope
criteria
auc
roc
analysi
bpw
diagnosi
sepsi
slope
odd
ratio
develop
sepsi
relat
posit
bpw
odd
ratio
develop
bpw
patient
statin
time
present
five
subject
die
day
bpw
bpw
util
ed
predict
develop
sepsi
atrisk
patient
develop
bpw
time
hospit
stay
correl
increas
risk
sepsi
mortal
baselin
statin
therapi
may
reduc
chanc
develop
bpw
object
know
whether
function
protein
c
fpc
level
critic
septic
patient
could
intend
evolut
marker
correl
prognosi
mortal
materi
method
prospect
studi
determin
fpc
level
septic
patient
admit
icu
use
il
pc
kit
instrument
laboratori
synthet
chromogen
substrat
consid
abnorm
low
fpc
level
normal
fpc
level
low
fpc
level
data
includ
patient
age
diagnosi
sap
ii
sofa
score
osf
mortal
analyt
data
includ
serum
lactat
fpc
patient
divid
three
group
group
fpc
group
ii
fpc
group
iii
fpc
statist
studi
perform
analyseit
program
sever
defin
usual
criteria
sap
ii
score
lactat
level
compar
differ
fpc
group
mortal
consid
result
includ
patient
total
mortal
rate
patient
conclus
found
direct
progress
relat
statist
signific
higher
mortal
rate
lower
protein
c
valu
result
could
mean
level
protein
c
use
evolut
marker
septic
patient
sever
sepsi
microcirculatori
dysfunct
caus
inflamm
endotheli
activ
procoagul
respons
lead
mithocondri
dysfunct
term
microcirculatori
mitochondri
distress
syndrom
undetect
condit
lead
parenchym
cellular
distress
organ
failur
region
microcirculatori
distress
independ
system
hemodynamicderiv
oxygenderiv
variabl
record
cours
microvascular
paramet
microscan
video
microscop
microvis
netherland
four
patient
sever
sepsi
studi
sublingu
region
embryolog
correl
splanchnic
circul
thin
mucosa
instrument
use
new
improv
imag
modal
observ
microcircul
call
sidestream
darkfield
imag
consid
four
patient
sever
sepsi
relat
esophagectomi
sever
polytrauma
splanchnic
organ
damag
mediastin
treat
drotrecogin
alpha
activ
da
hour
patient
admit
icu
ventil
mechan
monitor
hemodynam
via
picco
system
support
dobutamin
videomicroscopi
made
administr
da
repeat
everi
hour
treatment
da
hour
suspens
record
valu
blood
pressur
cardiac
function
lactat
level
acidbas
balanc
temperatur
dobutamin
dosag
admiss
sublingu
microcircul
show
low
capillari
densiti
vessel
heterogen
qualit
low
flow
flowno
flow
first
hour
begin
da
infus
sublingu
flow
show
increas
vessel
densiti
particularli
number
small
vessel
number
continu
perfus
vessel
increas
post
therapi
da
analyz
microvascular
flow
simpl
semiquantit
method
divid
imag
four
equal
quadrant
quantif
flow
hyperdynam
continu
sluggish
flowno
flow
flow
cohort
vessel
diamet
small
medium
larg
analyz
mean
valu
result
three
imag
patient
pre
post
da
therapi
data
present
median
start
therapi
da
microvascular
flow
index
mfi
small
vessel
medium
vessel
larg
vessel
da
infus
mfi
respect
small
medium
larg
avail
onlin
http
vessel
differ
group
assess
use
mannwhitney
u
test
show
statist
signific
differ
p
mfi
post
da
therapi
demonstr
quantit
qualit
improv
sublingu
microcircul
increas
capillari
densiti
distribut
areawidth
averag
veloc
versu
vessel
width
cours
microvascular
blood
flow
may
play
import
role
sepsi
septic
shock
relat
develop
multipl
organ
failur
death
sever
studi
demonstr
chang
microvascular
perfus
independ
predictor
outcom
improv
microcircul
vascular
tone
septic
shock
da
probabl
relat
anticoagulantantithrombot
antiinflammatori
action
decreas
product
inhibit
ino
induct
improv
endotheli
barrier
function
inhibit
chemotaxi
investig
requir
elucid
exact
mechan
observ
could
suggest
da
could
particular
interest
earli
manag
sever
sepsi
discuss
year
treatment
sever
sepsi
icu
apc
import
chang
observ
faster
recognit
diagnosi
transfer
refer
hospit
introduct
adequ
therapi
decreas
surviv
ratio
probabl
due
seriou
state
admit
patient
initi
infect
locat
abdomen
surgeri
conclus
educ
program
essenti
increas
number
fast
recognit
influenc
surviv
ratio
introduct
one
treatment
intervent
demonstr
mortal
efficaci
random
control
trial
level
prescript
drotrecogin
alfaactiv
drotaa
appropri
play
import
role
manag
sever
sepsi
howev
concern
regard
potenti
seriou
bleed
event
help
sustain
degre
sceptic
regard
use
drotaa
earli
adopt
evidencebas
medicin
cardiff
critic
care
unit
prescrib
drotaa
sinc
late
consider
experi
respect
use
aim
studi
demonstr
safeti
profil
efficaci
drotaa
treatment
within
larg
univers
hospit
critic
care
unit
method
demograph
data
obtain
unit
daili
updat
riyadh
icu
programm
databas
clinic
data
collect
patient
medic
note
observ
chart
data
prospect
enter
drotaa
registri
result
shown
result
octob
novemb
patient
sever
sepsi
treat
drotaa
mean
age
year
rang
year
male
mean
admiss
apach
ii
score
rang
day
drotaa
infus
median
number
organ
fail
rang
mechan
ventil
vasopressor
median
time
start
drotaa
document
diagnosi
sever
sepsi
hour
rang
hour
median
durat
drotaa
infus
hour
rang
hour
incid
seriou
lifethreaten
bleed
event
n
gastrointestin
n
intraabdomin
n
intrathorac
n
nonfat
intracrani
bleed
mortal
icu
mortal
hospit
mortal
mortal
conclus
one
largest
uk
registri
drotaa
usag
publish
date
result
demonstr
low
incid
seriou
bleed
event
associ
drotaa
treatment
vs
prowess
interest
note
three
advers
event
occur
prior
detail
combin
low
median
time
start
drotaa
infus
steadili
decreas
past
year
would
suggest
presenc
learn
curv
drotaa
usag
icu
also
encourag
note
overal
hospit
mortal
lower
predict
apach
ii
hospit
mortal
patient
vs
final
one
first
uk
studi
describ
longterm
mortal
outcom
patient
receiv
drotaa
therapi
studi
requir
formal
assess
impact
drotaa
treatment
longterm
surviv
sever
sepsi
audit
adher
nation
institut
clinic
excel
guidelin
use
drotrecogin
alfa
activ
introduct
activ
protein
c
apc
endogen
protein
fibrinolyt
antiinflammatori
properti
avail
human
recombin
apc
use
treatment
patient
sever
sepsi
nation
institut
clinic
excel
nice
suggest
guidelin
use
apc
retrospect
audit
record
patient
receiv
apc
admiss
icu
januari
august
audit
practic
three
paramet
complianc
nice
guidelin
accuraci
data
form
outcom
treatment
januari
august
use
apc
treat
sever
septic
patient
icu
obtain
complet
data
patient
collect
data
case
note
icu
chart
drotrecogin
alfa
activ
data
form
record
relev
data
excel
spreadsheet
proforma
result
nice
guidelin
compliant
patient
select
criteria
apc
administr
includ
known
suspect
site
infect
sir
criteria
organ
dysfunct
criteria
prescript
made
intens
care
consult
fulli
compliant
exclud
patient
met
exclus
criteria
patient
although
case
justifi
clinic
consult
prior
administr
data
entri
case
patient
select
field
complet
exclus
outcom
field
complet
patient
lactat
time
normal
list
one
inclus
criteria
associ
ph
base
deficit
howev
patient
organdysfunct
criteria
henc
still
met
inclus
criteria
outcom
seven
patient
die
within
day
apc
administr
standardis
mortal
ratio
smr
lower
patient
receiv
apc
compar
rest
patient
admit
period
smr
vs
twentyeight
patient
apach
ii
score
effect
cost
per
survivor
patient
apach
ii
score
effect
cost
per
survivor
nine
patient
drotrecogin
alfa
activ
infus
interrupt
discontinu
variou
reason
includ
seven
patient
hemorrhag
complic
three
seriou
use
apc
complianc
nice
guidelin
apc
costeffect
patient
year
primari
sourc
infect
intraabdomin
respiratori
genitourinari
sourc
grh
icu
mortal
hospit
mortal
analysi
age
reveal
overal
surviv
rate
patient
year
year
year
year
patient
year
age
hemorrhag
complic
rate
higher
publish
report
treatment
record
total
nine
hemorrhag
mortal
rate
cohort
conclus
data
suggest
field
perform
daa
may
replic
favor
clinic
endpoint
report
prowess
ontario
ministri
health
consid
implement
provinci
registri
system
patient
sever
sepsi
septic
shock
empow
icu
track
relev
demograph
acuiti
outcom
data
view
optim
daa
use
patient
select
risk
stratif
introduct
object
establish
whether
activ
protein
c
apc
safe
surgic
patient
intraabdomin
sepsi
ia
apc
use
treatment
ia
hospit
sinc
fear
persist
regard
potenti
clinic
signific
bleed
surgic
subgroup
patient
method
fortyfour
patient
ia
receiv
apc
standard
regim
march
august
retrospect
medic
icu
chart
review
undertaken
data
collect
includ
clinic
signific
bleed
episod
mortal
descript
subgroup
analysi
unexpect
nonsurvivor
die
icu
apach
ii
apii
predict
mortal
unexpect
survivor
surviv
icu
discharg
apii
predict
mortal
perform
statist
analysi
small
patient
number
inappropri
result
one
episod
clinic
signific
bleed
mucou
fistula
selflimit
intracrani
haemorrhag
event
icu
mortal
mean
apii
predict
mortal
inhospit
mortal
exceed
rate
apctreat
surgic
cohort
literatur
unexpect
survivor
like
admit
theatr
shorter
mean
time
hospitalicu
admiss
vs
day
durat
ventil
vs
day
vasopressor
vs
day
renal
replac
therapi
vs
day
depend
unexpect
nonsurvivor
diagnosi
fistula
perfor
like
transfer
icu
anoth
hospit
ward
theatr
comorbid
sever
conclus
apc
safe
use
group
critic
ill
surgic
patient
although
patient
may
fulfil
standard
criteria
apc
use
definit
surgic
cure
ia
apc
inappropri
delay
commenc
apc
surgic
patient
due
bleed
concern
may
contribut
high
mortal
earlier
periop
use
apc
select
case
may
offer
improv
mortal
benefit
undertak
prospect
audit
investig
result
total
patient
admit
icu
diagnosi
sepsi
sever
sepsi
one
hundr
fortynin
sever
septic
patient
assess
apc
patient
receiv
apc
patient
could
receiv
apc
due
financi
problem
due
bleed
coagul
derang
recent
surgeri
total
septic
patient
admit
icu
patient
expir
mortal
posit
blood
cultur
patient
receiv
inotrop
total
averag
apach
ii
score
expir
patient
total
septic
patient
assess
apc
patient
fulfil
criteria
receiv
apc
mortal
patient
receiv
apc
mortal
suspect
septic
patient
admit
icu
receiv
appropri
antibiot
therapi
within
hour
icu
admiss
upgradedchang
accord
cultur
sensit
report
necessari
nonreceiv
group
ie
patient
patient
could
receiv
apc
due
financi
restrict
initi
foreign
entitl
drug
bahrain
later
restrict
remov
remain
patient
could
receiv
either
due
bleed
recent
surgeri
patient
could
receiv
complet
treatment
either
due
bleed
complic
die
mortal
measur
day
furthermor
per
experi
apc
start
earli
stage
sepsi
cours
complet
outcom
better
patient
receiv
apc
patient
receiv
earli
stage
complet
dose
patient
surviv
mortal
averag
three
ventilatorfre
organ
fail
surviv
group
two
ventilatorfre
organ
fail
expir
group
seventeen
patient
start
treatment
earli
stage
could
complet
cours
due
bleed
complic
patient
expir
patient
start
late
stage
complet
cours
five
patient
expir
patient
start
late
stage
eight
patient
expir
conclus
basi
experi
result
multipl
trial
recommend
apc
given
patient
meet
inclus
criteria
sever
sepsi
hospit
mortal
mortal
sever
sepsi
respect
standard
mortal
ratio
sever
sepsi
patient
median
durat
stay
itu
sever
sepsi
cohort
surviv
day
iqr
number
episod
infect
primari
reason
admiss
itu
rest
episod
itu
acquir
see
figur
infect
characterist
conclus
sepsi
common
indian
itu
predomin
medic
popul
itu
mortal
higher
compar
western
literatur
gramposit
infect
less
common
although
incid
parasit
viral
infect
higher
west
unit
nccu
moment
unknown
known
patient
intens
care
environ
risk
factor
develop
bacteraemia
per
admiss
sever
paper
higher
amount
invas
procedur
sever
ill
group
patient
blame
aim
studi
identifi
incid
bacteraemia
nccu
recognis
incid
bloodstream
infect
sir
bacteraemia
identifi
common
pathogen
associ
bacteraemia
promot
continu
collect
data
aim
follow
behaviour
problem
time
method
prospect
observ
studi
look
presenc
posit
blood
cultur
patient
admit
nccu
period
june
august
blood
cultur
taken
peripher
site
asept
condit
per
nccu
guidelin
tri
identifi
mani
patient
posit
blood
cultur
evid
concomit
sirssepsi
describ
modifi
bone
criteria
sever
attempt
made
identifi
frequent
microorgan
involv
problem
well
antibiot
suscept
secondari
aim
studi
describ
number
fatal
patient
bacteraemia
tri
focu
approach
fact
serv
larg
neurologicalsurg
popul
well
gener
patient
see
whether
could
pinpoint
differ
two
group
result
patient
admit
unit
period
studi
neurosci
ns
patient
rest
gener
g
either
medic
surgic
patient
men
mean
apach
ii
score
ns
group
g
group
total
episod
posit
blood
cultur
bc
episod
accompani
inflammatori
sign
incid
bloodstream
infect
total
admiss
twentyf
episod
associ
clinic
sign
infect
patient
least
one
episod
posit
bc
ns
group
g
group
episod
ns
group
associ
degre
inflammatori
respons
sir
sever
sepsi
mod
episod
g
group
develop
inflammatori
respons
posit
bc
organ
isol
coagulaseneg
staphylococcu
cn
g
group
due
specialist
origin
unit
case
neurosci
group
gener
group
howev
incid
sepsi
mof
patient
almost
group
note
well
larger
number
death
patient
sepsi
mof
need
studi
aim
establish
casual
relationship
explain
cn
frequent
isol
organ
differ
among
group
potenti
increas
mortal
patient
develop
bloodstream
infect
unit
need
implement
urgent
measur
decreas
research
done
area
earli
recognit
rapid
start
goaldirect
treatment
egdt
import
element
better
outcom
sever
sepsi
action
take
place
emerg
depart
ed
admiss
icu
aim
studi
determin
egdt
perform
evalu
impact
egdt
principl
mortal
septic
shock
finland
studi
conduct
nation
guidelin
sever
sepsi
publish
intellivu
patient
monitor
data
collect
compar
use
bedsid
monitor
display
without
horizon
screen
trend
care
patient
sepsi
group
n
complet
sepsi
scenario
use
standard
screen
display
group
n
addit
horizon
trend
display
point
mark
onset
sepsi
physiolog
paramet
met
current
evidencebas
screen
criteria
hr
rr
map
temperatur
result
studi
found
statist
signific
differ
standard
screen
horizon
screen
particip
group
speed
clinician
abl
reach
measur
outcom
true
five
outcom
measur
onset
sepsi
p
initi
fluid
bolu
p
initi
vasopressor
p
blood
cultur
order
p
antibiot
administr
p
background
direct
microbiolog
input
critic
care
essenti
manag
septic
patient
earli
broadspectrum
antimicrobi
therapi
appropri
diagnost
studi
ascertain
caus
organ
well
establish
reassess
aim
use
narrowspectrum
antibiot
prevent
develop
antimicrobi
resist
reduc
toxic
reduc
cost
systemat
analysi
ward
round
icu
inform
commonli
miss
patient
file
concern
microbiolog
find
ask
rate
valu
ward
round
mean
score
possibl
rang
mode
unit
without
microbiolog
ward
round
desir
servic
score
averag
rang
mode
conclus
direct
microbiolog
advic
bedsid
highli
valu
icu
consult
antibiot
prescrib
gener
well
control
twothird
unit
agre
antibiot
polici
place
work
continu
determin
whether
result
reflect
nation
pictur
unit
kingdom
impact
select
digest
decontamin
nasal
mupirocin
incid
ventilatoryassoci
pneumonia
emerg
bacteri
resist
introduct
select
digest
decontamin
sdd
reduc
incid
ventilatoryassoci
pneumonia
vap
concern
rais
risk
select
resist
bacteria
evalu
impact
sdd
regimen
incid
vap
develop
resist
pathogen
method
polyval
eightb
icu
retrospect
analysi
perform
two
period
month
nosdd
patient
mean
sap
ii
sdd
patient
mean
sap
ii
use
sdd
amphotericin
tobramycin
colistin
oropharyng
gastric
decontamin
mupirocin
nasal
decontamin
result
analyz
chisquar
test
result
incid
vap
reduc
sdd
group
even
though
statist
signific
vs
p
mortal
vap
septic
shock
reduc
respect
p
p
sdd
period
gramposit
infect
increas
gramneg
infect
candida
infect
show
reduct
percentag
resist
speci
show
reduct
categori
pathogen
tabl
result
ninetythre
ct
critic
care
patient
receiv
tunnel
subclavian
cvc
indic
inotrop
n
antibiot
administr
n
rrt
n
unknown
n
mean
durat
cathet
remain
situ
day
sd
rang
cultur
result
present
tabl
twelv
patient
establish
cvcrelat
bsi
mean
infect
catheterday
result
cathet
insert
could
evalu
colon
crbsi
fortynin
uncoat
group
coat
group
clinic
characterist
patient
risk
infect
similar
two
group
use
propofol
frequent
uncoat
group
presenc
vascular
devic
studi
cathet
frequent
antibioticco
group
three
rmcoat
cathet
colon
compar
nine
control
cathet
rel
risk
confid
interv
p
three
case
crbsi
occur
patient
receiv
rm
cathet
compar
five
control
group
signific
differ
incid
crbsi
rmcoat
uncoat
cathet
uncoat
cathet
frequent
colon
differ
fail
show
statist
signific
durat
cathet
placement
taken
consider
kaplanmei
analysi
show
signific
differ
risk
colon
crbsi
rmcoat
uncoat
cathet
rate
crbsi
seven
per
catheterday
rmcoat
group
compar
per
catheterday
uncoat
group
p
gramposit
gramneg
organ
similarli
respons
colon
cathet
studi
differ
rate
colon
candida
speci
conclus
pilot
studi
show
trend
toward
lower
rate
colon
rmcoat
cathet
compar
uncoat
control
cathet
incid
rate
crbsi
similar
two
group
probabl
small
number
cathet
studi
develop
prospect
random
trial
larger
number
patient
underway
confirm
refut
result
signific
differ
antibiot
prescrib
practic
public
privat
sector
compar
appropri
earli
antibiot
prescript
reduc
mortal
attent
educ
system
address
prescrib
practic
indic
introduct
studi
aim
assess
associ
time
admiss
outcom
patient
admit
pneumonia
icu
unit
kingdom
method
patient
admit
icu
primari
reason
admiss
pneumonia
extract
case
mix
programm
databas
earli
admiss
admit
icu
day
admiss
hospit
compar
late
admiss
admit
icu
later
date
icu
hospit
mortal
number
organ
fail
renal
dysfunct
length
stay
hospit
compar
two
group
associ
sought
time
admiss
mortal
patient
stratifi
curb
score
admiss
icu
mortal
compar
two
group
odd
ratio
use
analys
data
p
consid
signific
result
small
statist
signific
differ
two
group
mean
age
apach
ii
score
curb
score
number
organ
failur
presenc
introduct
patient
develop
ventilatorassoci
pneumonia
vap
caus
either
multidrugresist
organ
mdro
pseudomona
may
poor
clinic
outcom
sought
clarifi
potenti
relationship
use
databas
larg
multicent
trial
diagnost
therapeut
strategi
patient
suspect
vap
method
patient
receiv
mechan
ventil
mv
hour
develop
suspect
vap
new
worsen
pulmonari
opac
cxr
least
two
fever
leukocytosi
chang
sputum
purul
increas
need
isol
potenti
pathogen
bacteria
sputum
elig
enrol
patient
cultur
obtain
either
bal
endotrach
aspir
mdro
defin
resist
class
antibiot
patient
follow
day
enrol
death
hospit
discharg
result
seven
hundr
thirtynin
patient
icu
canada
usa
enrol
enrol
cultur
ci
patient
grew
mdro
pseudomona
preval
mdro
enrol
differ
apach
ii
mod
pao
fio
baselin
whose
specimen
grew
mdro
pseudomona
whose
specimen
patient
mdro
pseudomona
higher
mortal
rr
ci
p
inhospit
mortal
rr
ci
p
trend
toward
higher
icu
mortal
rr
ci
p
whose
specimen
grow
organ
median
durat
mv
vs
day
icu
length
stay
vs
day
hospit
length
stay
vs
day
greater
patient
mdro
pseudomona
whose
specimen
grow
pathogen
p
adequaci
initi
empir
therapi
patient
whose
specimen
grew
mdro
pseudomona
compar
without
organ
p
conclus
isol
mdro
pseudomona
respiratori
tract
specimen
patient
suspect
vap
associ
prolong
mv
increas
icu
hospit
stay
increas
risk
death
inadequ
initi
empir
antibiot
treatment
may
contribut
factor
introduct
cytokin
play
import
role
pulmonari
host
defens
howev
nonuniform
find
report
correl
bronchoalveolar
bacteri
burden
lung
inflammatori
respons
object
aim
present
studi
evalu
relationship
bronchoalveolar
cytokin
express
bacteri
burden
mechan
ventil
patient
suspect
pneumonia
method
mechan
ventil
patient
suspect
pneumonia
admit
icu
novemb
januari
prospect
enrol
fiberopt
bronchoalveolar
lavag
bal
perform
ml
steril
isoton
salin
three
aliquot
ml
local
anesthet
use
bal
sampl
microbiolog
quantit
cultur
bal
cytokin
il
granulocyt
colonystimul
factor
gcsf
granulocytemonocyt
colonystimul
factor
gmcsf
measur
result
fiftynin
patient
includ
patient
prior
antibiot
therapi
twentytwo
patient
posit
bacteri
cultur
defin
diagnost
threshold
colonyform
unitsml
concentr
significantli
higher
group
patient
posit
bal
tabl
conclus
signific
correl
bal
fluid
lung
bacteri
burden
bal
earli
marker
pneumonia
mechan
ventil
patient
despit
prior
antibiot
therapi
clinic
implic
cytokin
measur
bal
may
diagnost
tool
support
diagnosi
initi
phase
pneumonia
exclud
fungi
unspecifi
isol
multisensit
isol
isol
sensit
colistin
meropenem
gentamicin
accord
data
earli
late
vap
adequ
therapeut
combin
cover
possibl
pathogen
meropenem
colistin
use
combin
cover
possibl
pathogen
deescal
accord
suscept
result
follow
atsidsa
guidelin
would
cover
isol
conclus
atsidsa
guidelin
may
applic
institut
countri
thu
clinician
incorpor
local
microbiolog
data
institutionspecif
guidelin
goal
studi
evalu
clinic
efficaci
meropenem
continu
infus
administr
cia
bolu
intermitt
infus
bii
treatment
vap
caus
pseudomona
aeruginosa
histor
control
group
vap
caus
p
aeruginosa
receiv
initi
empir
antibiot
therapi
meropenem
bii
n
compar
prospect
cohort
treat
meropenem
cia
n
surgic
icu
surgic
complex
district
hospit
look
demographi
apach
ii
score
mortal
attribut
mortal
vap
day
mechan
ventil
mv
icu
length
stay
vap
treat
day
meropenem
hour
intraven
antibiot
clinic
effect
categor
cure
failur
differ
group
test
mean
student
test
end
exact
chisquar
test
use
medcalc
program
consid
valu
p
signific
differ
result
signific
differ
found
group
patient
sex
age
apach
ii
score
diagnosi
cia
group
show
significantli
greater
clinic
cure
bii
group
cia
vs
bii
p
smaller
signific
attribut
mortal
vap
vs
p
conclus
result
suggest
administr
meropenem
cia
may
clinic
efficaci
administr
bii
treatment
vap
studi
requir
confirm
random
trial
combin
therapi
versu
monotherapi
empir
treatment
suspect
ventilatorassoci
pneumonia
introduct
delay
adequ
antibiot
therapi
ventilatorassoci
pneumonia
vap
associ
poor
outcom
earli
use
broadspectrum
antibiot
may
improv
clinic
outcom
howev
indiscrimin
use
broadspectrum
antibiot
associ
emerg
antibioticresist
bacteria
fungal
infect
increas
healthcar
cost
purpos
studi
determin
optim
empir
treatment
vap
compar
strategi
combin
therapi
monotherapi
broadspectrum
antibiot
method
multicent
trial
random
mechan
ventil
adult
patient
suspect
vap
develop
hour
icu
receiv
either
meropenem
ciprofloxacin
meropenem
alon
initi
therapi
addit
start
antibiot
diagnost
specimen
obtain
use
either
bronchoalveolar
lavag
quantit
cultur
standard
endotrach
aspir
result
random
patient
icu
canada
unit
state
baselin
characterist
etiolog
vap
similar
group
differ
mortal
combin
monotherapi
group
rr
confid
interv
p
durat
icu
hospit
stay
clinic
microbiolog
respons
treatment
emerg
antibioticresist
bacteria
isol
clostridium
difficil
fungal
colon
similar
group
combin
therapi
result
higher
rate
adequ
empir
therapi
compar
monotherapi
vs
p
subgroup
patient
infect
due
pseudomona
speci
acinetobact
speci
multidrugresist
gramneg
bacilli
enrol
n
adequaci
initi
antibiot
combin
group
versu
monotherapi
group
p
differ
associ
increas
microbiolog
erad
infect
organ
vs
p
differ
clinic
outcom
conclus
patient
suspect
vap
empir
treatment
combin
therapi
compar
monotherapi
safe
associ
higher
rate
adequ
antimicrobi
coverag
effect
clinic
outcom
introduct
prospect
pilot
studi
set
develop
anim
model
pseudomona
aeruginosa
would
suitabl
applic
molecular
techniqu
evalu
virul
instil
refer
strain
p
aeruginosa
result
monocultur
ventilatorassoci
pneumonia
purpos
male
adult
greyhound
use
anim
research
laboratori
method
anim
anaesthetis
oral
intub
mechan
ventil
inoculum
p
aeruginosa
strain
instil
oropharynx
hour
hour
postintub
anim
termin
hour
result
pneumonia
evalu
base
macroscop
grade
microbiolog
bacteri
count
find
abl
maintain
anaesthet
haemodynam
respiratori
support
studi
durat
hour
monobacteri
pulmonari
infect
establish
four
five
anim
administr
ceftriaxon
g
daili
effect
suppress
bacteria
allow
prolifer
singl
strain
p
aeruginosa
inocul
cultur
organ
conclus
short
period
time
abl
reproduc
monocultur
ventilatorassoci
pneumonia
signific
percentag
anim
success
develop
anim
icu
model
abl
sustain
hour
canin
model
p
aeruginosa
ventilatorassoci
pneumonia
suitabl
applic
molecular
techniqu
signaturetag
mutagenesi
differenti
fluoresc
induct
vivo
express
technolog
decreas
intraven
antibiot
use
adjunct
aerosol
amikacin
treatment
intub
mechan
ventil
patient
gramneg
pneumonia
safeti
iv
antibiot
use
inhal
amikacin
amk
adjunct
treatment
intub
patient
gramneg
pneumonia
method
doubleblind
placebocontrol
studi
aerosol
amk
deliv
via
pulmonari
drug
deliveri
system
pdd
nektar
therapeut
ventil
patient
gramneg
pneumonia
adjunct
iv
therapi
per
at
guidelin
patient
random
receiv
aerosol
contain
mg
amk
daili
placebo
normal
salin
hour
later
mg
amk
twice
daili
placebo
twice
daili
iv
antibiot
agent
durat
determin
attend
physician
amk
peak
serum
concentr
trough
concentr
tracheal
aspir
drawn
result
mean
number
iv
antibiot
end
studi
mean
day
two
time
greater
placebo
twicedaili
amk
p
figur
daili
twicedaili
amk
serum
c
max
respect
day
day
mean
trough
level
tracheal
aspir
level
mean
day
mgml
daili
mgml
twice
daili
aerosol
amk
well
toler
differ
advers
event
across
treatment
group
conclus
repeat
dose
adjunct
inhal
amk
mechan
ventil
patient
gramneg
pneumonia
safe
well
toler
associ
less
iv
antibiot
use
placebo
despit
isol
mrab
spread
infect
eight
patient
separ
room
differ
section
icu
day
later
transmiss
occur
within
day
three
male
patient
multipl
trauma
year
old
patient
cardia
carcinoma
femal
year
old
patient
necrot
pancreat
femal
year
old
patient
splenomegali
owe
polycythaemia
vera
male
year
old
patient
mrab
diagnosi
postmortem
rectal
carcinoma
femal
year
old
patient
isol
mrsa
infect
even
respiratori
failur
gastric
band
femal
year
patient
patient
suffer
septic
shock
high
fever
need
high
volum
replac
catecholamin
sever
time
prolong
mechan
ventil
mrab
isol
tracheal
secret
bal
patient
abdomin
drainag
patient
central
venou
cathet
patient
environment
investig
show
problemat
circumst
colistin
iv
avail
germani
procur
usa
caus
delay
treatment
day
anoth
delay
occur
rapid
grow
number
patient
need
colistin
patient
treat
adjust
dosag
day
patient
icu
isol
avoid
new
infect
precaut
convalesc
two
patient
mrab
patient
move
imc
convert
icu
period
isol
infect
patient
uninfect
three
nine
patient
die
labori
measur
great
expenditur
logist
work
well
transmiss
observ
object
gramneg
bacilli
includ
multidrugresist
acinetobact
baumannii
mdrab
respons
sever
icuacquir
infect
mainli
pneumonia
bacteraemia
aim
studi
determin
incid
mortal
multiresist
strain
acinetobact
patient
undergo
cardiac
surgeri
elucid
effect
treatment
colistin
identifi
whether
addit
measur
abl
prevent
control
dissemin
mdrab
isol
institut
method
total
patient
attend
surgic
icu
sicu
cardiovascular
surgeri
septemb
august
review
prophylact
measur
sicu
tri
identifi
epidemiolog
link
mdrabinfect
patient
implement
twoscal
multipl
program
scale
includ
classic
infect
control
measur
strict
contact
droplet
isol
surveil
throat
nasal
anal
flora
mdr
pathogen
patient
transfer
hospit
separ
nurs
staff
infect
colon
case
strict
antibiot
polici
scale
refer
geograph
isol
mdrab
case
exclus
medic
nurs
personnel
use
separ
suppli
facil
intens
environment
surveil
result
fifteen
patient
infect
mdrab
present
respiratori
tract
infect
one
suffer
deep
surgic
site
infect
bacteraemia
one
catheterrel
infect
treat
intraven
aerol
colistin
combin
rifampicin
ampicillin
sulbactam
avail
onlin
http
despit
signific
vitro
activ
colistin
virul
organ
accept
safeti
profil
result
discourag
surviv
fact
cure
clinic
improv
observ
four
patient
patient
develop
sepsi
multipl
organ
failur
scale
measur
implement
whole
period
scale
two
separ
period
follow
infect
control
strategi
achiev
intermitt
erad
pathogen
period
continu
function
sicu
conclus
increas
preval
mdrab
icu
patient
demand
instal
strict
screen
contact
precaut
due
signific
mortal
mdrabinfect
patient
addit
measur
like
geograph
isol
posit
case
exclus
medic
nurs
personnel
use
separ
suppli
facil
intens
environment
surveil
highli
recommend
introduct
tigecyclin
wyeth
new
glycylcyclin
antimicrobi
use
treatment
deepseat
multidrugresist
acinetobact
mdra
infect
unexpect
chang
routin
hematolog
serum
chemistri
report
method
patient
manag
within
liver
icu
receiv
standard
care
laboratori
data
collect
daili
enter
onto
specialist
databas
mdraposit
cultur
blood
bronchoalveolar
lavag
drain
fluid
sampl
taken
laparotomi
context
system
inflammatori
respons
syndrom
result
initi
tigecyclin
mg
iv
follow
mg
iv
hourli
result
eleven
patient
receiv
tigecyclin
treatment
mdra
infect
seven
male
ten
patient
singl
cours
whilst
one
patient
three
cours
underli
diseas
state
necrotis
pancreat
one
polytrauma
one
post
hepatectomi
one
acut
acut
chronic
liver
failur
four
postorthotop
liver
transplant
four
median
durat
treatment
day
rang
day
cours
day
patient
death
mean
apach
ii
score
initi
therapi
rang
four
surviv
icu
discharg
hospit
discharg
tigecyclin
well
toler
increas
correct
calcium
observ
patient
patient
receiv
three
cours
treatment
elev
correct
calcium
cours
patient
mean
correct
calcium
treatment
tigecyclin
mmoll
mean
correct
calcium
finish
cours
increas
mmoll
p
correl
durat
treatment
tigecyclin
degre
chang
correct
calcium
level
r
hypercalcaemia
resolv
discontinu
drug
surviv
day
treatment
mean
correct
calcium
mmoll
significantli
differ
pretreat
level
p
conclus
tigecyclin
well
toler
appear
associ
elev
correct
calcium
critic
ill
patient
return
baselin
valu
discontinu
drug
introduct
object
studi
quantifi
impact
continu
venoven
haemodiafiltr
cvvhdf
aminoglycosid
pharmacokinet
suggest
dose
strategi
improv
therapeut
outcom
drug
critic
ill
patient
treat
cvvhdf
limit
publish
data
aminoglycosid
pharmacokinet
crrt
data
deficit
led
subtherapeut
dose
identifi
retrospect
evalu
amikacin
gentamicin
serum
concentr
patient
treat
cvvhdf
undertaken
part
research
method
prospect
pharmacokinet
evalu
aminoglycosid
pharmacokinet
cvvhdf
undertaken
pharmacokinet
profil
oncedaili
dose
intraven
amikacin
gentamicin
obtain
blood
dialys
ultrafiltr
sampl
critic
ill
patient
treat
cvvhdf
use
vari
flow
rate
lhour
dialys
plu
lhour
filtrat
fluid
lhour
dialys
plu
lhour
filtrat
fluid
extracorpor
blood
flow
mlmin
drug
concentr
measur
use
immunoassay
result
mean
clearanc
gentamicin
due
cvvhdf
lhour
total
bodi
clearanc
tbc
siev
coeffici
sc
cvvhdf
clearanc
amikacin
lhour
tbc
sc
amikacin
differ
gentamicin
clearanc
versu
amikacin
clearanc
reflect
differ
cvvhdf
condit
mean
effluent
flow
rate
among
patient
sampl
treat
gentamicin
lhour
compar
lhour
amikacin
strong
correl
creatinin
clearanc
filter
measur
drug
clearanc
p
individu
patient
estim
aminoglycosid
pharmacokinet
paramet
k
vd
obtain
cvvhdf
use
allow
appropri
dosag
adjust
individu
pharmacokineticpharmacodynam
goal
eg
cpmaxmic
ratio
use
indic
adequ
aminoglycosid
dose
mean
gentamicin
amikacin
halfliv
approxim
hour
cvvhdf
therapi
far
shorter
previous
report
literatur
less
effici
form
renal
replac
therapi
failur
adjust
increas
aminoglycosid
clearanc
capac
due
cvvhdf
carri
risk
subtherapeut
dose
therapi
failur
conclus
dose
strategi
basi
pharmacokinet
analysi
serum
drug
concentr
effluent
fluid
drug
concentr
cvvhdf
condit
improv
therapeut
outcom
aminoglycosid
drug
therapi
influenza
develop
acut
renal
failur
proport
requir
haemofiltr
data
determin
elimin
oseltamivir
carboxyl
activ
metabolit
haemofiltr
vitro
studi
determin
elimin
measur
adsorpt
siev
coeffici
oseltamivir
carboxyl
use
two
haemofilt
type
undertaken
method
vitro
onecompart
model
continu
venoven
haemofiltr
use
phase
oseltamivir
carboxyl
adsorpt
haemofilt
circuit
studi
circul
bloodcrystalloid
mixtur
contain
clinic
relev
concentr
oseltamivir
carboxyl
haemofilt
circuit
return
ultrafiltr
mix
chamber
phase
ultrafiltr
remov
replac
bicarbonatebas
fluid
enabl
calcul
siev
coeffici
studi
repeat
time
two
haemofilt
type
polyamid
polyacrylonitril
pan
final
oseltamivir
carboxyl
ad
bloodcrystalloid
mixtur
without
circul
circuit
determin
stabil
solut
blood
sampl
collect
assay
hplcmsm
result
oseltamivir
carboxyl
remain
stabl
solut
mean
percentag
chang
baselin
min
min
min
mean
sd
initi
oseltamivir
carboxyl
concentr
pan
polyamid
show
signific
differ
mean
sd
adsorpt
min
pan
polyamid
haemofilt
statist
differ
adsorpt
haemofilt
initi
drug
concentr
signific
predictor
adsorpt
r
mean
sd
siev
coeffici
oseltamivir
carboxyl
pan
polyamid
haemofilt
show
statist
differ
haemofilt
conclus
total
adsorpt
low
unlik
clinic
signific
adsorpt
siev
coeffici
independ
type
haemofilt
membran
siev
coeffici
oseltamivir
carboxyl
therefor
clearanc
haemofiltr
estim
ultrafiltr
rate
openlabel
multicentr
observ
studi
patient
receiv
teicoplanin
suspect
diagnos
gramposit
infect
data
collect
includ
demograph
method
administr
load
mainten
dose
creatinin
advers
event
trough
peak
concentr
determin
minut
prior
drug
administr
minut
serum
separ
store
analysi
level
determin
abbott
tdx
flx
analyz
seradyn
teicoplanin
innofluor
assay
kit
seradyn
intern
teicoplanin
control
run
within
batch
mean
trough
peak
plasma
level
calcul
day
therapi
result
seventyfour
patient
complet
record
analyz
whilst
patient
receiv
mg
load
dose
day
receiv
mg
twice
daili
thereaft
bd
group
daili
od
group
nosocomi
pneumonia
n
skin
soft
tissu
infect
burn
nonburn
includ
diabet
foot
n
bacteraemia
n
intraabdomin
infect
n
bone
joint
infect
n
preemptiv
therapi
sever
trauma
n
od
group
mean
trough
level
remain
day
peak
level
remain
mean
bd
group
mean
trough
level
increas
hour
day
mean
peak
level
increas
hour
day
conclus
higher
trough
level
glycopeptid
target
improv
efficaci
reduc
resist
develop
od
group
convent
target
achiev
whilst
bd
arm
exceed
time
day
day
bd
dose
recommend
patient
sever
infect
particularli
critic
ill
prematur
discontinu
advers
event
report
studi
introduct
incid
hivinfect
patient
complic
skin
soft
tissu
infect
risen
advanc
immun
suppress
slower
respons
antibacteri
treatment
increas
risk
bacteraemia
rel
noninfect
patient
choic
initi
appropri
empir
antibacteri
therapi
import
aspect
care
hivinfect
patient
howev
recent
year
dramat
increas
resist
among
staphylococci
class
antimicrobi
agent
includ
glycopeptid
report
patient
method
studi
patient
skin
soft
tissu
infect
coinfect
hiv
noninfect
patient
soft
tissu
infect
age
year
patient
underw
oper
aim
surgic
remov
dead
tissu
pu
receiv
differ
combin
antibacteri
agent
twentythre
patient
adequ
surgeri
receiv
linezolid
dose
mg
twice
day
intraven
day
oral
followup
mg
twice
day
result
frequent
pathogen
staphylococci
group
patient
soft
tissu
infect
note
among
noninfect
patient
among
hivinfect
patient
mrsa
identifi
staphylococci
hivinfect
patient
among
patient
receiv
linezolid
mrsa
identifi
nine
case
two
case
vancomycinintermedi
aureu
strain
one
case
vancomycinresist
aureu
strain
three
case
reveal
staphylococcu
bacteraemia
one
case
mrsa
bacteraemia
patient
retroperiton
phlegmon
statist
differ
identifi
durat
high
temperatur
purul
wound
heal
comparison
patient
receiv
differ
combin
antibacteri
agent
patient
receiv
linezolid
discharg
hospit
length
stay
day
comparison
patient
receiv
antibacteri
agent
day
length
stay
hospit
among
noninfect
patient
soft
tissu
infect
day
modif
antibacteri
treatment
requir
group
patient
avail
onlin
http
receiv
linezolid
signific
laboratori
abnorm
side
effect
note
reveal
statist
differ
platelet
count
group
patient
receiv
linezolid
day
oper
comparison
group
receiv
antibacteri
agent
thrompocytopenia
character
hivinfect
patient
deterior
patient
receiv
linezolid
conclus
linezolid
complex
treatment
hivinfect
patient
complic
skin
soft
tissu
infect
may
improv
result
therapi
may
use
initi
empir
intravenoustoor
antibacteri
therapi
clinicomicrobiolog
studi
extend
spectrum
intens
care
unit
introduct
extend
spectrum
esbl
produc
organ
emerg
common
nosocomi
pathogen
icu
worldwid
earli
detect
prevent
spread
primari
measur
overcom
challeng
pose
difficult
treat
esbl
infect
aim
studi
find
incid
risk
factor
microbiolog
clinic
outcom
patient
infect
esbl
produc
escherichia
coli
klebsiella
icu
tertiari
care
cardiac
center
india
method
prospect
observ
casecontrol
studi
patient
conduct
august
juli
esbl
test
perform
phenotyp
confirmatori
disc
diffus
method
clinic
data
risk
factor
esbl
acquisit
analys
well
antimicrobi
therapi
clinic
microbiolog
outcom
studi
result
high
incid
esbl
produc
e
coli
klebsiella
observ
meropenem
imipenem
resist
esbl
produc
seen
multivari
analysi
logist
regress
central
venou
cathet
independ
risk
factor
esbl
acquisit
p
ci
median
icu
length
stay
day
day
esbl
nonesbl
group
respect
overal
mortal
two
group
respect
microbiolog
outcom
similar
clinic
outcom
microbiolog
success
rate
among
esbl
produc
conclus
esbl
produc
e
coli
klebsiella
problemat
pathogen
icu
emerg
carbapenem
resist
seriou
concern
stringent
infect
control
practic
asept
insert
proper
handl
central
line
within
icu
follow
introduct
antibiot
resist
pattern
continu
chang
new
problem
emerg
gramneg
bacteria
primarili
escherichia
coli
klebsiella
pneumonia
produc
extend
spectrum
enzym
esbl
antibiot
use
measur
presum
import
intervent
prevent
clonal
outbreak
risk
factor
esbl
includ
intens
antibiot
exposur
especi
thirdgener
cephalosporin
monotherapi
present
studi
perform
determin
impact
use
piperacillintazobactum
reduc
acquisit
rate
esbl
produc
gramneg
bacteria
icu
method
openlabel
prospect
studi
carri
adult
patient
admit
icu
period
month
divid
two
phase
phase
preintervent
phase
month
upon
admiss
icu
besid
standard
investig
addit
rectal
swab
cultur
taken
detect
esbl
within
hour
admiss
repeat
everi
day
stay
icu
routin
prescrib
antibiot
allow
phase
ii
intervent
phase
month
subdivid
first
month
month
piperacillintazobactum
primari
antibiot
use
replac
cephalosporin
b
last
month
month
rectal
swab
cultur
taken
piperacillintazobactum
primari
antibiot
use
mcnemar
test
fisher
exact
test
use
statist
analysi
result
eightyf
patient
phase
patient
phase
ii
enrol
thirdgener
cephalosporin
primari
antibiot
case
phase
case
phase
ii
p
incid
esbl
phase
came
intervent
phase
ii
p
conclus
data
intervent
studi
support
concept
thirdgener
cephalosporin
substanti
import
emerg
esbl
decreas
level
thirdgener
cephalosporin
use
increas
piperacillin
tazobactum
use
notabl
reduct
acquisit
rate
esbl
produc
e
coli
import
way
prevent
infect
icu
respect
asepsi
numer
invas
procedur
patient
expos
central
venou
cathet
urinari
cathet
orotrach
tube
ott
fibrobronchoscopi
fob
surgic
drainag
patient
nurs
surgic
medic
object
determin
incid
colon
infect
mrsa
critic
ill
patient
method
prospect
studi
month
patient
admit
icu
hour
throat
swab
tracheal
aspir
urin
taken
admiss
twice
weekli
colon
infect
mrsa
regist
infect
diagnos
accord
cdc
criteria
infect
classifi
base
throat
flora
primari
endogen
pe
caus
germ
alreadi
colon
throat
icu
admiss
secondari
endogen
se
caus
germ
colon
throat
icu
admiss
acquir
stay
icu
exogen
ex
caus
germ
colon
throat
infect
classifi
base
onset
moment
earli
onset
eo
develop
first
day
icu
stay
late
onset
lo
develop
day
icu
admiss
introduct
emerg
depart
ed
major
hospit
entranc
case
mix
consist
patient
high
risk
introduc
acquir
infect
alert
rise
hospitalacquir
mrsa
infect
ed
teach
hospit
set
ed
infect
control
ic
programm
programm
impact
discuss
method
campaign
consist
applianc
proactiv
mrsa
admiss
screen
protocol
select
contact
isol
quarantin
improv
hand
hygien
hh
mrsa
admiss
screen
strategi
took
account
past
medic
histori
actual
suspicion
mrsa
carriag
transfer
hospit
longterm
care
facil
admiss
hospitalis
patient
ed
upgrad
care
accord
critic
ill
statu
patient
subject
quarantin
improv
hh
achiev
promot
alcoholbas
hand
disinfect
refrain
health
care
worker
hcw
wear
hand
jewelleri
artifici
fingernail
suppli
hcw
clip
watch
develop
promot
materi
educ
hcw
regard
principl
techniqu
hh
provid
ic
depart
supervis
link
person
select
among
medic
nurs
domest
staff
number
new
hospitalacquir
mrsa
infect
per
admiss
record
complianc
hh
measur
observ
microbiolog
analysi
total
count
colonyform
unit
fingerprint
monitor
consumpt
handrub
solut
hh
moment
per
patientcar
day
result
select
mrsa
admiss
screen
polici
increas
carrier
detect
rate
compar
preoper
outpati
clinic
observ
complianc
hh
increas
consumpt
handrub
solut
l
per
patientday
number
hh
moment
increas
total
count
colonyform
unit
less
improv
analys
concomitantli
decreas
mrsa
attack
rate
six
one
new
case
per
patientday
seen
conclus
ed
tailor
select
mrsa
screen
contact
isol
protocol
chang
hh
behaviour
ed
mainli
contribut
decreas
mrsa
attack
rate
hospit
far
nation
rate
introduct
candida
airway
colon
common
mechan
ventil
icu
patient
signific
impact
outcom
well
defin
aim
describ
candida
airway
colon
assess
clinic
outcom
patient
clinic
suspicion
ventilatorassoci
pneumonia
vap
colon
candida
method
retrospect
posthoc
analysi
prospect
multicentr
vap
studi
enrol
patient
clinic
suspicion
vap
admit
icu
hour
mechan
ventil
mv
hour
airway
cultur
done
random
patient
posit
candida
cultur
site
exclud
remain
patient
divid
two
group
accord
candida
airway
cultur
statu
demograph
admiss
diagnosi
comorbid
pao
fio
ratio
apach
ii
score
record
random
length
mv
icu
hospit
stay
compar
well
hospit
icu
mortal
appropri
parametr
statist
test
appli
accord
data
result
patient
enrol
vap
studi
includ
analysi
candida
airway
colon
c
nc
signific
differ
note
demograph
apach
ii
score
vs
p
except
frequent
admiss
sepsi
vs
p
respiratori
condit
vs
p
group
c
colon
patient
antibiot
random
vs
p
trend
increas
icu
vs
p
mortal
vs
p
signific
differ
hospit
mortal
vs
p
observ
group
c
trend
found
increas
median
length
icu
stay
vs
day
p
durat
mv
vs
p
hospit
stay
significantli
longer
vs
day
p
group
c
conclus
respiratori
tract
candida
colon
patient
clinic
suspicion
vap
associ
increas
burden
ill
whether
candida
colon
respons
wors
outcom
remain
establish
introduct
candida
spp
third
common
reason
sepsi
icu
differenti
result
classic
pattern
icuacquir
infect
prevent
sepsi
develop
identif
potenti
modifi
risk
factor
import
goal
intens
care
patent
preemptiv
treatment
candida
sepsi
accept
author
defin
earli
antifung
treatment
given
patient
evid
substanti
colon
presenc
multipl
risk
factor
candida
infect
prior
establish
diagnosi
cultur
aim
form
focus
group
patient
signific
risk
candida
sepsi
prove
feasibl
efficaci
preemptiv
scheme
antimycot
treatment
order
reduc
risk
develop
prove
candida
sepsi
method
period
studi
perform
gener
icu
divid
two
phase
casecontrol
retrospect
studi
control
compris
repres
subpopul
sever
bacteri
sepsi
compar
case
patient
candida
sepsi
respect
multipl
demograph
clinic
factor
univari
analysi
prospect
phase
creat
preemptiv
scheme
base
result
retrospect
part
follow
progress
implement
among
target
patient
result
identifi
case
candida
sepsi
control
sever
bacteri
sepsi
allcaus
mortal
rate
mortal
rate
candida
sepsi
attribut
risk
associ
wors
score
system
injuri
sap
ii
compar
mortal
rate
sap
ii
bacteri
sepsi
candida
sepsi
alway
accompani
concurr
bacteri
sepsi
microorganismspati
isol
blood
cultur
identifi
risk
factor
great
signific
addit
alreadi
known
one
candida
colon
diabet
number
antibiot
use
noth
per
os
regimen
icu
length
stay
length
antibiot
use
pancreat
shock
admiss
ventil
daysicu
stay
ratio
day
multipl
resist
bacteri
strain
patient
gastrointestin
surgeri
risk
develop
earli
fungal
sepsi
day
admissioncompar
clinic
case
day
admiss
incid
rate
posit
blood
cultur
candida
group
expos
scheme
calcul
vs
control
group
conclus
base
result
accept
algorithm
perform
preemptiv
therapi
observ
clinic
efficaci
consid
indic
follow
target
group
patient
presenc
clinic
featur
unresolv
sepsi
plu
three
defin
risk
factor
ppv
patient
length
icu
stay
day
lack
clinic
improv
combin
antibiot
treatment
establish
bacteri
strain
evid
sepsi
accompani
multifoc
candida
colon
steril
bodi
space
candida
colon
without
risk
factor
requir
continu
monitor
import
presumpt
accept
preemptiv
strategi
certain
patient
seriou
clinic
convict
invas
fungal
infect
still
pend
prove
aim
studi
evalu
incid
candida
colon
cardiac
surgic
icu
predispos
risk
factor
impact
candidemia
outcom
method
effort
answer
question
prospect
studi
conduct
among
patient
admit
cardiac
surgic
intens
care
unit
icu
decemb
octob
candida
colon
candidemia
identifi
fungal
colon
defin
colon
index
exceed
g
least
two
sampl
seven
grow
candida
spp
candidemia
defin
isol
candida
spp
least
one
blood
cultur
patient
tempor
relat
clinic
sign
demograph
characterist
patient
develop
candidemia
well
underli
diseas
comorbid
record
result
period
critic
ill
patient
evalu
candida
spp
isol
site
patient
patient
present
icuacquir
candidemia
hospit
day
rang
day
icu
expos
broadspectrum
antibiot
agent
mean
age
year
rang
year
mean
icu
stay
day
candidemia
appear
mean
day
icu
admiss
candida
albican
common
isol
pathogen
candiduria
count
detect
patient
none
experienc
candidemia
seven
patient
candida
isol
urin
respiratori
tract
six
patient
major
postop
complic
mortal
due
candidemia
patient
receiv
appropri
antifung
treatment
prophylact
antifung
treatment
use
patient
multifoc
colon
patient
spend
day
icu
cardiac
surgeri
conclus
c
albican
common
fungal
pathogen
icu
seven
percent
colon
patient
develop
candidemia
major
postop
complic
excess
antibiot
exposur
acut
renal
failur
seem
predispos
develop
candidemia
patient
candidemia
high
inhospit
mortal
perhap
reflect
ill
sever
object
evalu
util
pattern
outcom
associ
iv
fluconazol
therapi
within
icu
spain
germani
method
prospect
longitudin
observ
studi
conduct
within
hospit
icu
spain
five
germani
patient
iv
fluconazol
therapi
includ
follow
one
hospit
period
admiss
discharg
data
collect
use
electron
case
report
form
data
includ
patient
diseas
characterist
patient
risk
statu
apach
score
type
fluconazol
therapi
drugrel
advers
event
length
fluconazol
therapi
length
hospit
stay
switch
fluconazol
therapi
dose
chang
addit
concomit
antifung
therapi
overal
mortal
clinic
outcom
also
evalu
logist
regress
model
determin
univari
multivari
associ
mortal
result
total
patient
enrol
fluconazol
use
initi
prophylaxi
patient
preemptiv
therapi
patient
empir
therapi
patient
definit
therapi
patient
thirtysix
patient
switch
fluconazol
broader
spectrum
antifung
agent
seven
receiv
second
concomit
antifung
drug
reason
switch
therapi
includ
lack
respons
due
suspect
resist
document
resist
clinic
reason
resist
thirtytwo
patient
experienc
fluconazolerel
advers
event
overal
studi
mortal
rate
patient
mortal
significantli
associ
switch
iv
treatment
odd
ratio
ci
presenc
advers
event
odd
ratio
ci
conclus
observ
natur
studi
preclud
establish
causal
research
mere
document
experi
icu
patient
prescrib
iv
fluconazol
therapi
result
show
high
mortal
rate
enrol
icu
patient
patient
develop
advers
event
complic
requir
switch
fluconazol
experienc
wors
outcom
introduct
toxoplasma
gondii
worldwidedistribut
parasit
could
caus
opportunist
infect
high
mortal
immunosuppress
individu
associ
sever
manifest
immunosuppress
known
sever
decad
occurr
enceph
dissemin
diseas
sinc
observ
differ
clinic
condit
lymphoreticular
neoplasia
solid
organ
transplant
mainli
patient
aid
knowledg
toxoplasmosi
seroposit
rate
icu
patient
critic
ill
induc
immunosuppress
yet
investig
studi
seroposit
incid
gondii
icu
patient
assess
igg
igm
antibodi
materi
method
one
hundr
three
icu
patient
mean
age
year
men
women
healthi
volunt
mean
age
year
men
women
control
group
includ
studi
antit
gondii
igg
igm
antibodi
determin
elisa
statist
analys
done
chisquar
test
kolmogorovsmirnov
onesampl
test
p
consid
statist
signific
result
gondii
igg
antibodi
posit
icu
patient
n
healthi
volunt
n
p
igm
antibodi
posit
icu
patient
n
healthi
volunt
n
howev
differ
could
reach
statist
signific
increas
mortal
cmv
patient
although
cmv
diseas
occur
strike
differ
group
respect
period
ventil
day
vs
day
median
cmv
cmvpatient
respect
p
similarli
cmv
patient
longer
median
lo
enrol
either
icu
day
vs
day
p
hospit
day
vs
day
p
differ
assur
analysi
restrict
survivor
conclus
data
suggest
cmv
reactiv
lead
increas
morbid
treatment
expenditur
independ
cmv
diseas
analysi
point
crucial
role
lung
patholog
due
cmv
reactiv
introduct
polymyxin
b
immobil
fiber
column
pmx
toray
industri
inc
tokyo
japan
develop
japan
use
treatment
endotoxemia
septic
shock
patient
materi
method
patient
receiv
urgent
oper
due
intraabdomin
infect
case
treat
polymyxin
b
immobil
column
direct
hemoperfus
pmxdhp
chang
hemodynam
pulmonari
oxygen
pao
fio
variou
mediat
ilra
plasminogen
activ
inhibitor
examin
pmxdhp
stratifi
outcom
survivor
die
pmxdhp
perform
doubl
lumen
cathet
fr
place
femor
vein
intern
jugular
vein
blood
flow
rate
mlmin
use
nafamostat
mesil
anticoagul
hour
result
pmxdhp
significantli
increas
system
arteri
pressur
mean
arteri
pressur
greater
increas
surviv
group
also
appear
trend
pao
fio
improv
blood
pressur
increas
mechan
improv
pulmonari
oxygen
pmxdhp
shown
clearli
remain
examin
valu
significantli
decreas
survivor
group
ngml
immedi
pmxdhp
also
intracellular
adhes
endotheli
leukocyt
adhes
tend
decreas
group
discuss
elev
endotoxin
thrombin
cytokin
indic
vascular
endotheli
cell
activ
septic
dissmin
intravascular
coagul
gramneg
bacilli
massiv
amount
produc
vascular
endotheli
cell
along
elev
cytokin
product
coagul
activ
addit
one
fibrinolysi
inhibitori
factor
play
import
role
regul
fibrinolysi
inhibit
tissu
plasminogen
activ
convert
plasminogen
activ
plasmin
fibrin
block
unnecessari
fibrinolysi
conclus
determin
may
use
clinic
paramet
predict
pmxdhp
efficaci
mechan
effect
polymyxin
bimmobil
fiber
column
remov
mediat
glycerol
anandamid
protein
c
septic
shock
patient
introduct
septic
shock
remain
major
caus
multipl
organ
failur
high
mortal
rate
remov
endotoxin
patient
plasma
direct
hemoperfus
dhp
use
polymyxin
bimmobil
fiber
column
pmx
toray
industri
inc
tokyo
japan
develop
japan
sinc
use
treatment
septic
shock
precis
role
pmx
clear
treat
septic
shock
patient
use
dhppmx
patient
separ
two
group
analysi
whose
systol
blood
pressur
sbp
increas
mmhg
immedi
dhppmx
case
whose
sbp
increas
mmhg
dhppmx
case
furthermor
patient
separ
two
group
analysi
whose
pf
ratio
increas
immedi
dhppmx
case
whose
pf
ratio
increas
dhppmx
case
mediat
measur
four
point
dhppmx
day
day
afterward
patient
group
consist
male
femal
year
old
averag
apach
ii
score
averag
sofa
score
dhppmx
nineteen
patient
surviv
eight
die
chang
protein
c
atiii
high
mobil
group
box
protein
compar
group
level
improv
significantli
sbp
increas
group
p
sbp
increas
significantli
dhppmx
group
p
improv
pf
ratio
reduct
glycerol
dhppmx
significantli
correl
p
conclus
show
circul
dynam
septic
shock
patient
improv
reduc
level
respiratori
function
improv
reduc
glycerol
level
use
dhppmx
character
coupl
plasma
filtrationadsorpt
resin
cartridg
adsorpt
capac
cytokin
inflammatori
mediat
adsorpt
profil
septic
patient
plasma
vitro
endotoxinstimul
whole
blood
vitro
experi
includ
static
dynam
evalu
resin
bind
whole
human
blood
stimul
endotoxin
hour
addit
ad
cytokin
toxin
evalu
static
condit
ml
plasma
ml
resin
incub
hour
aliquot
withdrawn
hour
cytokin
inflammatori
mediat
toxin
adsorpt
determin
standard
elisa
multianalyt
protein
array
hplc
diod
array
adsorpt
spectroscopi
dynam
condit
involv
defin
optim
linear
veloc
evalu
adsorpt
capac
flow
condit
experi
use
close
circuit
consist
plasma
filter
resin
cartridg
sampl
taken
blood
port
immedi
plasma
cartridg
addit
serum
precartridg
postcartridg
plasma
sampl
also
taken
septic
patient
undergo
cpfa
result
endotoxinstimul
blood
sampl
septic
patient
high
level
cytokin
inflammatori
mediat
resin
use
cpfa
adsorpt
cartridg
show
higher
adsorpt
static
dynam
condit
mcp
myoglobin
appear
particularli
adsorb
cartridg
sever
septic
patient
great
variabl
often
high
level
rang
normal
level
pgml
pgml
mean
patient
treat
cpfa
pgml
postsess
pgml
plasma
level
cartridg
rang
pgml
pgml
postcartridg
level
level
detect
conclus
resin
cpfa
high
adsorpt
capac
sever
cytokin
mediat
involv
sever
sepsi
septic
shock
studi
current
ongo
correl
cytokin
reduct
clinic
relev
improv
patient
method
twentyfour
patient
septic
shock
induc
periton
underw
laparotomi
drainag
endocannabinoid
absorpt
pmxdhp
examin
two
group
patient
patient
systol
arteri
bp
increas
mmhg
bp
elev
group
n
patient
bp
increas
increas
mmhg
bp
constant
group
n
result
level
aea
chang
pmxdhp
either
bp
constant
group
bp
elev
group
wherea
level
decreas
significantli
pmxdhp
bp
elev
group
bp
constant
group
figur
gradual
increas
pmxdhp
hand
level
remain
constant
bp
elev
group
figur
patient
septic
shock
consider
oxid
stress
play
import
role
cardiovascular
statu
patient
remov
pmxdhp
benefit
patient
septic
shock
stabil
cardiovascular
statu
decreas
longterm
oxid
stress
examin
relationship
proinflammatori
cytokin
adipocytederiv
adiponectin
hyperglycemia
patient
requir
long
period
icu
rel
high
mortal
tight
glucos
control
insulin
infus
shown
improv
surviv
prevent
complic
method
prospect
observ
studi
academ
icu
sequenti
sampl
taken
period
ethic
approv
obtain
univers
ethic
committe
avail
onlin
http
baselin
blood
adiponectin
adipo
total
cholesterol
tc
triglycerid
tg
insulin
cpeptid
cpep
cortisol
cort
collect
admiss
repeat
day
day
discharg
dc
routin
blood
order
also
use
data
icu
chart
also
use
chang
icu
protocol
requir
note
insulin
infus
start
blood
glucos
concentr
greater
mmoll
exclus
criteria
includ
patient
diabet
mellitu
chronic
renal
failur
liver
failur
cirrhosi
result
forti
patient
admit
icu
enrol
follow
discharg
median
age
year
minimum
maximum
median
apach
ii
score
minimum
maximum
median
durat
day
minimum
maximum
dc
glucos
concentr
differ
kruskalw
anova
p
peak
pgml
start
decreas
administ
insulin
insad
accompani
peak
decreas
adipo
peak
pgml
peak
coincid
decreas
pgml
endogen
insulin
indic
cpep
peak
adipo
tg
level
increas
parallel
increas
mmoll
mmoll
declin
tc
lowest
increas
dc
remain
rel
low
tabl
show
sever
variabl
chang
time
admiss
discharg
tabl
show
correl
variabl
survivor
lower
median
tnf
nonsurvivor
mannwhitney
u
test
p
conclus
tnf
contribut
increas
insulin
need
tnf
known
caus
insulin
resist
shown
tnf
correl
invers
adipo
adipo
increas
insulin
need
decreas
invers
correl
insad
also
tnf
contribut
increas
tg
indic
increas
free
fatti
acid
ffa
lipolysi
impair
glucos
clearanc
adipo
insulin
sensit
protein
known
neg
regul
tnf
level
indic
studi
adipo
contribut
decreas
tg
indic
lower
ffa
better
glucos
clearanc
dc
also
contribut
higher
glucos
concentr
dc
increas
age
contribut
lower
adipo
level
dc
indic
lower
insulin
sensit
higher
bmi
contribut
higher
glucos
level
increas
insulin
need
final
higher
tnf
level
appear
relat
increas
mortal
object
aim
studi
investig
effect
octreotid
differ
dose
reduc
hypoglycem
attack
need
dextros
treatment
refractori
recurr
hypoglycemia
relat
toxic
sulfonylurea
method
studi
new
zealand
type
rabbit
use
weigh
g
rabbit
randomli
divid
four
group
consist
anim
anim
given
gliclazid
mg
oral
treatment
hypoglycem
attack
group
cm
dextros
g
intraven
iv
use
group
ii
group
iii
group
iv
octreotid
singl
dose
use
subcutan
respect
octreotid
given
group
ii
iii
group
iv
eighth
hour
hypoglycem
attack
onset
group
ii
iii
iv
given
addit
cm
dextros
g
iv
infus
hypoglycem
attack
develop
follow
toxic
dose
anim
given
amount
dextros
use
octreotid
administr
number
hypoglycem
attack
record
result
signific
differ
group
ii
iv
number
hypoglycem
attack
number
dextros
requir
hour
p
group
receiv
octreotid
show
less
hypoglycem
attack
dextros
requir
control
conclus
experi
suggest
octreotid
may
use
reduc
number
refractori
recurr
hypoglycem
attack
develop
due
overdos
sulfonylurea
larg
prospect
studi
would
need
valid
find
introduct
acut
hyperglycemia
insulin
resist
characterist
metabol
endocrin
imbal
critic
ill
patient
subject
substanti
inflammatori
respons
partli
mediat
cytokin
produc
peripher
blood
mononuclear
cell
pbmc
treatment
intens
insulin
therapi
keep
patient
normoglycem
shown
reduc
inflammatori
respons
unclear
whether
hyperglycemia
insulin
osmolar
chang
exert
direct
effect
proinflammatori
cytokin
investig
direct
effect
substanc
cytokin
product
pbmc
vitro
method
pbmc
isol
peripher
blood
healthi
volunt
via
ficol
gradient
cell
incub
hour
withwithout
lowhigh
concentr
glucos
mannitol
urea
insulin
stimul
ngml
lp
hour
concentr
measur
elisa
method
result
increas
concentr
glucos
mannitol
urea
result
signific
increas
cytokin
product
insulin
effect
tabl
conclus
high
concentr
glucos
mannitol
urea
lead
signific
increas
cytokin
product
pbmc
vitro
profound
effect
seen
hyperglycemia
besid
hyperglycemia
also
uremia
high
osmolar
seem
augment
inflamm
insulin
could
revers
increas
inflamm
find
may
relev
explain
benefici
effect
normoglycemia
inflammatori
respons
critic
ill
patient
insulin
therapi
inhibit
poli
adpribos
polymeras
activ
endotoxin
shock
nuclear
enzym
poli
adpribos
polymeras
parp
activ
variou
form
circulatori
shock
trigger
cellular
energet
dysfunct
promot
proinflammatori
gene
express
parp
activ
significantli
contribut
pathogenesi
shock
activ
parp
usual
trigger
dna
strand
breakag
typic
result
overproduct
reactiv
oxid
speci
present
studi
test
whether
endotoxininduc
parp
activ
proinflammatori
mediat
product
modifi
insulin
therapi
rat
subject
bacteri
lipopolysaccharid
lp
without
insulin
pretreat
studi
lpsinduc
parp
activ
circul
leukocyt
measur
flow
cytometri
product
measur
elisa
lp
induc
signific
hyperglycem
respons
activ
parp
circul
leukocyt
induc
product
insulin
treatment
prevent
lpsinduc
hyperglycem
respons
block
activ
parp
blunt
lpsinduc
respons
hyperglycemia
known
induc
cellular
format
reactiv
speci
propos
parp
activ
endotoxin
shock
occur
result
hyperglycemiainduc
reactiv
oxid
free
radic
gener
current
find
may
signific
implic
context
emerg
concept
tight
glycem
control
critic
ill
patient
influenc
diabet
cours
outcom
sepsi
intens
care
unit
hdl
signific
differ
group
mortal
rate
ldl
hdl
neg
correl
organ
function
among
nonsurvivor
conclus
target
blood
glucos
level
mgdl
insulin
therapi
prevent
morbid
probabl
due
better
control
lipid
metabol
express
rapid
serum
ldl
normal
avoid
greater
decreas
serum
hdl
level
first
hour
septic
shock
effect
intens
insulin
therapi
coagul
fibrinolysi
respiratori
critic
ill
patient
intens
care
death
beyond
first
day
critic
ill
attribut
nonresolv
multipl
organ
failur
mof
either
due
coincid
sepsi
one
mechan
thought
contribut
pathogenesi
mof
microvascular
thrombosi
recent
report
improv
surviv
prevent
mof
critic
ill
patient
use
intens
insulin
therapi
maintain
normoglycemia
least
sever
day
hypothes
intens
insulin
therapi
also
prevent
sever
coagul
abnorm
therebi
contribut
less
organ
failur
better
surviv
studi
subgroup
longstay
critic
ill
patient
respiratori
diseas
upon
icu
admiss
enrol
random
control
trial
evalu
impact
intens
insulin
therapi
medic
icu
patient
plasma
sampl
analyz
panel
coagul
marker
prothrombin
time
activ
partial
thromboplastin
time
fibrinogen
ddimer
level
use
assign
point
toward
intern
societi
thrombosi
haemostasi
overt
dissemin
intravascular
coagul
dic
score
circul
plasma
thrombinantithrombin
complex
plasminogen
inhibitor
type
level
also
determin
marker
inflamm
measur
circul
serum
level
sever
cytokin
crp
mortal
intens
insulintr
patient
lower
convent
treat
patient
class
uponadmiss
dic
score
except
patient
dic
score
higher
effect
insulin
therapi
fibrinolyt
coagul
inflammatori
paramet
test
accuraci
dic
score
predict
mortal
patient
sampl
moder
compar
crp
sofa
score
also
circul
plasminogen
inhibitor
type
thrombinantithrombin
complex
level
correl
well
mortal
dic
score
find
indic
coagul
system
play
key
role
mediat
surviv
benefit
intens
insulin
therapi
introduct
intens
insulin
therapi
reduc
morbid
mortal
postop
critic
care
howev
treatment
also
increas
risk
hypoglycemia
possibl
caus
unstabl
blood
glucos
bg
level
could
variabl
adsorpt
insulin
plastic
materi
infus
tube
evalu
vitro
vivo
adsorpt
insulin
standard
tube
materi
polyethylen
pe
polyurethan
pu
effect
adsorpt
process
blood
glucos
level
method
vitro
standard
perfusor
syring
perfusor
bbraun
germani
fill
ie
normal
insulin
actrapid
novonordisk
germani
dissolv
ml
salin
syring
connect
pe
pu
tube
bbraun
infus
rate
mlhour
insulin
concentr
syring
end
tube
measur
hourli
interv
hour
hour
bradford
protein
assay
insulin
concentr
compar
use
student
test
prospect
doubleblind
crossov
studi
approv
ethic
committe
patient
surgic
icu
receiv
insulin
via
pe
pu
tube
hour
random
sequenc
blood
bg
valu
total
infus
insulin
solut
volum
critic
care
score
document
statist
analys
wilcoxon
test
result
insulin
concentr
syring
alway
estim
valu
initi
concentr
insulin
end
pe
pu
tube
lower
expect
anticip
concentr
first
min
pe
concentr
rose
pu
hour
p
vivo
mean
bg
valu
differ
pe
pu
pe
mgdl
pu
mgdl
signific
sever
ill
differ
group
tiss
pe
vs
pu
sap
pe
vs
pu
day
neither
catecholamin
dose
fluid
balanc
howev
significantli
insulin
solut
infus
pe
ml
hour
compar
pu
hour
p
conclus
infus
insulin
use
pe
pu
tube
lead
relev
adsorpt
drug
materi
adsorpt
pe
significantli
higher
compar
pu
thu
larg
variat
insulin
applic
patient
possibl
differ
tube
materi
use
furthermor
variabl
adsorpt
competit
adsorpt
drug
insulin
infus
via
singl
line
well
chang
effect
insulin
applic
follow
routin
chang
tube
may
one
caus
unexpect
hypoglycemia
deleteri
patient
introduct
hyperglycemia
critic
ill
patient
frequent
relat
hypermetabol
stressrespons
associ
increas
morbid
mortal
aim
studi
assess
relationship
blood
glucos
level
clinic
outcom
mix
cohort
critic
ill
patient
nosocomi
bloodstream
infect
bsi
method
retrospect
observ
cohort
studi
conduct
includ
adult
patient
microbiolog
document
bsi
admit
period
icu
blood
glucos
level
evalu
day
prior
onset
bsi
day
onset
bsi
contribut
hyperglycemia
divid
three
subgroup
mgdl
mgdl
mgdl
respect
inhospit
mortal
estim
logist
regress
mean
age
studi
popul
year
inhospit
mortal
hyperglycemia
mgdl
mgdl
observ
often
among
nonsurvivor
seven
studi
day
differ
found
daili
morn
blood
glucos
level
survivor
n
nonsurvivor
n
p
although
nonsurvivor
evolut
glycemia
tend
higher
trend
statist
signific
compar
survivor
multivari
logist
regress
reveal
age
p
apach
ii
score
p
antibiot
resist
p
hyperglycemia
mgdl
upon
onset
bsi
p
independ
associ
inhospit
mortal
wherea
appropri
antimicrobi
therapi
hour
p
previou
histori
diabet
p
associ
better
outcom
conclus
trend
blood
glucos
level
higher
among
nonsurvivor
hyperglycemia
mgdl
upon
onset
nosocomi
bsi
advers
affect
outcom
heterogen
icu
popul
system
autom
discontinu
venou
blood
withdraw
glucos
determin
patient
intens
care
unit
high
workload
perform
staff
henc
usag
autom
discontinu
venou
blood
sampl
system
might
altern
improv
adjust
insulin
therapi
primari
aim
studi
investig
whether
glucos
concentr
manual
withdrawn
blood
sampl
correl
autom
withdrawn
blood
sampl
method
trial
six
volunt
investig
male
femal
age
year
bmi
nondiabet
g
ogtt
perform
enabl
better
dynam
rang
glucos
valu
two
venou
cannula
insert
dorsal
hand
refer
measur
connect
autom
blood
sampl
system
reduc
volunt
health
risk
pressur
air
bubbl
sensor
flush
fluid
monitor
integr
system
blood
sampl
obtain
frequent
interv
roch
microsampl
omni
glucos
analys
use
determin
blood
read
autom
blood
sampl
system
perform
oper
volunt
whole
trial
period
median
pearson
coeffici
correl
manual
autom
withdrawn
blood
furthermor
result
data
pair
analys
via
recent
publish
insulin
titrat
error
grid
analysi
suggest
accept
treatment
result
tradit
error
grid
analysi
show
data
zone
zone
b
conclus
autom
discontinu
blood
withdraw
system
provid
reproduc
blood
sampl
peripher
venou
blood
combin
glucos
sensor
algorithm
might
use
futur
close
loop
system
insulin
glucos
infus
icu
introduct
propos
intens
insulin
therapi
iit
aim
blood
glucos
bg
mmoll
reduc
mortal
critic
ill
patient
compar
convent
insulin
therapi
cit
target
bg
mmoll
difficulti
iit
includ
inadvert
hypoglycaemia
low
efficaci
achiev
target
bg
propos
computeris
decis
support
may
mitig
problem
object
comprehens
describ
bg
outcom
decisionsupport
iit
method
clinic
inform
system
bedspac
guid
staff
iit
algorithm
time
spent
within
glucos
rang
calcul
assum
linear
trend
success
measur
result
patient
characterist
shown
tabl
iit
group
frequent
bg
evalu
patienthour
testshour
cit
group
hour
testshour
median
interquartil
rang
iqr
proport
time
spent
target
rang
mmoll
similar
iit
cit
group
vs
respect
p
similarli
time
spent
bg
mmoll
differ
two
group
iqr
iit
iqr
p
iit
cit
group
five
six
patient
experienc
bg
mmoll
respect
discuss
computeris
decisionsupport
intens
monitor
improv
bg
control
reduc
incid
hypoglycaemia
introduct
object
studi
determin
efficaci
safeti
subcutan
sc
oncedaili
od
glargin
insulin
longact
insulin
comparison
sc
regular
insulin
base
protocol
slide
scale
regimen
achiev
glycem
control
patient
admit
icu
method
one
hundr
patient
admit
icu
admiss
capillari
blood
glucos
cbg
mgdl
mmoll
involv
prospect
random
studi
patient
age
year
pregnanc
shock
requir
continu
intraven
insulin
infus
renal
failur
exclud
patient
randomli
assign
receiv
either
sc
glargin
insulin
u
cbg
mmoll
u
cbg
mmoll
sc
od
group
g
n
sc
regular
insulin
base
slide
scale
group
r
n
cbg
record
interv
hour
icu
discharg
whichev
earlier
target
cbg
group
mgdl
mmoll
patient
group
g
receiv
rescu
dose
regular
insulin
requir
demograph
characterist
mean
median
cbg
episod
hypoglycemia
studi
result
demograph
profil
compar
two
group
signific
differ
mean
cbg
group
group
g
mgdl
mmoll
group
r
mgdl
mmoll
p
median
cbg
compar
time
point
group
except
hour
glargin
arm
cbg
hour
group
g
mmoll
median
capillari
blood
glucos
cbg
differ
time
point
mmoll
group
r
mmoll
mmoll
p
respect
figur
three
episod
hypoglycemia
group
g
one
group
r
correct
conclus
od
sc
glargin
insulin
safe
effect
altern
regular
insulin
glycem
control
critic
ill
patient
investig
insulin
clearanc
sever
acut
ill
patient
glucos
intoler
evalu
mean
bedsidetyp
artifici
pancrea
background
purpos
glucos
intoler
acut
ill
patient
one
risk
factor
morbid
mortal
glucos
control
insulin
therapi
improv
outcom
investig
relationship
among
insulin
clearanc
ic
consid
one
factor
relat
effect
insulin
therapi
glucos
toler
glucos
intoler
sever
diseas
order
clarifi
signific
ic
sever
diseas
includ
glucos
intoler
therapi
materi
method
twentythre
icu
patient
glucos
intoler
strict
blood
glucos
control
perform
mean
bedsidetyp
artifici
pancrea
nikkiso
corp
japan
investig
diabet
exclud
item
investig
ic
mlkgmin
measur
glucos
clamp
method
daili
mean
blood
glucos
level
paramet
glucos
intoler
bgm
mgdl
proport
septic
patient
sofa
score
mortal
indic
sever
diseas
blood
concentr
free
fatti
acid
ffa
stress
hormon
glucagon
growth
hormon
cortisol
adrenalin
noradrenalin
factor
might
affect
glucos
intoler
method
investig
involv
patient
classifi
four
group
accord
ic
group
compar
low
ic
group
group
l
ic
n
normal
ic
group
group
n
ic
n
high
ic
group
group
h
ic
n
sever
high
ic
group
group
ic
n
group
subgroup
group
h
result
ffa
valu
low
normal
group
signific
differ
stress
hormon
among
group
n
group
h
group
hormon
group
l
significantli
higher
tendenc
higher
group
n
group
h
group
mean
valu
bgm
group
tendenc
higher
order
group
group
h
group
n
group
l
sever
diseas
sepsi
sofa
scoremort
group
significantli
higher
order
group
l
group
group
h
group
n
increas
ic
relat
glucos
intoler
ic
increas
glucos
intoler
becam
sever
sever
diseas
progress
sever
state
neartermin
state
howev
ic
decreas
glucos
intoler
improv
although
stress
hormon
increas
significantli
therapi
focus
improv
ic
consid
import
acut
ill
sever
patient
glucos
intoler
well
blood
glucos
control
insulin
therapi
result
compar
glucos
valu
collect
time
consecut
patient
valu
lower
remain
valu
mean
sd
mgdl
n
vs
mgdl
n
p
hypothes
smaller
varianc
f
test
p
inspect
timeaverag
data
reveal
diurnal
variat
blood
glucos
peak
occur
pm
figur
diurnal
pattern
may
account
observ
variat
insulin
requir
contribut
episod
hypoglycemia
critic
ill
conclus
glucos
varianc
increas
time
valu
consid
rather
singl
time
point
diurnal
pattern
glucos
icu
patient
receiv
insulin
consider
diurnal
variat
treat
hyperglycemia
icu
may
avoid
hypoglycemia
facilit
better
glucos
control
insulin
infus
avail
onlin
http
introduct
tight
glycem
control
reduc
mortal
surgic
intens
care
patient
longterm
medic
intens
care
patient
incid
sever
hypoglycaemia
glucos
mmoll
intens
treatment
group
recent
larg
studi
intens
insulin
therapi
prematur
discontinu
due
safeti
issu
incid
hypoglycaemia
intens
treatment
group
mortal
among
patient
experienc
hypoglycaemia
safeti
intens
insulin
therapi
question
screen
patient
period
see
incid
hypoglycaemia
effect
prognosi
patient
method
retrospect
studi
perform
two
icu
one
eightb
gener
icu
one
surgic
icu
patient
treat
februari
june
includ
studi
nursedriven
intens
insulin
protocol
target
blood
glucos
level
mmoll
introduc
blood
glucos
measur
perform
icu
treatment
analys
patient
divid
two
group
accord
lowest
detect
blood
glucos
valu
mmoll
result
total
patient
treatment
period
includ
studi
thirti
patient
exclud
due
incomplet
data
studi
period
blood
glucos
measur
perform
target
valu
mmoll
sever
hypoglycaemia
mmoll
occur
patient
measur
incid
measur
patient
median
age
sex
apach
ii
score
sap
ii
diagnosi
categori
differ
group
median
iqr
icu
hospit
length
stay
day
patient
lowest
blood
glucos
day
patient
lowest
blood
glucos
p
p
respect
hospit
mortal
respect
differ
statist
signific
introduct
insulin
resist
hyperglycemia
common
critic
ill
patient
associ
higher
morbid
mortal
patient
control
intens
insulin
therapi
shown
reduc
morbid
mortal
clear
howev
whether
patient
indic
admiss
icu
relat
time
achiev
glycaem
control
total
dose
insulin
requir
studi
design
audit
efficaci
intens
insulin
therapi
protocol
achiev
glycaem
control
patient
present
differ
condit
method
prospect
observ
studi
perform
week
patient
admit
adult
icu
receiv
nutrit
support
hour
intens
insulin
therapi
administ
patient
develop
hyperglycemia
demograph
blood
glucos
insulin
dose
document
haemoglobin
white
cell
count
neutrophil
count
antioxid
crp
prealbumin
measur
outcom
measur
mean
total
insulin
dose
time
achiev
glycaem
control
result
forti
patient
male
femal
receiv
nutrit
support
hour
studi
mean
sd
age
year
enter
feed
given
parenter
feed
patient
six
patient
receiv
enter
parenter
feed
mean
sd
energi
hour
kcal
mean
sd
insulin
iu
mean
sd
blood
glucos
mmoldl
total
insulin
achiev
glycaem
control
iu
time
taken
sd
achiev
glycaem
control
hour
expect
relationship
total
insulin
dose
time
achiev
three
consecut
glycaem
control
r
p
also
total
insulin
dose
mean
blood
glucos
r
p
signific
relationship
total
insulin
dose
indic
icu
admiss
total
insulin
dose
bodi
mass
index
conclus
find
studi
show
indic
admiss
affect
either
total
dose
insulin
requir
achiev
glycaem
control
time
take
achiev
three
consecut
glycaem
control
introduct
glycaem
control
anoth
exampl
protocoldriven
therapi
intens
care
medicin
improv
outcom
critic
ill
patient
advantag
approach
seem
obviou
littl
known
problem
implement
protocol
intent
studi
evalu
problem
implement
develop
strategi
overcom
set
surgic
icu
univers
teach
hospit
critic
care
nurs
parttim
employ
method
period
patient
stay
longer
hour
icu
hyperglycaemia
mg
three
consecut
measur
includ
studi
patient
treat
accord
protocol
discret
attend
nurs
daili
round
everi
week
supervis
perform
protocol
modifi
three
time
period
accord
staff
comment
medic
well
nonmed
problem
implement
analys
discuss
attitud
perceiv
imped
aspect
implement
process
record
mean
questionnair
sinc
insulin
sensit
show
enorm
variabl
glycaem
control
requir
high
nurs
effort
imped
aspect
titrat
blood
glucos
target
rang
absenc
nutrit
protocol
high
carbohydr
intak
despit
inflammationinfect
lead
hyperglycaemia
difficult
control
fear
hypoglycaemia
mg
lead
lowdos
insulin
consecut
hyperglycaemia
lack
commun
therefor
loss
inform
critic
care
nurs
intensivist
poor
accept
physician
leav
field
intens
care
medicin
nurs
addit
factor
slow
implement
process
conclus
implement
protocoldriven
medicin
requir
high
qualiti
inform
flow
lack
linear
blood
glucos
insulin
dose
variabl
insulin
sensit
requir
sometim
intuit
experienc
decis
titrat
insulin
dose
conflict
physician
new
role
critic
care
nurs
might
due
lack
understand
evolut
nurs
profess
introduct
tight
blood
glucos
bg
control
shown
decreas
morbid
mortal
patient
surgic
icu
difficult
achiev
use
standard
insulin
infus
protocol
previous
evalu
softwar
model
predict
control
mpc
insulin
administr
algorithm
postcardiac
surgeri
patient
studi
investig
use
enhanc
mpc
algorithm
empc
sever
ill
patient
hour
method
fourteen
seven
male
critic
ill
ventil
medic
surgic
patient
mean
age
year
arteri
bg
mmoll
within
hour
icu
admiss
rbh
alreadi
receiv
insulin
infus
expect
requir
mechan
ventil
hour
treat
either
bg
control
standard
icu
insulin
intraven
infus
protocol
empcadvis
insulin
infus
n
hour
empc
algorithm
instal
bedsid
comput
requir
input
current
insulin
requir
bodyweight
carbohydr
intak
bg
concentr
algorithm
advis
time
next
bg
sampl
hour
insulin
infus
rate
target
maintain
bg
mmoll
patient
empc
group
bg
measur
hourli
safeti
valu
enter
request
algorithm
mean
sd
glucos
concentr
significantli
lower
empc
group
vs
mmoll
p
mean
insulin
infus
rate
significantli
differ
vs
iuhour
empc
vs
standard
care
bg
sampl
occur
frequent
empc
group
mean
everi
vs
hour
p
patient
either
group
bg
measur
mmoll
conclus
empc
algorithm
effect
maintain
tight
bg
control
sever
ill
patient
group
without
episod
hypoglycaemia
bg
mmoll
requir
frequent
bg
measur
acknowledg
studi
part
clinicip
project
fund
ec
framework
univers
cambridg
also
receiv
support
epsrc
tabl
singl
bg
measur
mm
detect
mpc
group
vs
control
group
sampl
frequenc
significantli
higher
mpc
group
introduct
evid
accumul
tight
glucos
control
improv
outcom
critic
ill
patient
studi
perform
evalu
effect
lower
blood
glucos
level
critic
ill
patient
outcom
unit
closedformat
medicalsurg
icu
gener
hospit
start
insulin
prescrib
icu
patient
use
sever
nursedriven
computeris
protocol
subsequ
protocol
aim
lower
glucos
level
februari
may
protocol
use
aim
glucos
mmoll
juli
decemb
protocol
use
aim
glucos
mmoll
serum
glucos
measur
patient
blood
deriv
arteri
line
venou
punctur
rest
day
blood
glucos
measur
either
use
glucotouch
protocol
accucheck
protocol
devic
elimin
differ
due
differ
method
measur
glucos
measur
done
central
laboratori
studi
data
deriv
icu
laboratori
databas
result
see
tabl
median
morn
glucos
reduc
mmoll
protocol
mmoll
protocol
result
small
nonsignific
improv
outcom
subgroup
analysi
focus
medic
surgic
patient
patient
specif
length
stay
icu
also
reveal
nonsignific
differ
outcom
conclus
small
signific
decreas
serum
glucos
probabl
result
small
statist
nonsignific
decreas
mortal
length
stay
hospit
israelita
albert
einstein
paulo
brazil
critic
care
suppl
doi
introduct
increas
risk
hypoglycemia
major
drawback
strict
glycem
control
extens
use
critic
ill
patient
fast
precis
glucos
measur
therefor
mandatori
aim
evalu
accuraci
two
method
bedsid
pointofcar
test
glucos
measur
use
arteri
capillari
venou
blood
sampl
icu
patient
method
crosssect
studi
prospect
data
collect
includ
patient
admit
clinicalsurg
icu
tertiari
care
hospit
result
two
differ
method
glucos
measur
compar
central
laboratori
arteri
blood
measur
accuchek
advantag
roch
arteri
venou
capillari
sampl
precis
pcx
abbott
arteri
sampl
sampl
collect
simultan
agreement
measur
test
blandaltman
method
result
comparison
pair
measur
shown
figur
conclus
two
glucos
meter
evalu
might
suffici
reliabl
use
icu
set
especi
patient
strict
blood
glucos
control
moreov
mark
differ
equip
decreas
precis
capillari
venou
sampl
use
introduct
implement
tight
glycaem
control
tgc
icu
requir
accur
blood
glucos
bg
monitor
evalu
perform
two
bedsid
glucomet
gm
icu
patient
method
four
hundr
fiftytwo
arteri
blood
sampl
prospect
analys
adult
icu
patient
subject
tgc
arteri
bg
simultan
determin
use
refer
test
abl
two
gm
accuchek
hemocu
data
result
correl
refer
method
gm
overal
bg
rang
reason
perfect
r
underlin
ba
analysi
figur
show
bia
overestim
bg
gm
tgc
rang
mgdl
correl
low
gm
r
confirm
ba
analysi
demonstr
broad
limit
agreement
mgdl
accuchek
mgdl
hemocu
conclus
accuraci
test
gm
icu
patient
insuffici
safe
clinic
practic
therefor
avoid
potenti
harm
hypoglycaemia
caution
warrant
tgc
implement
exclus
base
bg
result
obtain
gm
introduct
bedsid
capillari
arteri
blood
glucos
monitor
mandatori
icu
patient
tight
glycem
control
pointofcar
method
base
glucoseoxidas
go
glucosedehydrogenas
gd
enzymat
method
wherea
laboratori
refer
method
hexokinas
measur
plasma
glucos
level
method
prospect
observ
studi
blood
glucos
simultan
measur
glucocard
arkray
go
capillari
accuchek
inform
roch
gd
capillari
arteri
rapidlab
bayer
go
arteri
valu
compar
refer
laboratori
result
result
total
match
analys
done
patient
bias
defin
glucos
laboratori
valu
minu
pointofcar
valu
bia
limit
agreement
number
observ
discrep
pair
result
report
tabl
conclus
go
method
underestim
gd
method
overestim
blood
glucos
level
compar
plasma
glucos
level
measur
refer
method
hexokinas
capillari
method
wider
limit
agreement
measur
carri
arteri
blood
continu
glucos
monitor
intens
care
patient
use
whole
blood
microdialysi
introduct
object
studi
investig
whether
continu
glucos
monitor
intens
care
patient
could
implement
use
blood
microdialysi
md
tight
glycaem
control
reduc
mortal
morbid
critic
ill
patient
current
investig
whether
subcutan
tissu
adequ
repres
site
glucos
monitor
design
test
novel
system
allow
continu
measur
glucos
concentr
whole
blood
base
md
method
naheparin
pump
tip
doubl
lumen
cathet
bloodheparin
mixtur
withdrawn
continu
mix
ratio
flow
mlhour
bloodheparin
mixtur
microdialys
planar
flowthrough
md
unit
discard
thereaft
dialys
collect
analys
glucos
concentr
via
beckman
analysi
refer
venou
blood
sampl
taken
refer
arm
eight
healthi
volunt
underw
investig
includ
ogtt
glucos
read
dialys
venou
blood
obtain
minut
interv
result
eight
subject
success
complet
trial
coeffici
correl
continu
withdrawn
microdialys
blood
venous
taken
refer
blood
sampl
r
clark
error
grid
analysi
ega
reveal
data
pair
rang
appli
novel
insulin
titrat
ega
yield
data
pair
accept
treatment
area
conclus
blood
md
base
continu
blood
withdraw
extracorpor
md
promis
approach
obtain
dialys
reliabl
safe
continu
longterm
determin
blood
glucos
concentr
onlin
sensor
correl
glucos
concentr
dialys
refer
venou
blood
sampl
excel
patenc
doubl
lumen
cathet
current
form
could
improv
introduc
avail
onlin
http
introduct
earli
adequ
nutrit
support
ns
critic
ill
patient
improv
clinic
outcom
although
enter
nutrit
consid
best
method
carri
risk
develop
ventilatorassoci
pneumonia
particularli
patient
nurs
horizont
aim
prospect
audit
assess
complianc
nutrit
practis
icu
aspect
recommend
canadian
clinic
guidelin
method
demograph
data
head
elev
horizont
posit
daili
nitrogen
calori
intak
record
daili
recommend
calori
requir
calcul
accord
bodi
weight
admiss
nasogastr
tube
size
gastric
residu
volum
threshold
grvt
abandon
enter
feed
also
record
result
month
patient
male
femal
admit
includ
emerg
admiss
thirtythre
patient
stay
unit
hour
averag
stay
day
thirtytwo
patient
receiv
ns
within
hour
admiss
enter
parenter
rout
use
six
patient
respect
five
patient
method
use
chang
rout
administr
daili
calori
intak
express
percentag
recommend
intak
present
tabl
measur
blood
sugar
mmoll
gastro
prokinet
use
feed
protocol
unit
low
grvt
use
abandon
enter
regim
result
thirtyon
patient
includ
figur
show
pdr
patient
differ
prokinet
drug
tabl
present
averag
percentag
ge
improv
bm
differ
therapi
averag
improv
individu
best
combin
compar
patient
bm
first
differ
time
reveal
differ
baselin
best
combin
p
p
respect
conclus
popul
metoclopramid
poor
improv
ge
combin
metoclopramid
continu
erythromycin
effect
breathid
conveni
novel
way
monitor
ge
order
studi
individu
tailor
effect
bm
prokinet
combin
introduct
critic
ill
patient
unabl
eat
enter
tube
feed
etf
prefer
mode
feed
studi
aim
investig
amount
enter
feed
obtain
patient
icu
busi
london
teach
hospit
effici
initi
feed
possibl
reason
failur
method
prospect
observ
studi
carri
month
patient
admit
gener
cardiothorac
icu
receiv
etf
baselin
data
includ
age
reason
admiss
ill
sever
score
sofa
document
length
time
admiss
start
feed
note
volum
feed
deliv
patient
record
quantiti
calori
deliv
patient
compar
patient
ideal
nutrit
requir
determin
icu
etf
protocol
feed
interrupt
also
record
result
fiftytwo
patient
receiv
etf
observ
total
hour
patient
surgic
medic
patient
receiv
median
ideal
calorif
requir
feed
start
median
hour
admiss
median
feed
time
interrupt
etf
start
reason
interrupt
includ
high
gastric
aspir
starvat
procedur
displac
blockag
feed
tube
time
start
etf
significantli
differ
accord
admiss
categori
p
abdomin
cardiothorac
surgic
patient
greatest
delay
abdomin
surgic
patient
also
higher
proport
feed
interrupt
due
high
gastric
aspir
starvat
procedur
sofa
score
day
significantli
correl
time
taken
start
feed
p
length
total
feed
interrupt
p
length
feed
interrupt
due
high
gastric
aspir
p
length
feed
interrupt
due
starvat
procedur
p
conclus
major
patient
receiv
high
proport
ideal
calorif
requir
began
feed
within
hour
data
indic
patient
abdomin
surgeri
sickest
patient
may
may
like
experi
delay
initi
interrupt
feed
introduct
clostridium
difficil
associ
diseas
cdad
recogn
major
caus
morbid
mortal
among
patient
hospit
report
associ
use
proton
pump
inhibitor
ppi
cdad
commun
hospit
set
aim
studi
investig
effect
introduc
ppi
prophylaxi
critic
ill
patient
incid
cdad
object
retrospect
studi
assess
incid
causal
factor
associ
longterm
dysphagia
follow
intens
care
discharg
method
questionnair
sent
month
post
icu
discharg
intens
care
patient
level
care
stay
hour
review
case
note
patient
report
swallow
difficulti
establish
whether
undergon
characterist
receiv
therapi
potenti
associ
dysphagia
respons
rate
questionnair
overal
dysphagia
post
icu
stay
rate
observ
fever
age
common
find
one
may
expect
show
highest
associ
subsequ
dysphagia
find
suggest
relationship
chang
tracheostomi
suggest
repeat
procedur
subsequ
difficulti
swallow
one
patient
within
group
subsequ
develop
tracheal
stenosi
see
tabl
conclus
found
percentag
patient
report
swallow
difficulti
post
percutan
tracheostomi
pct
portex
blue
line
ultra
tracheostomi
tube
higher
one
would
expect
may
confound
neurolog
injuri
necessit
need
pct
feel
may
area
concern
merit
investig
given
frequent
pct
icu
practic
intestin
corticotropinreleas
factor
decreas
shock
trauma
patient
may
affect
gut
function
reason
typic
bowel
dysfunct
follow
traumat
injuri
unclear
corticotropinreleas
factor
crf
peripher
bloodtissu
may
induc
intestin
barrier
dysfunct
via
receptormedi
mechan
independ
hypothalamicpituitaryadren
axi
mechan
seem
involv
interact
crf
enter
nerv
mast
cell
result
increas
gut
intercellular
tight
junction
permeabl
macromolecul
well
increas
epitheli
cell
apoptosi
lead
loss
mucos
integr
investig
whether
blood
intestin
tissu
crf
associ
postop
gut
dysfunct
shock
method
crf
analysi
perform
fullthick
bowel
specimen
obtain
shock
trauma
patient
requir
emerg
abdomin
surgeri
penetr
injuri
patient
undergo
small
bowel
resect
elect
bowel
surgeri
venou
blood
taken
anaesthesia
intraop
postop
day
crf
extract
tissu
blood
quantifi
use
radioimmunoassay
day
postop
intestin
permeabl
test
urinari
lactulos
mannitol
l
measur
institut
ethic
approv
grant
patient
gave
written
inform
consent
result
trauma
patient
n
malefemal
age
year
iss
younger
elect
patient
n
malefemal
age
year
p
significantli
lower
mean
tissu
crf
x
total
protein
tp
elect
patient
x
tp
p
median
iqr
intraop
blood
crf
level
higher
trauma
patient
pgml
vs
pgml
p
elect
patient
trauma
patient
correl
neg
postop
l
r
p
although
intestin
permeabl
greatli
equal
increas
group
combin
mean
sd
l
conclus
crf
detect
bowel
tissu
follow
trauma
significantli
lower
trauma
vs
elect
surgeri
patient
crf
blood
may
factor
associ
gut
barrier
chang
follow
shock
emerg
laparotomi
en
icu
howev
use
sedat
feed
proton
pump
inhibitor
make
standard
confirmatori
method
recommend
uk
nation
patient
safeti
agenc
uknpsa
unreli
result
need
multipl
chest
xray
cxr
increas
cost
feed
delay
studi
role
cortrak
viasi
medsystem
usa
standard
practic
assess
follow
outcom
time
requir
confirm
correct
ngt
posit
time
start
feed
potenti
cost
save
method
enrol
patient
admit
icu
requir
ngt
insert
en
corflow
ngt
cortrak
stylet
insert
posit
monitor
use
cortrak
magnet
sensor
cortrak
system
track
trail
stylet
tip
progress
toward
stomach
provid
visual
represent
ngt
posit
video
screen
allow
rapid
determin
insert
success
posit
ngt
also
assess
use
ph
paper
andor
cxr
appropri
accord
standard
uknpsa
guidelin
data
analys
use
pair
test
timetoev
analysi
result
fiftytwo
patient
recruit
insert
analys
first
insert
reinsert
gastric
content
success
aspir
insert
ph
fortysix
cxr
request
three
patient
requir
multipl
cxr
cortrak
correctli
confirm
posit
ngt
insert
time
requir
confirm
ngt
posit
significantli
less
cortrak
convent
method
mean
se
cortrak
min
ph
paper
min
cxr
min
p
background
aim
studi
determin
effect
propranolol
infect
clinic
paramet
acut
phase
postburn
sever
thermal
injuri
follow
period
hypermetabol
directli
proport
size
insult
sustain
infect
multiorgan
failur
lead
caus
death
sever
thermal
injuri
propranolol
anticatabol
agent
improv
hypermetabol
postburn
howev
evid
propranolol
worsen
immun
function
increas
incid
infect
critic
ill
patient
method
sixtysix
patient
burn
total
bodi
surfac
area
enrol
studi
random
receiv
standard
burn
care
control
n
standard
burn
plu
propranolol
day
propranolol
mgkg
everi
hour
n
biopsi
taken
three
time
week
microbiolog
determin
clinic
paramet
collect
blood
drawn
regular
interv
throughout
hospit
cours
analyz
hgh
patient
underw
weekli
rest
energyexpenditur
measur
statist
analysi
perform
use
analysi
varianc
bonferoni
correct
student
test
applic
result
propranolol
treatment
reduc
heart
rate
significantli
improv
stroke
volum
throughout
acut
hospit
stay
compar
control
p
rest
energi
expenditur
significantli
decreas
propranolol
group
compar
control
discharg
p
infect
rate
admiss
group
propranolol
vs
control
incid
infect
throughout
hospit
cours
significantli
lower
propranolol
group
compar
control
p
propranolol
significantli
increas
igfi
gh
prealbumin
significantli
decreas
crp
fatti
acid
p
conclus
follow
sever
burn
propranolol
attenu
infect
inflammatori
marker
fatti
acid
level
improv
cardiac
work
endogen
anabol
hormon
level
suggest
propranolol
safe
efficaci
modul
postburn
respons
studi
investig
effect
earli
enter
immunonutrit
patient
recoveri
extens
elect
surgeri
upper
abdomen
investig
speed
patient
recoveri
administ
earli
enter
immunonutrit
combin
total
parenter
nutrit
total
patient
undergon
type
surgeri
involv
studi
near
end
surgeri
procedur
percutan
jejunostomi
perform
patient
enter
nutrit
start
first
postop
day
small
dose
immunonutri
reconvan
mlhour
everi
hour
toler
estim
abdomin
distens
diarrhoea
vomit
everi
hour
immunonutri
dose
increas
mlhour
reach
maximum
mlhour
first
three
postop
day
patient
also
administ
total
parenter
nutrit
enter
nutrit
group
patient
administ
parenter
nutrit
first
postop
day
preoper
everi
patient
measur
bodi
weight
bodi
height
bodi
mass
index
use
laboratori
test
establish
level
albumin
transferin
blood
urea
nitrogen
creatinin
third
ninth
postop
day
repeat
laboratori
test
measur
daili
loss
nitrogen
excret
urea
urin
result
discuss
patient
recoveri
faster
averag
patient
stay
icu
day
vs
day
averag
hospit
stay
day
vs
day
peristalsi
detect
third
day
averag
vs
day
decreas
pulmonari
complic
achiev
one
pleural
effus
vs
eight
pleural
effus
laboratori
test
show
patient
lower
catabol
compar
patient
conclus
earli
enter
immunonutrit
jejunostomi
effici
safe
method
patient
nutrit
fewer
postop
complic
also
account
hospit
cost
decreas
introduct
larg
random
trial
need
evalu
safeti
efficaci
glutamin
gln
antioxid
aox
supplement
howev
high
dose
nutrient
via
enter
parenter
rout
earli
cours
critic
ill
often
interrupt
high
ill
acuiti
treatment
prioriti
purpos
pilot
trial
evalu
feasibl
deliv
highdos
gln
aox
supplement
earli
cours
critic
ill
estim
recruit
larger
redox
studi
method
six
canadian
center
use
x
factori
design
random
mechan
ventil
adult
two
organ
failur
within
hour
icu
admiss
one
four
group
gln
gkgday
iv
plu
g
enter
aox
selenium
iv
selenium
mg
zinc
mg
mg
vitamin
e
mg
vitamin
c
enter
aox
gln
placebo
supplement
continu
minimum
day
day
provid
independ
nutrit
support
record
time
icu
admiss
random
time
start
supplement
nutrit
support
paramet
result
april
april
patient
random
averag
median
time
icu
admiss
random
hour
rang
hour
patient
receiv
parenter
supplement
median
rang
time
start
hour
hour
receiv
enter
supplement
median
rang
hour
hour
random
mean
durat
supplement
day
enter
day
parenter
mean
volum
enter
parenter
supplement
receiv
rang
rang
prescrib
volum
respect
averag
prescrib
energi
protein
intak
kcalday
g
proteinday
averag
daili
percentag
energi
protein
receiv
nutrit
support
rang
rang
prescrib
respect
conclus
critic
ill
patient
organ
failur
provid
adequ
amount
studi
supplement
via
enter
parenter
rout
earli
phase
acut
ill
independ
nutrit
support
estim
recruit
least
two
patientssitemonth
futur
trial
introduct
standard
selenium
se
substitut
critic
ill
suffici
sustain
plasma
level
standard
se
substitut
keep
plasma
level
rang
highdos
se
substitut
correl
decreas
mortal
patient
sir
influenc
highdos
substitut
select
paramet
map
mortal
critic
ill
evalu
prospect
random
clinic
trial
method
one
hundr
twentythre
patient
male
femal
median
age
year
respect
random
group
sofa
group
b
sofa
group
receiv
standard
se
substitut
naselenit
ivday
group
b
receiv
highdos
se
substitut
accord
protocol
day
follow
day
naselenit
iv
plasma
level
se
prealbumin
albumin
crp
pct
cholesterol
gluthathionperoxidas
gshpx
ddimer
creatinin
clearanc
leucocyt
examin
daili
map
trend
mortal
evalu
clinic
marker
se
plasma
level
significantli
higher
highdos
sesubstitut
patient
vs
p
gshpx
significantli
higher
highdos
sesubstitut
patient
ul
vs
ul
p
signific
differ
found
level
albumin
prealbumin
crp
pct
leucocyt
fibrinogen
cholesterol
ddimer
creatinin
clearanc
map
mortal
lower
highdos
sesubstitut
patient
vs
significantli
conclus
critic
ill
increas
demand
se
essenti
synthesi
se
enzym
se
protein
increas
demand
se
cover
standard
substitut
highdos
se
substitut
normal
plasma
level
increas
gshpx
plasma
level
highdos
se
substitut
advers
reaction
decreas
mortal
highdos
sesubstitut
patient
signific
trial
highdos
se
substitut
continu
introduct
nutrit
therapi
integr
aspect
icu
support
influenc
outcom
delay
start
nutrit
support
hour
icu
admiss
associ
increas
morbid
mortal
certain
lipid
emuls
exacerb
inflammatori
cascad
appropri
evalu
impact
recent
research
find
inform
regard
use
parenter
nutrit
pn
icu
need
method
interim
analysi
multicent
prospect
cohort
studi
aim
obtain
inform
regard
use
pn
data
collect
month
icu
patient
year
age
use
pn
adult
icu
brazil
use
webbas
clinic
research
form
one
hundr
sixtysix
patient
includ
analysi
among
main
result
male
consid
malnourish
mean
sofa
score
mean
apach
ii
score
total
pn
use
brazil
manufactur
thirdparti
compani
associ
signific
delay
begin
infus
median
time
hour
elev
inicu
inhospit
mortal
rate
total
patient
immunosuppress
use
lipid
sourc
longchain
triglyceridesmediumchain
triglycerid
conclus
use
pn
brazil
associ
signific
delay
start
infus
high
mortal
rate
use
lipid
emuls
longchain
triglyceridesmediumchain
triglycerid
associ
apoptosi
compromis
lymphocyt
prolifer
overal
find
studi
indic
strategi
reduc
delay
start
pn
use
better
lipid
sourc
must
adopt
provid
better
assist
patient
need
pn
brazil
introduct
ultrasound
us
significantli
facilit
central
venou
catheter
reduc
percentag
failur
percentag
accident
arteri
punctur
percentag
complic
haematoma
haemothorax
pneumothorax
nonetheless
clear
whether
us
guidanc
usg
socal
dynam
realtim
us
techniqu
venipunctur
direct
us
control
may
better
us
assist
usa
socal
static
indirect
us
techniqu
us
imag
vein
without
skin
mark
blind
venipunctur
method
februari
septemb
cvc
team
adopt
follow
protocol
intern
jugular
vein
ijv
catheter
ijv
evalu
assess
posit
dimens
featur
known
affect
risk
catheter
b
decis
made
whether
continu
usa
usg
c
ijv
access
via
low
later
jernigan
approach
two
fail
usa
attempt
usg
venipunctur
adopt
ijv
avail
usg
venipunctur
central
vein
second
choic
e
fluoroscopi
use
paediatr
patient
patient
postop
chest
xray
rule
pneumothorax
malposit
result
month
central
venou
cathet
cvc
insert
adult
shortterm
cvc
tunnel
port
paediatr
patient
age
rang
year
averag
year
shortterm
tunnel
two
port
adult
procedur
start
usa
usg
case
shift
usa
usg
necessari
usg
first
choic
paediatr
case
ijv
success
cannul
adult
patient
except
innomin
vein
case
axillari
vein
two
case
femor
vein
one
case
usg
one
paediatr
patient
cvc
insert
subclavian
vein
via
supraclavicular
usg
approach
complic
failur
pneumothorax
haemothorax
accident
arteri
punctur
usa
vs
usg
haematoma
usa
malposit
exclus
left
ijv
conclus
conclus
minim
incid
complic
b
usg
associ
relev
reduct
risk
accident
arteri
punctur
haematoma
compar
usa
c
choos
left
ijv
associ
higher
risk
malposit
cathol
univers
hospit
roma
itali
critic
care
suppl
doi
introduct
critic
ill
reliabl
peripher
central
venou
access
paramount
import
nonetheless
access
may
difficult
may
carri
signific
risk
complic
pneumothorax
central
line
infect
etc
peripher
insert
venou
cathet
either
central
picc
peripher
midlin
cathet
mc
associ
low
risk
catheterrel
bacteremia
also
use
ultrasound
guidanc
microintroduc
techniqu
ug
mit
insert
patient
regardless
avail
superfici
vein
review
experi
peripher
insert
cathet
patient
differ
icu
surgic
icu
trauma
unit
coronari
unit
neurosurg
icu
stroke
unit
pediatr
icu
etc
cathet
posit
midarm
basil
vein
brachial
vein
use
ug
mit
assess
feasibl
techniqu
acut
ill
rate
complic
insert
picc
mc
patient
requir
prolong
venou
access
estim
day
nine
septic
six
coagulopathi
tracheostomi
use
silicon
polyurethan
fr
cathet
procedur
perform
team
train
physician
nurs
cathet
insert
easi
case
immedi
complic
failur
one
hematoma
arteri
nerv
injuri
late
complic
one
local
infect
three
thrombosi
two
requir
remov
four
case
damag
extern
cathet
due
poor
nurs
inappropri
use
cathet
rx
procedur
easili
repair
one
disloc
cathet
occlus
catheterrel
bacteremia
cathet
stay
place
prolong
time
rang
day
median
day
three
remov
complic
conclus
experi
picc
mc
character
extrem
low
rate
infect
thrombot
complic
venou
access
achiev
patient
even
limit
avail
peripher
vein
use
usinsert
picc
mc
consid
central
access
advis
contraind
introduct
ultrasound
introduc
insert
central
venou
line
reduc
complic
associ
convent
landmark
techniqu
compar
techniqu
note
number
attempt
durat
insert
complic
method
thirti
patient
randomli
select
oper
theatr
icu
requir
placement
central
venou
cathet
central
venou
cathet
placement
perform
two
experienc
anaesthetist
year
experi
anaesthesia
intens
care
patient
intern
jugular
venou
cathet
placement
perform
use
extern
anatom
landmark
techniqu
patient
placement
ultrasound
guidanc
durat
insert
record
moment
needl
touch
skin
insert
cathet
remov
guid
wire
number
attempt
well
immedi
delay
complic
record
result
central
venou
cathet
placement
success
perform
first
attempt
group
immedi
delay
complic
note
howev
mean
time
insert
longer
ultrasoundguid
group
min
compar
extern
anatom
landmark
group
min
figur
discuss
studi
design
evalu
ultrasoundguid
central
venou
cathet
placement
compar
convent
method
base
extern
anatom
landmark
studi
demonstr
superior
ultrasoundguid
central
venou
line
placement
extern
anatom
landmark
techniqu
howev
time
gain
demonstr
ultrasoundguid
placement
hand
number
studi
express
sever
reserv
concern
systemat
use
ultrasound
guidanc
central
line
placement
patient
found
use
ultrasound
neither
alter
rate
complic
number
attempt
central
venou
cathet
placement
also
durat
placement
central
line
cathet
use
extern
recent
demonstr
isol
blood
perfus
rat
lung
subject
lpsinduc
pulmonari
oedema
continu
measur
inspiratori
resist
work
good
indirect
indic
progress
lung
oedema
extend
find
two
type
pulmonari
oedema
hydrostat
oedema
induc
elev
left
atrial
pressur
alveolar
oedema
alv
infus
normal
salin
trachea
two
differ
infus
rate
mlhour
min
see
tabl
result
indic
continu
measur
inspiratori
resist
work
good
indic
permeabl
hydrostat
lung
oedema
pure
alveolar
oedema
absenc
interstiti
oedema
studi
aim
establish
preval
home
ventilatori
respiratori
support
within
catchment
area
frimley
park
hospit
surrey
number
patient
receiv
respiratori
support
home
increas
nation
sinc
howev
local
data
exist
trend
like
continu
domiciliari
ventil
gain
popular
treatment
obstruct
sleep
apnoea
certain
group
copd
patient
method
postal
survey
sent
practic
manag
local
catchment
area
ask
provid
data
patient
home
ventilatori
support
reason
patient
longterm
tracheostomi
patient
copd
home
oxygen
would
classifi
end
stage
total
number
patient
regist
practic
follow
telephon
call
approxim
week
later
mani
email
questionnair
two
telephon
call
practic
made
necessari
order
obtain
data
result
surgeri
contact
achiev
respons
rate
thirtythre
practic
abl
provid
complet
data
six
provid
partial
data
five
unabl
unwil
provid
data
twentythre
practic
respond
total
patient
list
respond
practic
patient
live
longterm
tracheostomi
preval
patient
receiv
mechan
respiratori
support
home
preval
patient
receiv
oxygen
therapi
home
preval
discuss
studi
suggest
frimley
park
hospit
popul
current
contain
individu
requir
mechan
respiratori
support
home
concern
current
formal
support
highrisk
patient
ventil
mainten
simpl
problem
precipit
hospit
admiss
rapidli
trigger
outreach
intens
care
review
current
posit
clearli
unsatisfactori
must
address
pct
patient
number
increas
result
frequenc
mv
overal
specif
mortal
rate
respect
mean
age
year
male
mean
apach
ii
score
medic
patient
mean
durat
mv
day
invas
mv
multivari
analysi
perform
identifi
variabl
associ
death
includ
sepsi
p
mv
durat
p
renal
failur
p
prior
mv
follow
variabl
occur
mv
period
sepsi
p
acut
lung
injuryacut
respiratori
distress
syndrom
p
renal
failur
p
haematolog
failur
p
vasoact
drug
use
p
note
select
ventilatori
monitor
variabl
includ
multivari
model
howev
associ
mortal
studi
sampl
result
indic
frequenc
patient
mv
elev
specif
mortal
rate
sepsi
mv
durat
renal
failur
prior
mv
sepsi
acut
lung
injuryacut
respiratori
distress
syndrom
renal
failur
haematolog
failur
vasoact
drug
use
mv
period
risk
factor
mortal
day
start
mv
identif
factor
may
allow
earli
intervent
attempt
mitig
poor
outcom
background
hypercapnia
elev
intraabdomin
pressur
carbon
dioxid
co
pneumoperitoneum
advers
affect
respiratori
mechan
arteri
blood
gase
test
hypothesi
adapt
pressur
ventilationsynchronis
intermitt
mandatori
ventil
apvsimv
may
provid
better
pulmonari
mechan
co
homeostasi
pulmonari
ga
exchang
less
frequent
ventilatori
set
tidal
volum
tv
respiratori
rate
rr
lower
peak
inspiratori
pressur
p
peak
plateau
pressur
p
plat
pressurecontrol
synchronis
intermitt
mandatori
ventil
psimv
patient
undergo
laparocop
cholecystectomi
lp
method
studi
group
consist
patient
apvsimv
n
psimv
n
lp
perform
total
intraven
anesthesia
induct
anesthesia
rr
breath
minut
inspiratori
expiratori
rate
peep
cmh
set
group
apvsimv
start
target
tv
mlkg
psimv
start
inspiratori
pressur
p
in
provid
mlkg
tv
set
chang
target
paramet
maintain
normocapnia
normoxia
achiev
etco
mmhg
paco
mmhg
sao
target
paramet
could
achiev
first
rr
increas
breath
minut
breathsminut
volum
pressur
titrat
induc
mlkg
increas
tv
mlkg
initi
fio
set
fio
increas
increment
sao
fell
pao
fio
static
complianc
vdvt
p
peak
p
plat
etco
inspiratori
expiratori
resist
arteri
blood
ga
analysi
record
pneumoperitoneum
statist
analysi
carri
use
chisquar
test
pair
test
independ
sampl
test
appropri
result
demograph
data
similar
group
pneumoperitoneum
caus
signific
decreas
static
complianc
arteri
ph
increas
p
peak
p
plat
vdvt
etco
group
howev
apvsimv
result
fewer
set
chang
lower
peak
plateau
pressur
vdvt
etco
level
compar
psimv
p
conclus
apvsimv
may
provid
better
result
convent
psimv
patient
undergo
lp
influenc
cyclingoff
criteria
pressur
support
slope
respiratori
hemodynam
variabl
intens
care
unit
patient
clinic
use
ventil
limit
due
huge
varieti
differ
ventil
method
clinician
often
high
cognit
load
complic
technic
equip
icu
use
small
subset
avail
paramet
set
aim
present
studi
develop
closedloop
ventil
control
base
mathemat
model
fuzzi
logic
system
design
track
desir
endtid
co
pressur
paco
find
peep
lead
maximum
estim
respiratori
system
complianc
maintain
arteri
oxygen
satur
sao
optim
level
develop
program
labview
nation
instrument
austin
tx
usa
laptop
abl
read
intern
data
ventil
evita
medic
germani
real
time
respiratori
signal
exampl
sao
acquir
monitor
discret
measur
exampl
pao
either
assum
constant
next
measur
interpol
use
modelbas
approach
evalu
exampl
etco
data
cours
etco
follow
set
optim
frequenc
evalu
calcul
time
requir
equilibr
etco
result
modul
autom
initi
set
ventil
accord
local
icu
rule
realiz
modul
ad
optim
breath
frequenc
respect
paco
etco
fio
accord
whenev
pao
avail
lung
simul
michigan
instrument
inc
grand
rapid
mi
usa
connect
medic
use
evalu
system
exemplari
result
present
figur
show
minut
volumeetco
relationship
figur
parametr
fit
etco
data
figur
adjust
frequenc
base
current
etco
model
conclus
autom
sine
qua
non
achiev
optim
patient
individu
ventil
support
system
enabl
evalu
therapeut
strategi
base
set
ventil
current
trendsdrift
observ
data
conclus
nippv
associ
better
outcom
popul
hematolog
patient
acut
respiratori
failur
nippv
follow
ippv
independ
predictor
mortal
introduct
rapid
shallow
breath
index
rsbi
ratio
determin
frequenc
f
divid
tidal
volum
vt
rsbi
wide
accept
healthcar
profession
criteria
wean
extub
integr
mechan
ventil
wean
protocol
hypothes
convers
use
rsbi
wean
might
use
predict
need
noninvas
ventil
figur
plu
etco
flow
sensor
use
obtain
bedsid
measur
patient
would
breath
etco
flow
sensor
second
nose
clip
threshold
valu
rsbi
discrimin
best
niv
need
niv
determin
patient
thirtyf
patient
requir
ventilatori
support
mean
rsbi
patient
niv
mean
rsbi
p
receiveroperatingcharacterist
curv
construct
base
upon
dataset
increment
rsbi
figur
rsbi
yield
sensit
specif
determin
need
niv
likelihood
ratio
posit
lr
illustr
formid
predict
valu
rsbi
low
tidal
volum
ventil
tv
mlkg
prophylaxi
stress
ulcer
sup
deep
vein
thrombosi
dvtp
tabl
averag
low
tidal
volum
ventil
adopt
dvtp
sup
well
implement
without
train
effect
frequenc
pneumonia
icu
length
stay
surviv
introduct
aim
studi
compar
combin
intermitt
mandatori
ventil
plu
pressuresupport
ventil
simvpsv
intermitt
trial
spontan
breath
itsb
use
ttube
two
method
wean
surgic
icu
method
total
patient
ventil
hour
postop
period
octob
octob
enrol
studi
fulfil
wean
checklist
randomli
assign
two
group
simvpsv
group
n
itsb
group
n
patient
assign
simvpsv
group
ventil
rate
initi
set
breathsminut
plu
psv
cmh
reduc
possibl
breathsminut
cmh
time
patient
abl
maintain
adequ
ventil
simv
breathsminut
psv
cmh
least
hour
without
sign
distress
extub
patient
assign
itsb
group
disconnect
ventil
allow
breath
spontan
ttube
circuit
durat
trial
gradual
increas
trial
assistcontrol
ventil
provid
least
hour
patient
abl
breath
least
hour
without
sign
distress
extub
result
first
attempt
made
wean
patient
receiv
assistcontrol
ventil
haemodynam
instabl
follow
underli
condit
present
chronic
obstruct
pulmonari
diseas
patient
neuromuscular
disord
nine
patient
acut
lung
injuri
result
surgeri
patient
asthma
six
patient
miscellan
caus
eight
patient
durat
mechan
ventil
wean
day
simvpsv
group
vs
day
itsb
group
p
durat
wean
hour
vs
hour
two
group
respect
p
patient
remain
extub
hour
classifi
success
extub
rate
success
extub
first
hour
start
wean
higher
simv
group
itsb
group
p
total
durat
mechan
ventil
day
vs
day
icu
length
stay
day
vs
day
two
group
respect
p
conclus
use
simvpsv
wean
method
surgic
icu
lead
shorter
durat
wean
higher
rate
success
extub
shorter
durat
mechan
ventil
less
icu
stay
use
itsb
predict
success
wean
cohort
elderli
patient
introduct
acut
ill
advers
affect
patient
circadian
rhythm
minimis
delay
restor
rhythm
may
patient
benefit
aim
studi
investig
acut
effect
exogen
melatonin
restact
rhythm
patient
recov
critic
ill
furthermor
analys
rhythm
relationship
plasma
melatonin
cortisol
level
method
randomis
control
trial
critic
ill
patient
wean
mechan
ventil
ethic
committe
approv
grant
patient
provid
written
consent
twelv
patient
group
receiv
placebo
mg
exogen
melatonin
hour
four
night
twelv
plasma
sampl
taken
period
first
patient
period
actigraphi
use
monitor
patient
activ
rhythm
analysi
plasma
level
activ
data
use
singl
cosinor
analysi
nonparametr
paramet
respect
result
group
well
match
signific
differ
group
restact
measur
abnorm
compar
previous
report
weak
invers
correl
plasma
melatonin
cortisol
level
r
p
seven
patient
circadian
rhythm
plasma
cortisol
level
two
patient
normal
acrophas
four
nine
placebo
patient
circadian
rhythm
melatonin
one
normal
amplitud
acrophas
result
exclud
patient
whose
wean
interrupt
transfer
decis
withdraw
treatment
wean
attempt
analys
repres
success
unsuccess
us
wean
comparison
mean
sd
age
year
us
year
p
apach
score
us
p
two
group
show
major
differ
logist
regress
demonstr
worst
fio
prior
wean
durat
ventil
prior
wean
significantli
associ
unsuccess
sc
wean
attempt
p
p
respect
roc
curv
analysi
suggest
patient
fio
durat
ventil
prior
wean
hour
like
success
wean
conclus
sc
prove
success
patient
lower
worst
fio
prior
wean
lower
durat
ventil
prior
commenc
wean
assess
impact
introduc
ventil
bundl
outcom
mechan
ventil
patient
background
concept
bundl
develop
institut
healthcar
improv
individu
bundl
element
built
evidencebas
practic
bundl
concept
element
execut
togeth
produc
better
outcom
isol
howev
limit
evid
link
use
bundl
demonstr
chang
patient
outcom
preliminari
analysi
inform
multicentr
evalu
explor
effect
introduct
ventil
bundl
outcom
mechan
ventil
patient
singl
critic
care
unit
method
data
extract
mechan
ventil
admiss
singl
unit
particip
case
mix
programm
earli
adopt
ventil
bundl
risk
predict
model
develop
use
data
admiss
year
prior
introduct
bundl
appli
admiss
year
sinc
introduct
estim
cumul
excess
mortal
observ
minu
expect
death
result
ventil
admiss
prior
introduct
bundl
sinc
cumul
excess
mortal
plot
suggest
reduct
mortal
introduct
bundl
figur
statist
signific
rel
risk
reduct
confid
interv
interpret
result
suggest
benefici
carri
multicentr
evalu
ventil
bundl
case
mix
programm
unit
inform
design
studi
hemodynam
chang
due
expiratori
posit
airway
pressur
facial
mask
postop
period
cardiac
surgeri
method
collect
data
baselin
demograph
physiolog
characterist
outcom
newborn
treat
ncpap
neonat
icu
poland
period
conduct
stepwis
mlr
newborn
two
common
indic
use
evalu
three
outcom
need
intub
newborn
treat
elect
ncpap
rd
wean
failur
requir
reintub
mechan
ventil
newborn
wean
bad
outcom
result
rd
group
patient
found
ncpap
failur
highli
significantli
relat
estim
gestat
age
clinic
risk
index
babi
crib
popul
less
matur
rd
newborn
slightli
less
like
avoid
intub
mlr
model
show
control
initi
crib
less
onehalf
like
avoid
intub
failur
ncpap
wean
highli
significantli
relat
ph
prior
begin
ncpap
bad
outcom
highli
relat
estim
gestat
age
crib
rd
group
wean
popul
conclus
believ
understand
risk
ncpap
failur
also
bad
outcom
specif
patient
enhanc
clinic
decisionmak
patient
highest
risk
poor
outcom
ncpap
failur
aggress
use
intub
surfact
might
warrant
likewis
aggress
therapi
might
also
avoid
seemingli
low
chanc
poor
outcom
introduct
advoc
airway
pressur
releas
ventil
aprv
suggest
mode
lungprotect
patient
aliard
provid
addit
benefit
spontan
breath
includ
improv
haemodynam
decreas
need
sedat
better
patient
comfort
howev
avail
data
clinic
experi
aprv
method
conduct
retrospect
audit
consecut
patient
receiv
aprv
januari
august
three
academ
icu
toronto
aprv
initi
discret
attend
physician
protocol
guid
implement
aprv
introduc
juli
record
data
describ
baselin
characterist
aprv
use
potenti
ramif
includ
oxygen
sedationanalgesia
dose
outcom
result
thirti
patient
aliard
receiv
trial
aprv
studi
period
median
age
year
male
pulmonari
ali
risk
factor
median
apach
ii
score
ali
median
day
median
hour
cmv
aprv
receiv
median
hour
aprv
hour
oxygen
improv
significantli
pf
ratio
p
concomit
decreas
requir
p
hour
median
pf
ratio
improv
median
fio
p
administr
dosag
sed
midazolam
equival
propofol
analges
morphin
equival
chang
significantli
period
hour
hour
aprv
initi
two
episod
barotrauma
aprv
neither
requir
therapeut
drainag
mortal
commonli
due
multiorgan
failur
withdraw
lifesupport
conclus
patient
aprv
use
appear
safe
led
improv
oxygen
chang
need
sedationanalgesia
futur
studi
need
determin
optim
time
method
arpv
use
follow
random
trial
confirm
safeti
document
effect
aprv
patientcent
outcom
introduct
reduc
content
biophys
activ
larg
surfact
aggreg
common
find
acut
inflammatori
lung
diseas
cyclic
surfac
area
chang
carboxylesteras
activ
surfact
convertas
thought
mediat
subtyp
convers
howev
data
concern
regul
surfact
convertas
scarc
therefor
investig
express
activ
lung
surfact
convertas
potenti
macrophagederiv
human
convertas
normal
acut
inflammatori
condit
method
convertas
activ
lavag
fluid
balf
assess
use
vitro
cycl
assay
rel
larg
surfact
aggreg
content
determin
phospholipid
quantif
pellet
follow
centrifug
x
g
esteras
activ
assess
mean
chromogen
substrat
assay
express
convertas
hmse
upon
lp
challeng
assess
realtim
taqman
pcr
murin
alveolar
macrophag
murin
primari
type
ii
cell
human
monocyt
cell
line
respect
result
lavag
fluid
ard
patient
display
increas
esteras
activ
compar
balf
healthi
control
addit
pronounc
larg
small
aggreg
convers
observ
balf
lpschalleng
mice
balf
ard
patient
incub
lp
result
signific
increas
convertas
gene
express
primari
mous
type
ii
cell
well
gene
express
cell
monocyt
peripher
blood
convertas
express
found
cultur
murin
alveolar
macrophag
conclus
increas
convertas
activ
found
acut
inflammatori
condit
alveolar
compart
type
ii
cell
seem
relev
sourc
increas
convertas
activ
howev
leakag
esteras
activ
vascular
space
inflammatori
cell
rule
method
present
studi
gener
transgen
mice
express
surfact
protein
burokinas
fusion
protein
spuc
distal
respiratori
epithelium
control
kb
human
spc
promotor
surviv
determin
lethal
ali
model
inhal
lp
administr
spuc
mice
compar
wildtyp
mice
genet
background
furthermor
outcom
lung
function
collagen
content
histolog
assess
model
bleomycininduc
pulmonari
fibrosi
result
transgen
mice
show
improv
surviv
inhal
lp
bleomycin
administr
compar
wildtyp
mice
fibrot
respons
inhal
bleomycin
challeng
markedli
attenu
transgen
mice
evid
reduc
histolog
appear
fibrosi
improv
pulmonari
complianc
reduc
lung
hydroxyprolin
content
potenti
underli
mechan
attenu
fibrot
respons
observ
improv
alveolar
surfac
activ
decreas
pulmonari
fibrin
deposit
increas
hepatocyt
growth
factor
level
decreas
gelatinas
activ
bal
fluid
transgen
mice
compar
control
anim
conclus
lungspecif
express
surfact
protein
burokinas
fusion
protein
protect
ali
inhal
lp
challeng
prevent
fibrosi
associ
bleomycininduc
lung
injuri
result
ard
network
trial
demonstr
signific
reduct
mortal
use
mechan
ventil
protocol
tidal
volum
vt
mlkg
predic
bodi
weight
addit
computerdriven
wean
protocol
success
perform
reduct
mechan
ventil
durat
could
demonstr
implement
ard
network
protocol
routin
icu
practic
remain
modest
possibl
reason
increas
organis
tempor
burden
autom
execut
protocol
would
help
propag
daytoday
use
test
abil
autom
complex
protocol
design
pilot
studi
porcin
acut
lung
injuri
use
experiment
medic
expert
system
capabl
continu
control
respiratori
paramet
global
well
region
ventil
electr
imped
tomographi
eit
method
induct
salin
lavageinduc
lung
injuri
pig
n
autom
mechan
ventil
initi
medic
expert
system
use
closedloop
fuzzi
control
rule
base
ifthen
rule
base
ard
network
protocol
refer
card
protocol
algorithm
rule
therapeut
goal
oxygen
ph
e
vt
continu
control
ventilatori
set
electron
adjust
accordingli
medic
attend
personnel
constantli
inform
statu
messag
decis
made
trial
measur
made
use
onlin
blood
ga
monitor
trendcar
satellit
diametr
medic
inc
uk
monitor
hemodynam
paramet
sirecust
siemen
germani
capnograph
co
smo
respiron
inc
usa
eit
prototyp
system
eit
evalu
kit
draeger
medic
germani
subject
ventil
minut
computerdriven
ventil
set
could
stabilis
ventil
lunginjur
subject
predefin
threshold
compar
begin
studi
reduct
ventil
pressur
paco
could
observ
despit
initi
low
pao
fio
ratio
mmhg
subject
fio
could
decreas
system
given
time
without
penetr
threshold
oxygen
conclus
robust
execut
autom
ard
network
protocol
electron
control
ventil
possibl
lead
pulmonari
stabilis
trial
undertaken
success
approach
realis
ard
patient
introduct
optim
durat
prone
posit
ventil
ppv
acut
respiratori
distress
syndrom
ard
uncertain
point
pulmonari
ard
patient
respond
less
extrapulmonari
ard
patient
object
studi
effect
continu
longterm
ppv
ga
exchang
peep
lung
injuri
score
multiorgan
failur
pulmonari
ard
patient
materi
method
design
prospect
cohort
studi
ppv
period
pulmonari
ard
patient
measur
taken
supin
posit
ppv
hour
ppv
everi
hour
end
ppv
statist
valu
express
median
interquartil
rang
wilcoxon
kruskalw
test
use
p
consid
signific
result
mean
age
year
initi
lung
injuri
score
li
ppv
maintain
hour
pao
fio
ratio
mmhg
ppv
mmhg
hour
ppv
p
differ
supin
pao
fio
ratio
sustain
end
ppv
initi
valu
peep
set
cmh
construct
peepcompli
curv
differ
peep
valu
along
studi
initi
valu
paco
mmhg
signific
differ
along
studi
period
hour
ppv
li
significantli
decreas
comparison
supin
valu
ppv
vs
p
signific
complic
conclus
ppv
posit
effect
ga
exchang
even
hour
effect
last
ppv
period
effect
li
durat
hour
continu
ppv
could
use
patient
set
introduct
great
controversi
concern
protect
ventil
ard
recruit
maneuv
peep
titrat
suffici
avoid
collaps
tidal
recruit
major
goal
maxim
recruit
strategi
mr
object
describ
clinic
demograph
data
evalu
incid
complic
relat
transport
mr
method
fortythre
patient
ard
transport
ct
submit
mr
consist
step
ventil
fix
pcv
cmh
progress
peep
level
cmh
rr
e
fio
open
recruit
close
peep
titrat
pressur
determin
accord
least
amount
collaps
observ
ct
use
ventil
patient
afterward
result
clinic
data
present
tabl
complic
due
transport
one
patient
develop
pneumomediatinum
protocol
introduct
analysi
nonlinear
respiratori
complianc
guid
ventil
set
ali
ard
well
establish
pressur
depend
volum
depend
respect
respiratori
resist
patient
mostli
ignor
studi
perform
investig
pressur
depend
resist
ali
ard
wide
rang
pressur
method
twentyon
patient
ali
ard
analyz
ventil
interrupt
respiratori
manoeuvr
volum
increas
zeep
step
ml
constant
inspiratori
flow
plateau
pressur
reach
cmh
step
follow
hold
second
inspiratori
resist
step
determin
leastsquar
fit
procedur
result
resist
decreas
cmh
cmh
cmh
cmh
p
figur
show
individu
absolut
valu
mean
sd
patient
decreas
found
cmh
higher
pressur
chang
uniform
averag
rel
chang
inspiratori
resist
patient
shown
figur
conclus
inspiratori
resist
ali
ard
constant
especi
higher
pressur
individu
resist
may
chang
unpredict
assumpt
constant
resist
therefor
avoid
avail
onlin
http
introduct
alveolar
microscopi
seem
provid
import
insight
alveolar
dynam
mechan
ventil
util
method
limit
due
high
effort
need
evalu
sequenc
imag
respect
alveolar
geometri
evalu
done
hand
time
consum
place
high
cognit
load
examin
error
prone
reproduc
result
low
project
aim
establish
computerassist
tool
provid
semiautomat
evalu
video
sequenc
acquir
alveolar
endoscopi
method
develop
comput
program
base
matlab
mathwork
natick
usa
analys
video
sequenc
acquir
alveolar
endoscop
denzlingen
germani
user
provid
pointer
alveoli
shall
trace
whose
chang
size
shape
determin
filter
smooth
spline
expectationdriven
fine
tune
perform
achiev
robust
predict
result
intratid
chang
alveolar
geometri
result
anim
studi
relat
alveolar
mechan
artifici
ventil
conduct
figur
show
plot
frame
taken
video
obtain
experi
perform
healthi
anesthet
rat
overlaid
circl
indic
identifi
boundari
select
alveolu
figur
present
trace
alveolar
diamet
tidal
breath
evalu
success
frame
allow
one
compens
motion
artifact
analyz
intratid
chang
alveolar
geometri
conclus
given
synchron
respiratori
data
tool
allow
one
quantifi
pressurerel
chang
alveolar
size
thu
allow
one
monitor
alveolar
distens
varieti
anim
model
exampl
lavageinduc
ard
correl
find
exampl
outcom
introduct
alveolar
recruit
mainten
lung
volum
import
goal
treatment
acut
lung
injuri
ali
essenti
improv
oxygen
usual
employ
strategi
achiev
goal
use
posit
endexpiratori
pressur
peep
recruit
collaps
highli
dynam
phenomena
difficult
monitor
dynam
effect
region
ventil
monitor
electr
imped
tomographi
eit
bedsid
investig
abil
eit
provid
use
tool
detect
dynam
chang
region
breath
breath
recruit
bedsid
increment
decrement
peep
trial
experiment
lung
injuri
addit
analyz
pressurevolum
pv
curv
comput
eit
data
method
ali
induc
six
pig
repetit
lung
lavag
stabil
lung
injuri
model
hour
stepwis
peep
trial
perform
consist
step
tidal
ventil
cmh
cmh
peep
trial
subject
ventil
pressurecontrol
global
ventilatori
ga
exchang
paramet
continu
record
offlin
analys
eit
data
comput
amount
breath
breath
recruit
eit
pressur
level
lung
lavag
nondepend
depend
region
interest
defin
tomogram
eit
defin
mean
increas
decreas
endexpiratori
global
imped
per
breath
result
ventilatori
paramet
clearli
show
recruit
nonaer
lung
area
descend
part
pressur
ramp
shape
pv
curv
eit
data
particular
increas
slope
lower
level
upper
level
reflect
recruit
poorli
ventil
lung
region
flatten
curv
higher
pressur
especi
upper
level
reflect
less
amount
recruit
overdistens
region
pulmonari
recruitmentderecruit
high
lower
level
phenomena
impress
induc
lung
injuri
ventil
set
respiratori
mechan
crucial
develop
protect
lung
ventil
nonlinear
complianc
mainli
focu
interest
hypothes
airway
resist
also
chang
intratid
therefor
studi
perform
analyz
depend
resist
tidal
ga
volum
method
induct
anesthesia
tracheotomi
lung
surfactantdeplet
piglet
ventil
zero
endexpiratori
pressur
three
differ
tidal
volum
mlkg
random
order
addit
baselin
measur
mlkg
perform
salin
lavag
chang
ventil
set
recruit
maneuv
perform
nonlinear
intratid
airway
resist
analyz
use
slice
method
result
figur
show
intratid
resist
lavag
grey
surfact
deplet
black
plot
alveolar
pressur
curv
diagram
repres
intratid
cours
resist
one
ventil
set
resist
increas
surfact
deplet
intratid
declin
lavag
conclus
analysi
resist
show
depend
intratid
volum
nonlinear
cours
intratid
resist
interpret
volumerel
calib
effect
lead
increas
crosssect
area
larg
small
airway
introduct
alveolar
recruit
maneuv
arm
use
high
airway
pressur
shown
reexpand
atelectasi
improv
ga
exchang
gener
anesthesia
howev
arm
may
lead
lung
stretchinginduc
inflammatori
respons
object
studi
evalu
plasma
cytokin
behavior
arm
healthi
volunt
method
obtain
ethic
committe
approv
inform
consent
basal
blood
sampl
collect
healthi
volunt
continu
posit
airway
pressur
cpap
noninvas
appli
bipap
vision
respiron
usa
use
total
face
mask
cpap
increas
cmh
cmh
everi
five
breath
cpap
cmh
inspiratori
pressur
cmh
cpap
implement
breath
cpap
stepwis
decreas
invers
fashion
puls
oximetri
arteri
pressur
heart
rate
measur
arm
addit
blood
sampl
drawn
minut
hour
measur
flow
cytometri
techniqu
cytometr
bead
array
kit
highest
cytokin
valu
minut
hour
arm
consid
peak
valu
measur
data
analyz
use
pair
test
oneway
rm
anova
p
signific
result
four
men
six
women
mean
age
year
mean
bmi
kgm
studi
chang
observ
heart
rate
map
arm
puls
oximetri
increas
p
shown
figur
arm
induc
signific
increas
peak
plasma
level
concentr
cytokin
return
basal
level
within
hour
advers
effect
observ
arm
conclus
despit
benefici
effect
revers
atelectasi
arminduc
lung
stretch
associ
inflammatori
respons
healthi
volunt
introduct
recruitmentderecruit
rd
seem
play
import
role
develop
vili
mani
clinician
base
determin
peep
set
mechan
ventil
ardsali
patient
estim
alveolar
recruit
project
aim
establish
onlin
tool
provid
estim
rd
patient
bedsid
approach
model
fit
current
offlin
patient
data
acquir
control
mechan
ventil
data
acquisit
intern
respiratori
data
ventil
evita
medic
germani
read
real
time
simul
assum
quantit
partit
pressuredepend
timedepend
recruit
pure
pressurerel
approach
exampl
abl
describ
transient
exampl
volum
shift
chang
peep
result
multistep
optim
process
perform
reduc
differ
measur
data
model
predict
moment
tidal
breath
respiratori
maneuv
current
state
model
visual
inflat
volum
split
extens
open
alveoli
tempor
pressuredepend
recruit
distribut
compart
time
tidal
inflat
depict
figur
pressur
vs
time
flow
vs
time
curv
shown
figur
conclus
fit
recruit
model
provid
interest
insight
directli
observ
rd
may
use
monitor
trend
drift
recruit
current
result
reli
certain
assumpt
exampl
distribut
quantiti
superimpos
pressur
modern
imag
techniqu
exampl
ct
eit
valid
fit
model
come
reach
perform
next
step
introduct
result
frc
increas
group
statist
signific
w
step
ml
step
ml
p
vs
step
step
ml
p
vs
step
p
vs
step
frc
increas
group
b
signific
step
ml
step
ml
step
ml
frc
group
statist
higher
frc
group
b
step
p
mw
step
p
mw
ratio
increas
group
statist
signific
w
step
step
p
vs
step
step
p
vs
step
ratio
increas
group
b
signific
step
step
step
ratio
group
statist
higher
ratio
group
b
step
p
mw
step
p
mw
c
stat
increas
group
signific
group
c
stat
statist
higher
c
stat
group
b
everi
step
p
mw
step
mlcmh
group
vs
mlcmh
group
b
step
mlcmh
vs
mlcmh
step
mlcmh
vs
mlcmh
conclus
limit
low
sampl
size
preliminari
data
suggest
frc
evalu
system
good
paramet
optim
pulmonari
recruit
seem
posit
overcom
c
stat
limit
evalu
pulmonari
recruit
parenchyma
introduct
purpos
studi
report
clinic
experi
highfrequ
oscillatori
ventil
hfov
rescu
trauma
patient
acut
respiratori
distress
syndrom
ard
sever
hypoxemia
despit
optim
convent
ventil
experiment
clinic
data
suggest
mechan
ventil
contribut
mortal
ard
modern
ventilatori
strategi
requir
protect
measur
low
tidal
volum
low
airway
pressur
fraction
inspir
oxygen
fio
alway
possibl
convent
ventil
hfov
could
altern
achiev
protect
ventil
adequ
oxygen
method
retrospect
analyz
nine
trauma
patient
present
ard
criteria
fail
convent
mechan
ventil
requir
hfov
mean
airway
pressur
initi
set
cmh
higher
convent
ventil
subsequ
adjust
maintain
oxygen
satur
fio
paco
target
rang
mmhg
ph
collect
demograph
data
injuri
sever
scale
iss
apach
ii
score
time
hfov
time
spent
hfov
ventil
set
arteri
blood
ga
hfov
mortal
result
fifteen
total
patient
r
nr
group
similar
prior
hfov
term
apach
ii
score
number
organ
failur
peep
plateau
pressur
durat
ventil
hfov
baselin
po
fio
ratio
improv
hour
hour
r
group
statist
significantli
higher
compar
avail
onlin
http
nr
group
differ
improv
oxygen
index
oi
two
group
hour
also
statist
signific
rate
improv
po
fio
ratio
oi
nr
slower
r
differ
statist
signific
trend
test
see
figur
conclus
lower
po
fio
ratio
higher
oi
prior
hfov
slow
improv
po
fio
ratio
oi
hour
hfov
signific
neg
outcom
predictor
hfov
ard
monitor
slow
recruit
manoeuvr
highfrequ
oscillatori
ventil
adult
acut
respiratori
distress
syndrom
patient
use
electr
imped
tomographi
howev
chang
lung
volum
rm
lung
recruit
difficult
quantifi
bedsid
use
ct
impract
patient
hfov
studi
effect
standardis
protocol
slow
rm
srm
region
lung
volum
assess
noninvas
electr
imped
tomographi
eit
surviv
discharg
ward
admiss
ph
less
found
significantli
associ
p
failur
treatment
conclus
although
believ
unit
approach
hfov
one
treatment
rather
rescu
result
suggest
still
use
hfov
rescu
mode
result
support
find
studi
earlier
initi
hfov
show
trend
toward
improv
outcom
adult
patient
ard
studi
still
requir
identifi
appropri
paramet
select
patient
time
manner
may
benefit
hfov
howev
progress
acidosi
ard
appear
rel
import
predict
criterion
paramet
fail
oxygen
ventil
introduct
inadvert
endobronchi
intub
onelung
ventil
olv
standard
endotrach
tube
may
lead
seriou
complic
nonventil
lung
pneumothorax
hypoxemia
auscult
breath
sound
found
vcv
volum
control
ventil
inaccur
detect
olv
high
margin
error
vibrat
respons
imag
vri
novel
technolog
measur
vibrat
energi
lung
display
region
intens
visual
graphic
format
time
start
procedur
display
take
less
minut
investig
effect
vri
detect
olv
use
doublelumen
endotrach
tube
lung
surgeri
patient
method
doublelumen
tube
place
time
surgeri
tracheal
endobronchi
lumen
altern
clamp
produc
unilater
lung
ventil
right
left
lung
vri
perform
occlus
two
imag
exclud
priori
prior
analysi
due
technic
failur
extern
artifact
right
left
lung
distribut
vibrat
intens
shown
figur
mean
percentag
chang
vibrat
intens
clearli
demonstr
increas
vibrat
ventil
lung
vs
p
figur
conclus
auscult
insensit
endobronchi
intub
chest
radiographi
may
immedi
avail
vri
offer
potenti
rapidli
noninvas
determin
endobronchi
intub
current
vri
perform
sit
posit
capabl
supin
imag
soon
avail
introduct
airflow
mechan
ventil
patient
easili
measur
inspiratori
limb
ventil
region
airflow
insid
lung
point
black
box
vibrat
respons
imag
vri
novel
technolog
measur
vibrat
energi
lung
creat
realtim
structur
function
imag
region
vibrat
respir
sophist
surfac
skin
sensor
place
subject
back
record
analyz
display
vibrat
noninvas
goal
assess
correl
vibrat
measur
chest
wall
airflow
lung
method
assess
effect
constant
inspiratori
flow
lung
vibrat
vri
perform
mechan
ventil
patient
assist
volum
control
airflow
tube
record
concurr
assess
effect
increas
flow
rate
lung
vibrat
healthi
subject
record
sever
time
vri
take
tidal
volum
ml
respiratori
rate
inspiratori
tidal
volum
record
avail
onlin
http
mechan
ventil
patient
minim
flow
vibrat
lowest
flow
begin
ventil
vibrat
measur
lung
increas
flow
stop
vibrat
decreas
inspiratori
hold
perform
separ
inspiratori
expiratori
vibrat
figur
subject
take
increas
tidal
volum
vibrat
breath
cycl
increas
linearli
sampl
subject
shown
figur
r
conclus
vibrat
measur
use
vri
correl
lung
airflow
given
difficulti
assess
airflow
lung
measur
lung
vibrat
could
potenti
serv
surrog
region
lung
airflow
glidingslic
method
enhanc
tool
estim
intratid
respiratori
mechan
introduct
focus
lungprotect
ventil
analysi
nonlinear
dynam
respiratori
mechan
appear
crucial
base
slice
method
develop
glidingslic
method
tool
determin
respiratori
system
mechan
tool
test
nonlinear
waterfil
twochamb
lung
model
classic
slice
method
determin
paramet
respiratori
system
abut
volum
rang
glidingslic
method
enhanc
method
move
window
analysi
along
volum
axi
way
quasicontinu
cours
intratid
mechan
determin
test
new
method
build
physic
model
consist
two
connect
chamber
fill
water
inspir
water
displac
one
chamber
result
counter
pressur
use
wedg
certain
shape
simul
volumedepend
nonlinear
complianc
result
use
glidingslic
method
determin
nonlinear
cours
complianc
patient
figur
model
data
figur
conclus
glidingslic
method
allow
one
calcul
mechan
paramet
respiratori
system
quasicontinu
allow
intuit
interpret
data
method
limit
principl
constrict
enhanc
ventilatori
maneuv
exampl
separ
view
inspiratori
expiratori
respiratori
mechan
decreas
peep
reduc
cmh
decreas
peep
reduc
cmh
conclus
accur
measur
frc
obtain
constant
breath
pattern
easier
obtain
control
ventil
comparison
pressuresupport
ventil
patient
aliard
frc
decreas
peep
reduct
whether
largest
chang
frc
indic
optim
peep
need
research
method
percentag
v
non
v
non
rel
total
lung
volum
quantifi
ctimag
seri
n
sheep
gross
anesthesiainduc
atelectasi
perform
differ
combin
number
anatom
locat
ct
slice
result
compar
v
non
entir
lung
lung
combin
one
juxtadiaphragmat
slice
juxta
three
apic
hiliar
juxtadiaphragmat
slice
three
consecut
juxtadiaphragmat
slice
correl
v
non
arteri
oxygen
partial
pressur
pao
examin
combin
pao
measur
time
ct
transform
logarithm
lnpao
linear
relat
pao
v
non
linear
regress
blandaltman
plot
use
statist
analysi
result
rsquar
r
valu
correl
lnpao
v
non
lung
slice
combin
juxta
respect
v
non
lung
correl
best
v
non
slice
combin
juxta
r
respect
comparison
slice
combin
lung
also
result
least
bia
blandaltman
analys
respect
r
correl
lung
bia
lung
vs
blandaltman
analysi
conclus
depend
precis
requir
use
singl
juxtadiaphragmat
ct
slice
help
speed
analysi
process
therebi
propel
clinic
implement
ctderiv
inform
data
suggest
juxtadiaphragmat
slice
may
better
suit
tradit
combin
apic
hiliar
juxtadiaphragmat
slice
introduct
respiratori
physiotherapi
ever
util
treatment
critic
patient
howev
known
studi
effect
ga
exchang
patient
acut
lung
injuri
ali
acut
respiratori
distress
syndrom
ard
physiotherapi
techniqu
purpos
studi
assess
effect
pulmonari
expans
disobstruct
maneuv
close
system
ga
exchang
patient
ali
ard
method
patient
diagnosi
ali
ard
met
inclus
criteria
random
one
two
group
intervent
group
subject
pulmonari
expans
bronchial
disobstruct
maneuv
approxim
minut
associ
follow
physiotherapi
techniqu
sigh
side
posit
expiratori
ribcag
compress
endotrach
suction
close
system
observ
minut
patient
control
group
receiv
treatment
observ
minut
ventilatori
paramet
arteri
blood
gase
measur
time
minut
procedur
time
method
nebul
devic
consist
cylindr
glass
hous
bottom
end
spheric
lower
hous
part
serv
dri
powder
reservoir
ga
inlet
portion
nozzl
end
coaxial
align
hous
almost
reach
bottom
dri
powder
reservoir
induc
aerosol
gener
ga
pressur
bar
appli
upper
portion
hous
contain
cap
aerosol
exit
port
sever
nozzl
ensur
discharg
unsuit
larg
aerosol
particl
aerosol
characterist
determin
laser
diffractometri
efficaci
inhal
rspc
surfact
applic
assess
three
anim
model
acut
lung
injuri
includ
rabbit
acut
lung
injuri
due
either
repetit
lavag
prolong
injuri
ventil
due
inhal
applic
bleomycin
day
bleomycinchalleng
spontan
breath
mice
gener
aerosol
mass
median
aerodynam
diamet
particl
smaller
averag
mass
surfact
nebul
condit
approxim
gmin
biochem
biophys
studi
show
composit
surfac
tension
reduc
properti
rspc
surfact
remain
unalt
nebul
rabbit
model
administr
mgkg
bodi
weight
rspc
surfact
result
farreach
restor
ga
exchang
complianc
bleomycinchalleng
spontan
breath
mice
surfact
aerosol
result
restor
complianc
conclus
nebul
characterist
result
vivo
studi
suggest
hereindescrib
dri
powder
nebul
might
proffer
surfact
therapi
ard
object
studi
effect
bal
respiratori
mechan
mechan
ventil
patient
suspect
pneumonia
find
whether
effect
relat
extens
radiograph
infiltr
preced
respiratori
mechan
measur
method
bal
perform
ml
steril
isoton
salin
three
aliquot
ml
respiratori
mechan
static
complianc
airway
resist
measur
use
rapid
airway
occlus
techniqu
immedi
bal
minut
later
heart
rate
arteri
blood
pressur
bodi
temperatur
record
continu
patient
patient
classifi
accord
presenc
unilater
bilater
infiltr
result
fiftyeight
critic
ill
patient
undergo
mechan
ventil
includ
follow
bal
complianc
respiratori
system
cr
decreas
mlcmh
p
airway
resist
increas
cm
h
olseg
p
minut
later
paramet
return
prebal
valu
p
signific
patient
show
decreas
cr
higher
prebal
cr
patient
less
sever
decreas
vs
p
contrari
neither
prebal
airway
resist
extens
radiograph
infiltr
relat
chang
respiratori
mechan
conclus
bal
mechan
ventil
patient
lead
signific
transitori
deterior
pulmonari
mechan
character
decreas
cr
increas
airway
resist
patient
better
initi
cr
show
sever
affect
clinic
examin
ce
chest
xray
xray
limit
sensibl
specif
contrastenhanc
comput
tomographi
ct
scan
gold
standard
ct
scan
limit
take
time
perform
impli
transport
sever
injur
patient
ionis
effect
thorac
ultrasonographi
us
quickli
perform
bedsid
emerg
room
good
diagnosi
accuraci
ard
patient
purpos
studi
evalu
diagnosi
accuraci
us
sever
injur
patient
emerg
room
method
prospect
evalu
patient
median
age
year
admit
emerg
room
grenobl
univers
hospit
period
month
pneumothorax
hemothorax
alveolar
consolid
diagnos
ce
xray
us
physician
perform
us
involv
patient
manag
result
mission
adult
patient
underw
prehospit
endotrach
intub
cardiac
arrest
n
multipl
injuri
n
drug
poison
n
pulmonari
edema
n
bonfil
intub
fiberscop
use
either
plan
n
unplan
n
intub
success
first
attempt
even
two
cardiac
arrest
victim
unexpect
difficult
airway
cormack
lehan
grade
iv
direct
laryngoscopi
patient
multipl
injuri
cervic
immobil
collar
need
unfasten
remov
endotrach
intub
suffici
retropharyng
space
mandatori
suffici
use
bonfil
creat
digit
jaw
thrust
maneuv
first
three
patient
use
standard
mackintosh
laryngoscop
blade
significantli
enhanc
eas
insert
bonfil
fiberscop
visual
glottic
apertur
therebi
decreas
procedur
time
second
second
conclus
despit
first
promis
seri
inthefield
use
physician
paramed
familiar
bonfil
devic
optim
clinic
condit
use
emerg
prehospit
condit
experi
learn
curv
bonfil
devic
steep
intub
supervis
instructor
usual
prove
effect
achiev
suffici
skill
use
bonfil
one
less
optim
condit
summari
believ
bonfil
fiberscop
prove
valu
addit
airway
manag
devic
emerg
prehospit
set
introduct
studi
design
assess
abil
icu
deal
unanticip
difficult
intub
icu
locat
incid
difficult
intub
found
significantli
higher
theatr
vs
method
contact
adult
gener
icu
south
england
invit
physician
respons
airway
manag
take
part
structur
interview
interview
design
follow
difficult
airway
societi
da
guidelin
design
six
equipmentrel
question
identifi
unit
achiev
minimum
level
equip
necessari
includ
avail
laryngoscop
capnographi
lmailma
rescu
techniqu
introduct
occasion
rescuer
confront
hard
situat
establish
tracheal
intub
compar
doctor
anesthet
room
especi
confin
space
tracheal
intub
must
enter
technic
difficulti
support
devic
may
caus
fact
devic
develop
special
standpoint
clinic
emerg
use
object
airway
scope
aw
one
newest
intub
devic
manufactur
use
modern
technolog
allevi
tracheal
intub
emerg
scene
aw
equip
fullcolor
ccd
lcd
monitor
special
configur
introduc
guid
tracheal
tube
glotti
figur
aim
studi
confirm
potenti
aw
intubationsupport
devic
emerg
scene
method
six
doctor
emerg
depart
enrol
studi
doctor
experienc
use
aw
case
oper
avail
onlin
http
airway
equip
avail
icu
score
consid
minimum
conclus
portabl
easi
handi
excel
visual
inform
tubeguid
function
introduc
aw
may
potenti
allevi
variou
difficulti
intub
emerg
scene
even
confin
space
result
number
unsuccess
placement
attempt
none
ubbr
group
one
cbbr
group
two
ubbl
group
five
cbbl
group
fiberopt
aid
techniqu
appropri
leftsid
blocker
group
statist
differ
bronchial
blocker
malposit
lung
collaps
number
complic
among
two
group
furthermor
elect
thorac
surgic
case
lung
isol
manag
seem
similar
group
discuss
studi
demonstr
wireguid
bronchial
blocker
provid
high
torqu
control
easili
manipul
desir
site
lung
conclus
studi
show
use
coopdech
bronchial
blocker
tube
new
tracheal
tube
design
use
mechan
ventil
critic
ill
lotrach
shown
prevent
ubiquit
problem
microaspir
secret
associ
convent
hvlp
cuff
aspir
prevent
achiev
properti
lotrach
lowvolum
lowpressur
lvlp
cuff
previous
describ
import
alongsid
achiev
aspir
prevent
also
tracheal
wall
pressur
control
result
convent
hvlp
cuff
prevent
leakag
fluid
past
cuff
henc
neg
slope
graph
lotrach
cuff
leak
therefor
line
horizont
see
figur
clinic
studi
show
lotrach
portex
cuff
demonstr
gross
air
leak
equal
accept
tracheal
wall
pressur
cmh
respect
see
tabl
introduct
lung
injuri
gener
edema
burn
resuscit
complic
airway
manag
patient
care
need
longterm
ventil
multipl
surgeri
warrant
earli
tracheostomi
percutan
techniqu
well
describ
howev
burn
swollen
neck
increas
recogn
complic
report
modifi
semiopen
techniqu
perform
percutan
tracheotomi
pt
acut
burn
patient
consid
safer
method
review
medic
record
patient
admit
region
burn
center
requir
tracheostomi
prolong
mechan
ventil
procedur
took
place
burn
excis
plan
otherwis
perform
bedsid
blue
rhino
tracheostomi
kit
use
pt
major
differ
approach
includ
dissect
pretrach
fascia
allow
trachea
seen
palpat
bleed
control
use
electrocauteri
blood
vessel
retract
field
ligat
trachea
palpat
endotrach
tube
withdrawn
proxim
trachea
flexibl
bronchoscop
use
confirm
proper
placement
guidewir
proper
placement
tracheal
tube
confirm
capnographi
patient
deep
trachea
due
sever
neck
swell
proximallong
tracheostomi
tube
substitut
standard
one
event
airway
ventil
becam
compromis
techniqu
could
convert
rapidli
open
procedur
patient
admit
burn
center
juli
decemb
requir
tracheostomi
eighteen
perform
percutan
bedsid
total
burn
surfac
area
averag
rang
pt
perform
within
averag
day
admiss
rang
day
overal
mortal
tracheostomi
group
shortterm
complic
associ
method
conclus
pt
perform
safe
sever
burn
patient
use
semiopen
percutan
techniqu
expos
trachea
palpat
trachea
avoid
risk
lose
airway
permit
immedi
access
trachea
event
untoward
loss
airway
believ
method
safer
commonli
use
techniqu
requir
bronchoscop
visual
introduct
retrospect
analysi
year
cohort
tracheostomi
discharg
intens
care
specialist
cardiothorac
centr
undertaken
analys
whether
facilit
outreachl
discharg
safe
method
retrospect
analysi
icu
databas
undertaken
identifi
patient
tracheostomi
percutan
surgic
insert
icu
chart
review
patient
discharg
icu
tracheostomi
situ
perform
follow
variabl
collect
patient
demograph
diagnosi
number
day
tracheostomi
situ
number
day
noninvas
ventil
cpap
tracheostomyrel
complic
review
risk
manag
databas
perform
identifi
tracheostomyrel
report
advers
event
result
one
hundr
eight
tracheostomi
perform
intens
care
period
sixtytwo
patient
discharg
tracheostomi
situ
review
outreach
team
cumul
total
day
decannul
day
wherebi
patient
tracheostomi
situ
noninvas
ventil
three
report
critic
event
relat
tracheostomi
death
conclus
patient
tracheostomi
insert
discharg
critic
care
tracheostomi
situ
support
outreach
team
patient
success
manag
level
level
area
reduc
requir
critic
care
level
bedday
low
rate
complic
conclud
outreach
servic
facilit
earli
safe
discharg
tracheostomi
patient
critic
care
indic
levosimendan
therapi
acut
heart
failur
due
myocardi
infarct
case
acut
progress
chronic
heart
failur
nyha
iiiiv
case
bolu
levosimendan
infus
administ
rate
hour
hour
group
respect
investig
occurr
sustain
ventricular
supraventricular
arrhythmia
first
hour
begin
infus
ratio
hypertens
diabet
earlier
myocardi
infarct
acbg
respect
monitor
popul
femal
male
mean
age
year
three
ventricular
arrhythmia
one
supraventricular
arrhythmia
observ
period
occur
acut
heart
failur
patient
acut
myocardi
infarct
parallel
usag
catecholamin
noradrenalin
andor
dopamin
levosimendan
therapi
observ
three
case
one
ventricular
tachycardia
observ
hour
start
levosimendan
infus
arrhythmia
observ
chronic
heart
failur
patient
incid
proarrhythm
effect
levosimendan
therapi
whole
analys
popul
acut
heart
failur
acut
myocardi
infarct
conclus
result
author
would
like
draw
attent
proarrhythm
effect
levosimendan
acut
heart
failur
therapi
especi
case
parallel
usag
catecholamin
introduct
myocardi
depress
sepsi
among
factor
due
calcium
ca
desensit
myofila
use
ca
sensit
drug
may
play
benefici
role
situat
levosimendan
dual
mechan
caus
ca
sensit
bind
troponin
c
open
atpdepend
k
channel
vascular
smooth
muscl
method
prospect
observ
caseseri
studi
extend
period
month
novemb
april
analyz
data
patient
receiv
levosimendan
myocardi
depress
due
sever
sepsi
compar
histor
data
previou
year
group
patient
regard
mortal
patient
includ
studi
pulmonari
arteri
cathet
pac
initi
resuscit
earli
goaldirect
therapi
egdt
respond
treatment
cardiac
index
ci
patient
receiv
infus
levosimendan
without
load
dose
hemodynam
paramet
ci
mix
venou
satur
svo
mean
arteri
pressur
map
record
hour
noradrenalin
use
maintain
map
mmhg
patient
follow
day
document
mortal
spss
use
statist
analysi
student
test
use
test
signific
averag
age
year
apach
ii
score
patient
divid
three
subgroup
survivor
mortal
group
signific
differ
subgroup
regard
age
apach
ii
score
levosimendan
group
mortal
compar
histor
data
respect
chang
ci
survivor
group
signific
p
mortal
group
insignific
svo
increas
survivor
mortal
group
significantli
p
p
respect
show
signific
improv
group
map
also
show
signific
improv
survivor
group
p
insignific
other
conclus
evid
studi
levosimendan
improv
hemodynam
respons
septic
patient
although
improv
mortal
say
full
confid
improv
hemodynam
paramet
respons
randomis
control
trial
need
answer
question
underway
elderli
acut
coronari
syndrom
patient
neglect
popul
incid
acut
myocardi
infarct
ami
old
patient
increas
due
rapid
age
popul
particular
concern
ami
patient
year
old
associ
high
mortal
howev
role
reperfus
therapi
clear
patient
object
evalu
midterm
longterm
prognosi
octogenarian
patient
stelev
myocardi
infarct
stemi
treat
primari
coronari
angioplasti
pca
method
studi
retrospect
januari
march
patient
year
stemi
treat
pca
end
followup
assess
incid
death
myocardi
infarct
necess
new
procedur
revascular
treat
vessel
averag
age
year
women
locat
ami
anterior
diabet
averag
followup
time
month
followup
patient
develop
event
n
consist
death
cardiac
death
howev
event
occur
first
month
admiss
mortal
month
year
low
figur
conclus
data
show
octogenarian
patient
stemi
treat
primari
pca
develop
high
mortal
howev
mortal
especi
concentr
first
month
procedur
low
month
year
purpos
although
invas
manag
stsegment
elev
myocardi
infarct
stemi
improv
clinic
outcom
earli
mortal
remain
import
issu
purpos
assess
util
initi
electrocardiograph
ecg
pattern
detect
patient
increas
risk
despit
current
recommend
revascular
method
analyz
consecut
patient
age
year
male
admit
first
hour
stemi
coronari
unit
exclus
criteria
left
bundl
branch
block
admiss
previou
myocardi
infarct
patient
treat
primari
angioplasti
patient
treat
thrombolyt
earli
reperfus
criteria
program
coronari
angiographi
follow
day
two
group
defin
accord
presenc
stsegment
elev
ste
togeth
distort
termin
portion
qr
two
adjac
lead
group
absenc
pattern
group
figur
result
st
elev
distort
termin
portion
qr
present
initi
ecg
patient
group
lower
incid
rentrop
grade
group
p
figur
moreov
group
higher
enzym
releas
wors
maxim
killip
class
frequent
combin
variabl
deathshock
group
often
proxim
occlus
infarctionrel
arteri
nonreflow
multivari
analysi
found
ecg
independ
predictor
outcom
avail
onlin
http
result
patient
hemoglobin
valu
gl
use
refer
cardiovascular
mortal
increas
hemoglobin
level
fell
gl
rose
gl
inhospit
mortal
patient
hemoglobin
concentr
gl
patient
hemoglobin
concentr
gl
patient
hemoglobin
concentr
gl
patient
hemoglobin
concentr
gl
patient
hemoglobin
concentr
gl
greater
increas
risk
complic
associ
low
hemoglobin
concentr
pronounc
patient
anemia
patient
without
compar
patient
hemoglobin
concentr
gl
hemoglobin
concentr
gl
inhospit
complic
hemoglobin
concentr
gl
also
arrhythmia
pneumonia
p
respect
expect
signific
invers
correl
hemoglobin
concentr
age
r
p
observ
signific
posit
correl
hemoglobin
concentr
albumin
concentr
patient
acut
myocardi
infarct
conclus
demonstr
studi
revers
jshape
relationship
baselin
hemoglobin
valu
major
advers
cardiovascular
event
observ
patient
acut
myocardi
infarct
greater
incid
patient
hemoglobin
concentr
admiss
elderli
popul
younger
one
anaemia
moment
admitt
associ
higher
heart
failur
mortal
among
patient
acut
coronari
syndrom
preval
anaemia
hb
gdl
women
hb
gdl
men
patient
ac
group
characteris
follow
woman
p
higher
age
p
less
weight
p
higher
frequenc
high
blood
pressur
p
diabet
mellitu
p
histori
ischaem
heart
diseas
p
peripher
arteri
diseas
p
group
present
major
proport
nstemi
p
higher
level
renal
dysfunct
p
microalbuminuria
p
patient
anaemia
present
wors
intrahospit
prognosi
major
incid
cardiac
insuffici
p
refractori
angina
pectori
p
electr
complic
p
higher
mortal
p
presenc
anaemia
independ
predictor
cardiac
insuffici
death
moment
admitt
ccu
ci
p
conclus
presenc
anaemia
power
predictor
wors
prognosi
patient
ac
anaemia
associ
factor
wors
prognosi
renal
dysfunct
peripher
arteri
diseas
diabet
mellitu
longterm
prognost
impact
anemia
patient
stelev
acut
myocardi
infarct
treat
primari
coronari
angioplasti
group
p
control
varieti
baselin
clinic
laboratori
angiograph
variabl
anemia
strong
independ
predictor
death
rehospit
heart
failur
acut
coronari
event
hr
ci
p
figur
show
patient
anemia
present
wors
prognosi
introduct
aim
studi
investig
relationship
blood
pressur
plasma
magnesium
level
patient
refer
emerg
depart
hypertens
attack
epidemiolog
evid
effect
magnesium
blood
pressur
inconsist
metabol
experiment
studi
suggest
magnesium
may
role
regul
blood
pressur
magnesium
regul
variou
ion
channel
mani
tissu
includ
cardiovascular
system
magnesium
second
abund
intracellular
cation
import
element
numer
biolog
function
cardiovascular
system
furthermor
magnesium
act
calcium
antagonist
regul
calcium
metabol
method
patient
includ
taken
emerg
depart
due
hypertens
attack
age
gender
systol
diastol
blood
pressur
record
order
see
plasma
magnesium
level
venou
blood
sampl
taken
result
compar
chisquar
test
valu
p
accept
signific
result
seventythre
patient
femal
male
includ
studi
averag
age
rang
year
averag
blood
pressur
patient
found
systol
rang
mmhg
diastol
rang
mmhg
averag
plasma
magnesium
level
rang
mgl
plasma
magnesium
level
low
patient
rang
mgl
neg
relationship
systol
blood
pressur
plasma
magnesium
level
p
addit
neg
relationship
diastol
blood
pressur
plasma
magnesium
level
p
conclus
low
plasma
magnesium
level
would
import
factor
elev
blood
pressur
hypertens
attack
surgeri
patient
well
sever
hypertens
patient
clevidipin
ultrashortact
vascular
arterialselect
calcium
antagonist
current
develop
treat
acut
hypertens
method
analyz
data
two
doubleblind
placebocontrol
trial
evalu
abil
clevidipin
control
bp
highrisk
cardiovascular
surgeri
patient
addit
evalu
design
recent
initi
trial
analyz
clevidipin
sever
hypertens
veloc
trial
clevidipin
demonstr
statist
signific
decreas
mean
arteri
pressur
baselin
p
compar
placebo
time
point
bp
lower
effect
observ
within
minut
clevidipin
median
time
achiev
target
systol
blood
pressur
sbp
minut
respect
see
figur
patient
acut
sever
hypertens
veloc
trial
studi
percentag
patient
sbp
fall
lower
limit
patientspecif
predetermin
target
rang
initi
dose
mghour
within
minut
initi
infus
well
percentag
patient
reach
prespecifi
target
sbp
rang
within
minut
begin
studi
drug
conclus
studi
clevidipin
demonstr
abil
precis
achiev
target
blood
pressur
reduct
short
period
time
highrisk
patient
popul
analysi
rapid
decreas
note
clevidipin
conduct
patient
acut
sever
hypertens
veloc
trial
inflammatori
process
acut
pericard
pc
may
involv
epicardium
caus
myocardi
damag
reflect
cardiac
troponin
tni
releas
studi
perform
tni
demonstr
tempor
pattern
releas
similar
acut
myocardi
infarct
ami
howev
true
prognost
signific
tni
remain
unknown
set
introduct
earli
risk
stratif
essenti
manag
patient
acut
coronari
syndrom
ac
measur
renal
function
serum
creatinin
estim
creatinin
clearanc
carri
independ
prognost
inform
popul
cystatin
c
new
better
marker
renal
function
creatinin
aim
therefor
evalu
prognost
valu
cystatin
c
popul
method
four
hundr
twentyeight
patient
ac
admit
coronari
care
unit
ccu
studi
prospect
sixtythre
per
cent
present
nonstseg
elev
myocardi
infarct
nstemi
stsegment
elev
myocardi
infarct
stemi
hospit
regist
cardiovascular
risk
factor
determin
presenc
microalbuminuria
mgdl
urin
sampl
also
took
blood
sampl
first
hour
admitt
ccu
complet
hemogram
level
total
cholesterol
hdl
cholesterol
ldl
cholesterol
triglycerid
creatinin
creatinin
clearanc
cockroftgault
equat
glucos
highsens
creactiv
protein
cystatin
c
followup
level
troponin
ck
ckmb
patient
submit
coronari
angiographi
first
hour
give
clinic
score
coronari
arteri
diseas
diseas
one
two
three
arteri
result
determin
cystatin
c
level
patient
femal
male
patient
found
normal
level
call
group
group
group
found
higher
level
cystatin
c
patient
group
present
higher
age
higher
frequenc
high
blood
pressur
wors
killip
class
score
moment
admitt
higher
inflammatori
activ
leucocytosi
p
higher
level
c
reactiv
protein
p
higher
grade
renal
dysfunct
p
anaemia
p
patient
group
present
wors
intrahospit
prognosi
higher
incid
cardiac
insuffici
p
ventricular
arrhythmia
p
pericardi
effus
p
higher
mortal
p
multivari
analysi
cystatin
c
independ
predictor
cardiac
insuffici
ci
p
conclus
higher
level
cystatin
c
patient
ac
indic
wors
intrahospit
prognosi
also
higher
inflammatori
activ
renal
dysfunct
reduct
glomerular
filtrat
rate
presenc
microalbuminuria
moment
admitt
reduc
prognost
patient
acut
coronari
syndrom
introduct
determin
glomerular
filtrat
rate
gfr
patient
acut
coronari
syndrom
ac
import
prognost
valu
presenc
microalbuminuria
known
risk
factor
patient
hypertens
diabet
know
less
effect
reduct
gfr
patient
ac
method
four
hundr
twentyeight
patient
ac
admit
coronari
care
unit
ccu
studi
prospect
sixtythre
percent
present
nonstseg
elev
myocardi
infarct
stsegment
elev
myocardi
infarct
hospit
regist
cardiovascular
risk
factor
determin
presenc
mgdl
urin
sampl
also
took
blood
sampl
first
hour
admitt
ccu
complet
hemogram
level
total
cholesterol
hdl
cholesterol
ldl
cholesterol
triglycerid
creatinin
creatinin
clearanc
cockroftgault
equat
glucos
highsens
creactiv
protein
followup
level
troponin
ck
ckmb
result
thirtynin
percent
patient
ac
present
gfr
less
mlminut
present
moment
admitt
ccu
fortyfour
percent
patient
gfr
less
mlminut
also
present
contrari
patient
gfr
mlminut
p
group
contain
significantli
women
p
histori
ischem
brain
event
peripher
arteri
diseas
p
wors
killip
score
moment
admitt
p
develop
cardiac
insuffici
p
higher
mortal
hospit
stay
p
intrahospit
surviv
patient
gfr
less
mlminut
patient
without
gfr
mlminut
p
logrank
test
patient
gfr
less
mlminut
without
present
intrahospit
surviv
multivari
analysi
gfr
less
mlminut
ci
presenc
ci
independ
predict
factor
cardiac
insuffici
mortal
conclus
presenc
gfr
less
mlminut
moment
admitt
patient
ac
identifi
group
patient
bad
prognosi
futur
studi
reveal
whether
improv
renal
function
benefici
group
patient
background
elev
circul
level
brain
natriuret
peptid
bnp
cardiac
troponin
ctni
connect
advers
prognosi
patient
chronic
heart
failur
chf
howev
scant
data
predict
valu
biomark
combin
method
total
consecut
patient
mean
age
year
hospit
acut
decompens
nyha
class
iiiiv
ischem
etiolog
lowoutput
mean
lvef
chf
studi
biochem
marker
measur
upon
admiss
incid
death
prespecifi
primari
endpoint
incid
primari
endpoint
multivari
cox
analysi
includ
baselin
characterist
studi
biomark
elev
circul
level
rr
p
bnp
rr
p
ctni
rr
p
independ
associ
primari
endpoint
patient
divid
accord
number
posit
biomark
estim
roc
analysi
signific
gradual
increas
rate
primari
endpoint
increas
number
posit
biomark
mortal
rate
patient
zero
one
two
three
posit
biomark
respect
p
figur
present
result
suggest
patient
hospit
due
acut
decompens
sever
lowoutput
chf
serum
level
bnp
ctni
use
combin
enhanc
earli
risk
stratif
avail
onlin
http
introduct
past
decad
coronari
revascularis
help
reduc
mortal
morbid
rate
coronari
arteri
diseas
addit
revascularis
longterm
prognosi
depend
success
implement
secondari
prevent
particular
use
aspirin
statin
angiotensinconvert
enzym
ace
inhibitor
mani
previou
studi
highlight
underutilis
secondari
prevent
strategi
patient
popul
focus
review
secondari
prevent
medic
time
revascularis
provid
excel
opportun
ensur
optim
use
agent
aim
identifi
proport
patient
undergo
nonemerg
surgic
revascularis
discharg
four
secondari
prevent
medic
method
retrospect
analysi
inhous
cardiothorac
surgic
databas
perform
patient
undergon
surgic
revascularis
januari
novemb
patient
undergo
coronari
arteri
bypass
graft
includ
result
total
consecut
patient
includ
analysi
mean
age
year
total
isol
coronari
arteri
bypass
graft
procedur
combin
procedur
perform
see
tabl
introduct
normal
rest
condit
oxygen
deliveri
match
overal
metabol
demand
organ
oxygen
consumpt
vo
energi
produc
basic
aerob
mechan
cardiac
surgeri
extracorpor
circul
ecc
sever
factor
exampl
hemodilut
anemia
myocardi
stun
result
low
cardiac
output
co
determin
imbal
demand
may
affect
outcom
critic
linear
decreas
vo
co
product
vco
due
anaerob
vco
respiratori
quotient
increas
studi
aim
evalu
role
co
deriv
paramet
predict
postop
morbid
cardiac
surgeri
method
eight
hundr
twentyseven
consecut
adult
patient
underw
coronari
surgeri
studi
select
intraop
postop
co
deriv
paramet
could
associ
postop
morbid
postop
data
collect
first
hour
admiss
icu
influenc
predictor
outcom
analyz
morbid
defin
one
follow
event
cardiovascular
respiratori
neurolog
renal
infecti
hemorrhag
complic
univari
multivari
analys
perform
roc
curv
analysi
also
use
defin
best
predict
variabl
result
seventeen
patient
vs
men
six
women
longer
aortic
clamp
time
p
cpb
time
p
associ
vs
patient
show
higher
cardiac
index
hour
p
lactic
acid
within
first
hour
seven
patient
fulfil
vasopleg
shock
criteria
p
found
higher
level
hour
p
hour
p
solubl
tnf
receptor
hour
p
icu
admiss
hour
higher
coagul
activ
inr
p
fibrinogen
p
antithrombin
p
lower
level
plasminogen
activ
p
well
lower
plasminogen
activ
activ
ratio
p
higher
level
ddimer
p
lower
level
p
b
factor
p
p
well
significantli
higher
decreas
preoper
level
b
factor
lower
level
leptin
hour
found
vasopleg
patient
show
higher
blood
loss
along
time
point
figur
higher
incid
excess
bleed
vs
p
requir
hemoderiv
icu
stay
plasma
p
platelet
p
conclus
vs
postcpb
associ
activ
serin
proteas
system
lead
higher
blood
loss
excess
bleed
introduct
vasopleg
syndrom
vs
cardiac
surgeri
cardiopulmonari
bypass
cpb
vari
mild
sever
complic
appear
incid
rang
etiolog
complet
elucid
risk
factor
temperatur
durat
cardiopulmonari
bypass
preoper
treatment
angiotensinconvert
enzym
ace
inhibitor
associ
want
investig
possibl
role
sever
genet
polymorph
patient
vs
elect
cpb
method
perform
nest
casecontrol
studi
patient
undergo
cpb
men
women
mean
age
sd
year
vs
defin
system
vascular
resist
index
lower
cardiac
index
greater
lminm
within
first
hour
surgeri
record
data
relat
hemodynam
paramet
differ
postop
time
point
icu
admiss
hour
hour
surgeri
polymorph
follow
gene
plasminogen
activ
addit
neutral
marker
genotyp
follow
genom
control
strategi
would
detect
spuriou
associ
due
popul
substructur
use
pearson
chisquar
test
binari
logist
regress
spss
version
use
observ
patient
vasoplegia
criteria
men
six
women
age
year
one
associ
vs
polymorph
distribut
studi
popul
genotyp
patient
patient
introduct
bodi
mass
index
bmi
describ
risk
factor
coronari
arteri
diseas
associ
postop
bleed
cardiopulmonari
bypass
cpb
found
sever
studi
recent
nevertheless
strong
relationship
low
bmi
excess
bleed
remain
unexplain
sought
investig
bmi
role
postop
bleed
relationship
leptin
level
coagul
fibrinolysi
complement
paramet
method
perform
nest
casecontrol
studi
patient
receiv
antifibrinolyt
prophylaxi
use
bray
classif
bmi
lower
kgm
kgm
higher
kgm
variabl
collect
preoper
icu
admiss
hour
hour
surgeri
excess
bleed
defin
blood
loss
higher
l
first
hour
intervent
figur
bmi
present
direct
correl
leptin
fibrinogen
plasminogen
activ
arriv
meanwhil
bleed
show
invers
correl
paramet
bmi
tabl
patient
bmi
kgm
significantli
greater
coagul
fibrinolysi
complement
activ
therefor
patient
requir
significantli
greater
hemoderiv
conclus
lower
bmi
associ
higher
postop
bleed
lower
procoagul
factor
level
respiratori
control
ratio
vs
signific
hepat
mitochondri
state
higher
vs
respiratori
control
ratio
lower
vs
hemorrhageendotoxemia
group
compar
control
background
sepsisinduc
multipl
organ
failur
may
crucial
depend
develop
mitochondri
dysfunct
consequ
cellular
energet
failur
investig
whether
hepat
mitochondri
dysfunct
present
clinic
relev
porcin
model
fluidresuscit
septic
shock
method
anesthet
ventil
pig
kg
randomli
assign
septic
shock
fecal
periton
f
n
control
c
n
placement
portalhepat
vein
cathet
portal
vein
hepat
arteri
flow
probe
f
c
receiv
mlkghour
mlkghour
ringer
lactat
starch
respect
mean
arteri
pressur
map
total
liver
flow
tlf
hepat
deliveri
h
hepat
consumpt
vo
h
record
baselin
bl
hour
mlkgmin
activ
mitochondri
respiratori
chain
enzym
complex
iiv
assess
spectrophotometri
snapfrozen
liver
sampl
data
present
mean
sd
result
hyperdynam
circul
develop
f
increas
h
decreas
vo
h
tabl
complex
ii
activ
significantli
decreas
p
vs
bl
group
f
compar
c
complex
iiiiiv
function
decreas
parallel
f
monitor
mitochondri
nadh
redox
state
indic
intracellular
oxygen
level
togeth
microcirculatori
blood
flow
tbf
oxygen
hbo
could
serv
prefer
approach
evalu
tissu
balanc
viabil
hypothes
presenc
reduc
oxygen
deliveri
extract
blood
flow
redistribut
order
protect
vital
organ
increas
region
blood
flow
deliveri
less
vital
organ
diminish
thu
nadh
redox
state
less
vital
organ
could
serv
indic
overal
imbal
well
endpoint
resuscit
therefor
develop
optic
devic
embed
foley
cathet
provid
realtim
data
nadh
redox
state
tbf
hbo
critic
ill
patient
critiview
computer
optic
devic
integr
hardwar
softwar
order
provid
realtim
inform
tissu
viabil
modifi
threeway
foley
cathet
contain
fiberopt
probe
connect
critiview
mucos
side
urethr
wall
use
devic
five
femal
pig
underw
grade
hemorrhag
four
patient
monitor
aortic
abdomin
aneurysm
oper
preliminari
swine
model
human
studi
confirm
feasibl
collect
inform
mitochondri
function
urethr
wall
main
effect
grade
hemorrhag
start
blood
volum
decreas
blood
loss
minim
level
tbf
hbo
correl
maxim
nadh
level
valu
three
paramet
return
baselin
retransfus
shed
blood
aortic
clamp
patient
led
signific
decreas
tbf
hbo
nadh
level
increas
aortic
declamp
paramet
recov
normal
valu
preliminari
result
show
critiview
may
use
tool
detect
imbal
develop
emerg
metabol
state
nonvit
tissu
outcom
liver
transplant
steadili
improv
still
need
earlier
detect
complic
hepat
arteri
thrombosi
reject
earlier
vitro
studi
show
cma
microdialysi
system
kda
pore
size
membran
use
measur
select
cytokin
complement
monitor
patient
undergo
liver
transplant
microdialysi
continu
week
postop
analyz
paramet
detect
ischemia
cytokin
anaphylatoxin
explor
whether
reject
detect
earlier
standard
method
method
twenti
patient
undergo
liver
transplant
includ
two
microdialysi
cathet
introduc
liver
one
subcutan
tissu
analyz
metabol
paramet
glucos
pyruv
glycerol
lactat
result
fourteen
patient
unev
cours
postop
judg
clinic
routin
biochem
marker
ultrasound
doppler
patient
median
lactat
start
mm
hour
reperfus
fall
mm
first
hour
thereaft
stay
low
lp
ratio
specif
measur
ischemia
drop
patient
steadi
rise
pgml
also
slight
rais
initi
case
male
patient
steadili
increas
lp
ratio
day
microdialysi
measur
indic
insuffici
blood
suppli
underw
surgeri
day
later
hepat
arteri
thrombosi
found
biopsi
done
oper
show
acut
reject
signific
rise
pgml
day
diagnosi
reject
case
femal
patient
acut
reject
verifi
biopsi
day
postop
increas
liver
day
earlier
increas
liver
enzym
day
reject
verifi
biopsi
conclus
describ
normal
cours
four
cytokin
complement
liver
transplant
well
metabol
paramet
detect
ischemia
two
patient
reject
found
larg
increas
complement
splitproduct
liver
subcuti
day
paramet
liver
injuri
object
evalu
skelet
muscl
microcircul
nearinfrar
spectroscopi
nir
patient
chronic
heart
failur
chf
background
skelet
muscl
microcircul
impair
patient
chf
impair
seem
correl
diseas
sever
method
evalu
patient
chf
mean
age
year
healthi
volunt
chf
patient
endstag
heart
failur
eschf
undergo
treatment
intermitt
inotrop
agent
infus
period
studi
protocol
thenar
muscl
tissu
oxygen
satur
sto
measur
noninvas
nir
occlus
brachial
arteri
occlus
techniqu
result
patient
eschf
n
chf
n
present
significantli
lower
tissu
oxygen
satur
sto
healthi
subject
p
respect
oxygen
consumpt
rate
occlus
brachial
arteri
differ
significantli
patient
eschf
chf
healthi
subject
min
min
min
p
respect
reperfus
rate
differ
significantli
patient
eschf
chf
healthi
subject
min
min
min
p
respect
conclus
peripher
muscl
microcircul
assess
nir
impair
chf
patient
degre
dysfunct
associ
diseas
sever
acut
partial
revers
inotrop
agent
infus
introduct
cardiac
surgeri
patient
low
risk
postop
complic
may
involv
multipl
organ
failur
high
mortal
rate
complic
may
relat
occurr
organ
ischemia
reperfus
surgeri
investig
whether
microcirculatori
flow
alter
occur
cardiac
surgeri
method
observ
consecut
patient
underw
cardiac
surgeri
cardiopulmonari
bypass
cpb
microcircul
studi
use
sidestream
dark
field
sdf
imag
sublingu
capillari
flow
estim
use
semiquantit
microvascular
flow
index
mfi
small
diamet
medium
larg
size
microvessel
none
intermitt
sluggish
continu
flow
sdf
imag
perform
least
three
time
per
time
period
baselin
start
cpb
surgeri
patient
data
present
median
interquartil
rang
mfi
decreas
size
microvessel
minut
start
cpb
comparison
baselin
p
tabl
start
cpb
mean
arteri
pressur
map
lower
mmhg
mmhg
baselin
mmhg
mmhg
p
return
icu
mfi
increas
p
return
baselin
valu
microvessel
conclus
sdf
imag
use
bedsid
tool
evalu
sublingu
microcirculatori
chang
cardiac
surgeri
despit
maintain
common
circulatori
paramet
cpb
nonpulsatil
statu
hypothermia
temporari
drop
map
start
cpb
associ
decreas
sublingu
mfi
normal
surgeri
studi
reveal
whether
chang
relat
outcom
introduct
complic
oesophagectomi
gastric
tube
reconstruct
includ
leakag
stenosi
explain
compromis
local
perfus
although
unclear
extent
local
system
factor
contribut
process
aim
studi
observ
microvascular
blood
flow
unaffect
distant
tissu
periop
period
method
twelv
patient
includ
anesthesia
consist
thorac
epidur
analgesia
restrict
perop
fluid
therapi
net
perop
fluid
balanc
l
earli
extub
icu
fluid
infus
adjust
order
maintain
hourli
urin
product
mlkg
mean
arteri
pressur
maintain
mmhg
administr
noradrenalin
necessari
microcircul
visual
sublingu
tissu
microscan
sidestream
dark
field
imag
data
collect
five
time
point
immedi
induct
gastric
tube
reconstruct
directli
postop
day
postop
video
data
collect
microscan
analys
accord
semiquantit
analysi
describ
boerma
colleagu
divid
vessel
three
categori
small
medium
larg
divid
imag
four
quadrant
categor
flow
per
vessels
per
quadrant
calcul
microvascular
flow
index
mfi
result
see
figur
sublingu
microvascular
perfus
introduct
microcirculatori
dysfunct
hypothes
play
key
role
pathophysiolog
multipl
organ
failur
consequ
patient
outcom
object
present
studi
investig
differ
reactiv
hyperemia
respons
oscil
frequenc
survivor
nonsurvivor
patient
multipl
organ
dysfunct
syndrom
mod
method
twentynin
patient
survivor
nonsurvivor
two
organ
failur
elig
studi
entri
patient
hemodynam
stabil
demograph
clinic
data
record
laser
doppler
flowmet
use
measur
cutan
microcirculatori
respons
reactiv
hyperemia
oscillatori
chang
doppler
signal
measur
minut
period
forearm
ischemia
hyperemia
result
nonsurvivor
demonstr
significantli
higher
mod
score
compar
survivor
p
norepinephrin
requir
higher
nonsurvivor
p
nonsurvivor
higher
arteri
lactat
level
p
decreas
arteri
ph
level
p
decreas
arteri
po
valu
p
compar
survivor
higher
oscil
frequenc
skin
microvasculatur
rest
p
ischem
stimulu
p
observ
nonsurvivor
differ
observ
reactiv
hyperemia
respons
group
flowmot
frequenc
observ
reactiv
hyperemia
associ
sever
mod
p
although
statist
signific
arteri
lactat
concentr
p
conclus
increas
skin
microvascular
oscil
frequenc
rest
ischem
stimulu
associ
increas
mortal
patient
suffer
mod
suggest
underli
mechan
increas
flowmot
could
respons
skin
microvasculatur
hypoxia
impair
oxygen
util
skin
tissu
introduct
intermitt
posit
pressur
ventil
ippv
may
accompani
alter
microcircul
howev
effect
ippv
mention
interpret
result
studi
evalu
microcircul
use
orthogon
polar
spectral
sidestream
darkfield
imag
studi
aim
evalu
effect
ippv
microcircul
skeleton
muscl
serosa
small
intestin
rat
method
ten
anim
tracheostom
prepar
microcircul
studi
tissu
prepar
five
rat
allow
breath
spontan
group
sb
spontan
breath
five
rat
group
ippv
connect
small
anim
ventil
ippv
fio
respiratori
rate
tidal
volum
mlkg
inspiratori
time
respiratori
cycl
cmh
peep
sidestream
darkfield
imag
obtain
quadricep
femori
muscl
qfm
serosa
surfac
ileum
arteri
blood
pressur
rectal
temperatur
also
record
function
capillari
densiti
fcd
small
medium
vessel
rate
analys
offlin
use
ava
softwar
amc
univers
amsterdam
netherland
p
fcd
decreas
significantli
qfm
rat
ippv
respect
group
sb
resp
cmcm
fcd
intestin
serosa
affect
ippv
resp
cmcm
differ
mean
blood
pressur
temperatur
group
torr
group
sb
torr
group
ippv
conclus
use
ippv
taken
account
interpret
studi
examin
chang
microcircul
rat
examin
sublingu
microvascular
chang
experiment
human
endotoxemia
chang
microcircul
mitochondri
dysfunct
appear
key
mechan
sepsi
sinc
lead
region
mismatch
oxygen
suppli
demand
lipopolysaccharid
lp
use
induc
endotoxemia
model
sepsi
effect
microcirculatori
perfus
test
particularli
toler
induct
repeat
challeng
lp
method
six
healthi
volunt
receiv
intraven
inject
ngkg
escherichia
coli
lp
induc
endotoxemia
five
consecut
day
microvascular
perfus
sublingu
measur
use
sidestream
darkfield
imag
hour
lp
inject
day
measur
repeat
day
lp
administr
sublingu
capillari
flow
estim
use
semiqu
microvascular
flow
index
mfi
small
medium
larges
microvessel
flow
intermitt
flow
sluggish
flow
continu
flow
introduct
shock
defin
current
tissu
oxygen
metabol
disord
import
understand
oxygen
metabol
disord
individu
tissu
microdialysi
allow
determin
metabol
condit
region
tissu
appear
ideal
determin
region
metabol
tissu
condit
endotoxemia
object
studi
design
assess
region
metabol
tissu
condit
marker
tissu
metabol
lactat
region
tissu
tissu
lactat
tl
tissu
partial
oxygen
pressur
pto
sever
endotoxemia
compar
variabl
determin
standard
monitor
hemodynam
blood
ga
analysi
blood
lactat
bl
use
studi
rat
control
group
n
inject
salin
ml
intraperiton
rat
experiment
group
n
treat
intraperiton
inject
lipopolysaccharid
lp
mgkg
hemodynam
paramet
arteri
blood
ga
analysi
bl
pto
measur
group
tl
pyruv
subcutan
tissu
measur
use
microdialysi
paramet
measur
everi
minut
minut
lp
administ
control
group
paramet
chang
observ
period
minut
experiment
group
mean
arteri
pressur
map
remain
fairli
stabl
minut
inject
lp
map
gradual
decreas
subsequ
map
maintain
pto
gradual
decreas
linearli
figur
tl
increas
time
linearli
meanwhil
bl
chang
minut
minut
increas
abruptli
experiment
group
figur
conclus
experiment
endotoxemia
model
shown
partial
pressur
oxygen
subcutan
tissu
decreas
even
system
blood
pressur
maintain
boeksteg
colleagu
reveal
mean
skelet
muscl
po
increas
patient
sepsi
compar
patient
limit
infect
obtain
conflict
result
boeksteg
colleagu
reason
unknown
bl
abruptli
increas
minut
probabl
abnorm
metabol
induc
lp
wholebodi
organ
consid
bl
show
rise
minut
due
metabol
lactat
liver
muscl
tl
insuscept
lactat
metabol
organ
may
reflect
abnorm
tissu
metabol
precis
shunt
microcircul
contribut
patholog
sepsi
septic
shock
studi
hypothes
shunt
microcircul
occur
superior
mesenter
arteri
sma
ischemia
occlus
reperfus
explor
function
consequ
use
intravit
microscopi
spontan
breath
anim
rat
n
underw
occlus
sma
control
minut
follow
reperfus
hour
normal
salin
leukocyteendotheli
interact
mesenter
venul
quantifi
exterior
ileal
loop
use
intravit
microscopi
abdomin
blood
flow
record
continu
arteri
blood
gase
analyz
interv
continu
sma
blood
flow
measur
perform
compar
group
without
exterior
ileal
loop
adher
leukocyt
increas
shortli
reperfus
ischemia
group
plateau
group
centerlin
veloc
shear
rate
record
venul
significantli
reduc
reperfus
lowflownoflow
anim
undergo
minut
mesenter
arteri
occlus
compar
anim
minut
occlus
control
wherea
perfus
sma
ileal
vessel
persist
microcirculatori
chang
anim
minut
occlus
accompani
progress
metabol
acidosi
substanti
larger
volum
intraven
fluid
need
support
arteri
blood
pressur
significantli
reduc
surviv
group
continu
sma
blood
flow
measur
sma
blood
flow
increas
sma
occlus
minut
subsequ
reperfus
caus
perfus
abnorm
mesenter
microcircul
often
seen
sepsi
septic
shock
increas
microcircul
shunt
progress
metabol
acidosi
increas
mortal
detect
signific
chang
requir
prolong
observ
period
might
help
find
new
treatment
improv
poor
prognosi
mesenter
ischemia
introduct
target
oxygen
deliveri
postop
period
shown
reduc
hospit
length
stay
complic
use
nearinfrar
spectroscopi
devic
allow
measur
tissu
oxygen
satur
sto
noninvas
well
rudimentari
measur
blood
flow
beneath
probe
plausibl
chang
oxygen
deliveri
postop
optimis
may
reflect
chang
sto
provid
noninvas
surrog
method
adult
patient
admit
icu
surgeri
underw
protocolis
haemodynam
optimis
includ
patient
sto
record
thenar
emin
use
first
hour
stay
found
signific
correl
chang
sto
oxygen
deliveri
index
first
hour
intens
care
stay
n
correl
coeffici
p
figur
classifi
patient
achiev
mlminm
respond
respond
higher
sto
valu
hour
optimis
chang
remain
signific
throughout
durat
studi
figur
conclus
chang
sto
postop
optimis
appear
mirror
chang
may
allow
widespread
use
noninvas
tissu
oxygen
devic
surgic
optimis
method
random
healthi
subject
undergo
maxillofaci
surgeri
receiv
gener
anesthesia
sevofluoraneremifentanil
group
propofolremifentanil
associ
group
p
collect
noninvas
measur
hemoglobin
concentr
gastrocnemiu
muscl
subject
use
nir
devic
nimo
nirox
srl
itali
perform
quantit
assess
hbo
hb
exploit
precis
absorpt
measur
close
absorpt
peak
water
data
collect
seri
venou
occlus
differ
cuff
pressur
minut
induct
gener
anesthesia
muscl
blood
volum
microvascular
complianc
obtain
process
previous
describ
elsewher
data
analyz
oneway
analysi
varianc
test
result
demograph
data
subject
similar
group
p
gener
anesthesia
reduc
heart
rate
mean
arteri
pressur
increas
total
muscl
blood
volum
group
group
ml
ml
group
p
ml
p
gener
anesthesia
despit
differ
muscl
blood
volum
two
group
sevofluoraneremifentanil
significantli
decreas
microvascular
complianc
ml
p
wherea
propofolremifentanil
ml
p
avail
onlin
http
conclus
gener
anesthesia
affect
microvascular
bed
skelet
muscl
associ
opioid
ipnot
agent
increas
muscl
blood
volum
wherea
microvascular
complianc
reduc
sevofluoraneremifentanil
associ
hypothesi
tissu
oxygen
satur
sto
rate
tissu
deoxygen
stagnant
ischemia
earli
reliabl
detect
inadequ
tissu
oxygen
assess
prognosi
medic
emerg
room
patient
introduct
earli
recognit
patient
inadequ
tissu
oxygen
facilit
earli
diagnost
evalu
treatment
correl
improv
outcom
nearinfrar
spectroscopi
noninvas
emerg
set
rapidli
appliabl
method
measur
sto
method
prospect
observ
studi
includ
consecut
medic
emerg
room
patient
admiss
sto
rate
tissu
deoxygen
stagnant
ischemia
measur
nearinfrar
spectroscopi
method
inspectra
tissu
spectromet
hutchinson
technolog
inc
netherland
correl
clinic
sign
shock
lactat
outcom
result
three
hundr
forti
patient
includ
patient
admit
admit
icu
die
hospit
sto
higher
patient
admit
compar
patient
lo
day
vs
p
tissu
deoxygen
faster
min
vs
min
p
survivor
tissu
deoxygen
slower
group
patient
clinic
sign
shock
compar
patient
min
vs
min
p
age
lactat
rate
tissu
deoxygen
sto
signific
predictor
death
tabl
weak
signific
correl
sto
age
p
r
sto
lactat
p
r
sto
systol
blood
pressur
p
r
method
microcirculatori
hemoglobin
oxygen
satur
blood
flow
flow
au
measur
use
c
lea
medizintechnik
gmbh
giessen
germani
probe
appli
buccal
mucosa
thenar
emin
measur
obtain
simultan
two
depth
superfici
mm
deep
mm
everi
second
minut
record
later
analysi
procedur
repeat
anoth
occas
least
week
apart
studi
healthi
subject
male
femal
mean
age
year
rang
year
flow
measur
consist
higher
measur
deep
tissu
layer
mm
measur
superfici
layer
regardless
site
measur
buccal
mucos
rang
vari
minim
cv
wherea
mark
variabl
flow
measur
cv
reproduc
buccal
mucos
flow
measur
moder
good
intraindividu
reliabl
icc
rang
p
howev
measur
superfici
mucos
layer
show
moder
good
degre
interindividu
agreement
interindividu
reliabl
icc
rang
p
ldf
vl
valu
measur
thenar
emin
highli
variabl
reproduc
interindividu
agreement
poor
conclus
c
provid
reliabl
measur
buccal
microvascular
flow
skin
measur
thenar
emin
highli
variabl
unreli
central
venou
pressur
femor
access
true
evalu
introduct
tradit
invas
haemodynam
measur
pulmonari
arteri
occlus
pressur
use
assess
volum
statu
critic
ill
patient
vascular
pedicl
seen
chest
xray
scan
mediastin
silhouett
great
vessel
hypothes
vascular
pedicl
width
vpw
supin
portabl
chest
xray
scan
could
use
predict
intravascular
volum
overload
statu
critic
ill
patient
method
conduct
prospect
blind
observ
trial
pulmonari
arteri
occlus
pressur
paop
vpw
measur
patient
admit
icu
use
measur
paop
mmhg
indic
fluid
overload
state
measur
paop
mmhg
normal
low
volum
state
standard
portabl
chest
xray
scan
supin
posit
obtain
within
hour
paop
measur
receiveroper
characterist
roc
curv
construct
use
differ
cutoff
vpw
measur
identifi
sensit
specif
valu
see
figur
result
measur
obtain
patient
use
rocderiv
cutoff
vpw
measur
mm
found
sensit
specif
correctli
predict
fluid
overload
state
conclus
result
suggest
serial
measur
vpw
reliabl
use
predict
intravascular
volum
overload
icu
mean
selfrat
resid
n
similar
specialist
n
p
conclus
abil
physician
predict
advanc
cardiopulmonari
paramet
base
clinic
evalu
convent
monitor
alon
consider
limit
improv
experi
introduct
mani
therapeut
decis
made
icu
basi
clinic
judgment
convent
monitor
alon
although
may
inadequ
reliabl
estim
hemodynam
statu
therefor
measur
effect
advanc
cardiopulmonari
paramet
acp
major
therapeut
decis
method
cardiopulmonari
assess
done
critic
ill
patient
european
icu
independ
one
four
physician
per
patient
use
picco
monitor
pulsion
germani
follow
cardiopulmonari
evalu
predict
acp
report
elsewher
physician
suggest
therapeut
plan
first
set
picco
measur
cardiac
output
system
vascular
resist
global
enddiastol
volum
stroke
volum
variat
extravascular
lung
water
selfrat
accuraci
origin
therapeut
plan
male
requir
advanc
invas
hemodynam
monitor
due
cardiovascular
instabl
includ
prospect
observ
studi
univers
hospit
set
medic
icu
anaesthesiolog
icu
volumebas
hemodynam
paramet
determin
use
thermaldy
transpulmonari
dilut
techniqu
simultan
ivc
diamet
measur
throughout
respiratori
cycl
transabdomin
ultrasonographi
found
statist
signific
correl
inspiratori
expiratori
ivc
diamet
central
venou
pressur
p
p
extravascular
lung
water
index
p
p
intrathorac
blood
volum
index
p
p
intrathorac
thermal
volum
p
pao
fio
oxygen
index
p
p
respect
conclus
sonograph
determin
ivc
diamet
use
assess
volum
statu
mechan
ventil
septic
patient
approach
rapidli
avail
noninvas
inexpens
easi
learn
applic
almost
clinic
situat
without
harm
ivc
sonographi
may
contribut
faster
goalori
optim
fluid
statu
may
help
identifi
patient
deleteri
volum
expans
avoid
remain
elucid
whether
approach
influenc
outcom
septic
patient
introduct
hypothesi
measur
cardiac
index
ci
accur
ultrasound
cardiac
output
monitor
uscom
esophag
doppler
monitor
edm
edm
minim
invas
devic
demonstr
strong
correl
cardiac
output
measur
obtain
thermodilut
disadvantag
edm
need
probe
placement
esophagu
effect
limit
use
avail
onlin
http
method
includ
consecut
adult
patient
immedi
cardiac
surgeri
prospect
singlecent
studi
take
place
icu
co
measur
obtain
nicom
paccco
simultan
record
minut
minut
figur
evalu
accuraci
precis
respons
reliabl
nicom
detect
co
chang
toler
paramet
specifi
prospect
result
total
pair
co
measur
collect
mean
refer
valu
paccco
rang
lmin
period
stabl
paccco
slope
correl
nicom
paccco
r
bia
lmin
rel
error
patient
rel
error
period
increas
co
slope
similar
two
method
patient
intraclass
correl
posit
correspond
valu
period
decreas
co
respect
precis
alway
better
nicom
paccco
hemodynam
challeng
chang
minut
faster
nicom
p
amplitud
chang
differ
signific
final
sensit
nicom
detect
signific
direct
chang
specif
introduct
reliabl
continu
hemodynam
monitor
critic
ill
patient
essenti
effect
volum
manag
adequ
administr
vasoact
drug
picco
system
allow
continu
measur
cardiac
index
use
arteri
puls
contour
analysi
calibr
system
transpulmonari
thermodilut
recommend
everi
hour
studi
compar
differ
continu
measur
cardiac
index
use
arteri
puls
contour
analysi
cipc
cardiac
index
acquir
transpulmonari
thermodilut
citd
calibr
system
method
studi
includ
measur
critic
ill
patient
eight
male
two
femal
age
year
mean
year
requir
hemodynam
monitor
picco
system
five
patient
septic
shock
three
hepatoren
syndrom
two
acut
heart
failur
first
cipc
record
immedi
next
calibr
afterward
citd
measur
three
time
result
simultan
calibr
puls
contour
algorithm
picco
system
perform
mean
measur
per
patient
timelag
measur
hour
minut
hour
minut
comparison
cipc
immedi
calibr
calibrationderiv
citd
result
correl
coeffici
p
valu
blandaltman
analysi
cipc
mean
lminm
lower
citd
standard
deviat
lminm
correl
timelag
calibr
differ
cipc
citd
r
p
conclus
picco
system
allow
reliabl
continu
measur
cardiac
index
use
puls
contour
analysi
studi
could
find
increas
differ
cipc
citd
even
longer
time
period
calibr
use
transpulmonari
thermodilut
calibr
easi
achiev
addit
data
intrathorac
blood
volum
extravascular
lung
water
obtain
period
calibr
reason
precis
look
previous
strategi
improv
made
averag
three
four
measur
respiratori
cycl
yet
much
known
precis
transpulmonari
techniqu
term
repeat
studi
aim
look
coeffici
variat
cv
lithium
dilut
techniqu
mix
medicalsurg
intens
care
popul
propos
method
improv
precis
perform
four
consecut
lithium
dilut
cardiac
output
determin
critic
ill
patient
requir
haemodynam
monitor
heart
rate
hr
central
venou
pressur
cvp
mean
arteri
pressur
map
document
conjunct
cardiac
output
estim
data
exclud
chang
hr
cvp
map
occur
sequenti
measur
cv
sdmean
cardiac
output
x
calcul
singl
measur
averag
repeat
measur
order
clinic
accept
precis
techniqu
aim
obtain
cv
result
sixtyf
seri
suitabl
analysi
cv
show
normal
distribut
correl
magnitud
mean
cardiac
output
mean
cv
singl
lithium
dilut
cv
averag
n
lithium
dilut
n
n
n
conclus
cv
one
lithium
dilut
higher
clinic
accept
averag
two
lithium
dilut
measur
improv
precis
show
excel
cv
measur
cardiac
output
lidco
averag
two
lithium
dilut
curv
provid
excel
precis
suggest
popul
medicalsurg
approach
alway
use
calibr
puls
pressur
algorithm
pulseco
baselin
result
six
patient
studi
five
male
one
femal
intub
none
receiv
muscl
relax
mean
age
year
mean
apach
ii
score
ten
pair
result
obtain
see
tabl
mean
differ
lidco
picco
overal
correl
coeffici
r
p
conclus
gener
agreement
lidco
picco
signific
differ
three
measur
combin
result
lithium
calibr
may
improv
accuraci
result
promis
larger
trial
requir
introduct
measur
extravascular
lung
water
evlw
obtain
transpulmonari
thermodilut
picco
system
help
physician
guid
fluid
manag
critic
ill
patient
thorac
fluid
content
tfc
paramet
deriv
electr
conduct
thorax
determin
intravascular
alveolar
interstiti
fluid
introduct
new
devic
may
use
intens
care
measur
cardiac
output
co
arteri
puls
pressur
waveform
analysi
studi
evalu
reliabl
method
correl
method
co
determin
aim
studi
evalu
co
obtain
use
flow
correl
co
obtain
transthorac
echocardiographi
tte
materi
method
ten
critic
care
patient
admit
gener
icu
enrol
studi
patient
mechan
ventil
tidal
volum
mlkg
plateau
pressur
cmh
connect
integr
monitor
system
flow
ewdard
lifesci
irvin
ca
usa
attach
arteri
cannula
haemodynam
stabil
co
calcul
arteri
pressurebas
algorithm
utilis
relationship
puls
pressur
stroke
volum
time
tte
examin
perform
hewlett
packard
sono
co
calcul
doppler
measur
left
ventricular
outflow
area
lvot
velocitytim
integr
vti
lvot
assum
stroke
volum
crosssect
area
x
vti
everi
patient
two
co
determin
tte
flow
measur
regress
analysi
blandaltman
analysi
use
compar
two
method
co
determin
result
total
co
determin
perform
patient
tabl
report
main
result
figur
use
sever
sepsi
compar
seen
tabl
method
arteri
central
venou
blood
ga
analysi
done
admiss
hour
admiss
icu
hlo
incid
complic
determin
patient
low
normal
scvo
result
sixtythre
postop
patient
screen
patient
analys
patient
exclud
central
line
posit
superior
vena
cava
blood
sampl
time
point
patient
preicu
hlo
day
n
acut
spinal
cord
injuri
n
admit
postop
airway
manag
n
omit
scvo
low
patient
six
lower
gastrointestin
surgeri
hlo
median
iqr
longer
low
scvo
v
day
p
incid
complic
differ
differ
scvo
group
respect
age
gender
standard
base
excess
lactat
haemoglobin
mean
arteri
pressur
central
venou
pressur
volum
colloid
two
group
receiv
observ
period
differ
although
trend
low
group
receiv
crystalloid
p
conclus
signific
proport
patient
low
scvo
associ
increas
hlo
result
provid
basi
trial
postop
earli
goaldirect
therapi
highrisk
surgic
patient
admit
icu
howev
scvo
also
affect
arteri
oxygen
satur
spo
oxygen
consumpt
hemoglobin
hb
accord
formula
scvo
spo
vo
q
aim
studi
investig
rel
influenc
hypoxemia
anemia
measur
scvo
method
databas
pair
arteri
central
venou
blood
gase
drawn
patient
admit
icu
univers
hospit
consid
assess
technic
adequaci
sampl
defin
discrep
hematocrit
blood
glucos
arteri
venou
sampl
lower
coupl
select
analysi
sampl
cluster
accord
scvo
low
high
spo
partial
pressur
oxygen
pao
hb
consid
venou
arteri
differ
partial
pressur
co
dpco
arteri
venou
differ
oxygen
content
davo
oxygen
extract
ratio
er
also
consid
measur
perfus
adequaci
differ
low
high
scvo
sampl
estim
mannwhitney
rank
sum
test
sigma
stat
spss
accept
p
signific
data
present
median
percentil
expect
dpco
davo
er
differ
high
low
scvo
group
p
howev
hb
similar
p
spo
pao
significantli
lower
scvo
p
normal
scvo
spo
scvo
spo
allow
one
overcom
effect
hypoxemia
valu
low
group
high
group
p
conclus
consid
scvo
surrog
measur
perfus
adequaci
mandatori
consid
rel
effect
hypoxemia
anemia
less
relev
case
mix
introduct
increas
oxygen
deliveri
highrisk
surgic
patient
led
dramat
reduct
mortal
morbid
yet
still
wide
practis
due
logist
difficulti
associ
use
aim
evalu
whether
puls
power
analysi
calibr
lithium
dilut
techniqu
pragmat
minim
invas
techniqu
use
optim
oxygen
deliveri
index
highrisk
patient
major
surgeri
method
lithium
indic
dilut
puls
power
analysi
use
measur
cardiac
output
calcul
lidcoplu
system
prospect
evalu
oxygen
deliveri
pattern
perfus
variabl
highrisk
patient
lidco
group
submit
major
surgeri
goaldirect
therapi
surgeri
hour
postop
aim
maxim
level
higher
mlminm
use
dobutamin
either
restrict
mlkgmin
liber
mlkgmin
strategi
intraop
fluid
manag
partial
result
postop
group
receiv
mlkgmin
lactat
ringer
fluid
challeng
ml
colloid
done
presenc
sign
hypovolemia
addit
fluid
given
necessari
patient
consid
respond
achiev
therapeut
goal
histor
group
highrisk
surgic
patient
therapeut
goal
keep
mean
arteri
pressur
mmhg
central
venou
pressur
cmh
hematocrit
urin
output
mlkghour
first
hour
icu
admiss
use
control
result
median
dose
dobutamin
use
intraop
postop
respect
total
patient
respond
surgeri
postop
howev
much
better
pattern
surgeri
seen
liber
group
restrict
group
figur
valu
arteri
lactat
central
venou
oxygen
satur
scvo
icu
admiss
hour
later
group
shown
tabl
significantli
lower
arteri
lactat
higher
scvo
seen
optim
patient
p
vs
control
group
major
complic
occur
patient
histor
control
group
lidco
group
rr
ci
p
conclus
use
therapeut
approach
guid
calcul
lidco
plu
system
intraop
postop
seem
feasibl
practic
approach
guid
oxygen
deliveri
optim
therapi
major
surgeri
highrisk
patient
better
perfus
much
lower
rate
complic
seen
optim
patient
oxygen
deliveri
carbon
dioxid
product
ratio
continu
detect
anaerob
metabol
trauma
patient
conclus
find
show
mlkg
svo
rq
vco
ratio
may
use
interchang
mlkg
vco
ratio
seem
reliabl
predictor
svo
rq
vco
ratio
simpli
quickli
calcul
bedsid
puls
wave
analysi
allow
frequent
calcul
co
analyz
provid
vco
valu
continu
combin
ga
exchang
puls
wave
monitor
might
valuabl
use
approach
detect
trauma
patient
evalu
whether
chang
routin
measur
mean
radial
arteri
pressur
map
due
passiv
leg
rais
plr
use
assess
preload
depend
nonspontan
breath
patient
therefor
compar
chang
cardiac
output
co
chang
map
puls
pressur
pp
systol
pressur
sp
well
stroke
volum
variat
svv
plr
method
prospect
intervent
respons
studi
lr
leg
perform
supin
patient
receiv
mechan
ventil
elect
cardiothorac
surgeri
thermodilut
cardiac
output
cotd
heart
rate
central
venou
pressur
cvp
map
pp
sp
svv
measur
perform
plr
result
cotd
map
cvp
pp
sp
increas
plr
chang
heart
rate
system
vascular
resist
observ
found
signific
correl
plrinduc
chang
cotd
versu
svv
baselin
slope
p
chang
map
slope
p
pp
slope
p
sp
slope
p
chang
cvp
correl
chang
cotd
area
receiv
oper
curv
larger
differ
map
pp
sp
svv
conclus
baselin
svv
also
plrinduc
chang
map
pp
sp
reliabl
paramet
assess
preload
depend
cardiac
surgeri
patient
clinic
set
prefer
map
approach
base
simplic
avail
robust
introduct
known
corticosteroid
therapi
improv
hemodynam
state
patient
septic
shock
rel
avail
onlin
http
adren
insuffici
effect
partial
due
direct
action
vascular
tone
vasopleg
patient
may
hypovolem
tri
studi
determin
whether
puls
pressur
variat
measur
adrenocorticotropin
test
predict
adren
state
method
period
year
januari
realiz
prospect
observ
studi
patient
septic
shock
enrol
patient
arrhythmia
exclud
measur
hemodynam
data
mean
arteri
pressur
map
puls
pressur
variat
realiz
acth
short
test
inject
mg
acth
dosag
cortisol
level
inject
minut
result
one
hundr
one
patient
enrol
age
year
sap
ii
apach
ii
score
map
mmhg
lactat
mmoll
basal
cortisol
level
bcl
divid
patient
two
group
use
cutoff
n
n
differ
two
group
age
sap
ii
map
patient
low
significantli
p
low
bcl
vs
low
increas
cortisol
level
respons
acth
vs
p
low
maximum
variat
acth
test
vs
signific
rel
adren
defici
frequent
patient
low
vs
surviv
lower
low
group
vs
discuss
patient
low
seem
poor
prognosi
low
bcl
low
maximum
cortisol
increas
acth
test
high
death
rate
annan
colleagu
found
nonsurvivor
low
map
high
lactat
level
high
basal
cortisol
level
low
maximum
cortisol
level
increas
test
compar
survivor
find
contrast
patient
conclus
patient
low
realiz
acth
test
tend
probabl
adren
defici
probabl
receiv
corticosteroid
poor
prognosi
new
sequenti
leg
compress
devic
scd
tyco
mansfield
usa
pneumat
appli
sequenti
compress
lower
limb
maintain
pressur
gradient
throughout
compress
cycl
hypothes
scd
respons
system
could
shift
blood
volum
toward
thorac
compart
compar
volum
challeng
increas
preload
index
intrathorac
blood
volum
index
itbvi
stroke
volum
index
svi
aim
studi
evalu
relationship
chang
svi
induc
scd
induc
rapid
fluid
load
rfl
critic
ill
patient
method
twentyseven
patient
mean
age
year
admit
icu
studi
patient
receiv
convent
monitor
plu
hemodynamicvolumetr
monitor
picco
system
pulsion
medic
system
munich
germani
heart
rate
mean
arteri
pressur
central
venou
pressur
cardiac
index
itbvi
svi
record
supin
posit
treatment
scd
express
compress
system
data
collect
rfl
perform
mlkg
hydroxyethyl
starch
relationship
induc
scd
induc
rfl
analyz
linear
regress
analysi
statist
signific
consid
p
result
linear
regress
analysi
induc
scd
induc
rfl
show
r
p
analyz
subgroup
spontan
breath
versu
mechan
ventil
patient
relationship
observ
respect
r
p
figur
r
p
figur
conclus
scd
respons
system
could
shift
blood
volum
toward
thorac
compart
compar
rfl
better
mechan
ventil
spontan
breath
patient
larger
popul
studi
need
confirm
preliminari
data
amplitud
depend
stroke
volum
design
prospect
studi
evalu
correl
respiratori
arteri
pp
variat
pop
waveform
amplitud
variat
ventil
patient
influenc
acut
lung
injuri
ali
relationship
method
sixti
patient
includ
studi
thirtynin
diagnosi
ali
normal
ga
exchang
defin
relat
pao
fio
pf
respect
respiratori
variat
arteri
pp
pop
waveform
amplitud
record
simultan
beattobeat
basi
mean
valu
two
measur
paramet
compar
correl
agreement
result
respiratori
variat
pop
waveform
amplitud
could
accur
predict
variat
arteri
pp
sensibl
specif
posit
predict
valu
ppv
neg
predict
valu
npv
area
roc
curv
best
cutoff
valu
predict
variat
arteri
pp
kappa
index
agreement
p
eighteen
patient
variat
arteri
pp
show
variat
pop
waveform
amplitud
patient
without
ali
pf
sensibl
specif
npv
ppv
group
ali
pf
kappa
index
measur
agreement
group
without
ali
kappa
index
peep
level
differ
group
conclus
respiratori
variat
arteri
pp
accur
predict
variat
pop
waveform
amplitud
good
correl
agreement
result
confirm
find
recent
trial
suggest
correl
even
stronger
ali
absent
find
rais
potenti
clinic
applic
respiratori
variat
pop
waveform
amplitud
haemodynam
manag
patient
without
arteri
cathet
introduct
goaldirect
intraop
fluid
therapi
reduc
hospit
stay
major
surgeri
aortic
vascular
surgeri
associ
excess
blood
loss
massiv
fluid
shift
found
postop
urea
creatinin
improv
intravascular
fluid
volum
maintain
use
transoesophag
doppler
method
randomli
select
patient
underw
elect
infraren
aortic
surgeri
aortic
aneurysm
repairaortobifemor
graft
patient
cardiac
output
continu
monitor
use
transoesophag
doppler
probe
deltex
medic
inc
irv
tx
usa
correct
flow
time
ftc
record
immedi
induct
baselin
record
preextub
target
ftc
ms
aim
estim
total
blood
loss
calcul
patient
end
surgeri
preoper
postop
urea
creatinin
record
comparison
mean
baselin
ftc
ms
mean
target
ftc
ms
mean
averag
blood
loss
lpatient
mean
preoper
urea
creatinin
mmoll
respect
mean
postop
urea
creatinin
mmoll
mmoll
respect
see
figur
conclus
goaldirect
intraop
fluid
therapi
aim
ftc
ms
target
improv
avail
onlin
http
introduct
new
inform
emerg
basi
reconsid
albumin
key
homeostat
molecul
critic
ill
begin
understand
full
spectrum
albumin
properti
action
healthi
individu
hypoalbuminaem
patient
besid
function
regul
colloid
osmot
pressur
albumin
import
antioxid
capac
role
transport
wide
rang
drug
hormon
ion
amino
acid
fatti
acid
compar
studi
yet
perform
address
restrict
number
paramet
mostli
defin
european
pharmacopeia
object
studi
compar
main
albumin
function
eight
prepar
pharmaceuticalgrad
albumin
use
batteri
differ
techniqu
two
addit
albumin
prepar
prepar
without
stabilis
recombin
albumin
pichia
pastori
also
includ
studi
follow
biochem
physicochem
paramet
investig
total
protein
concentr
biuret
assay
albumin
antigen
nephelometri
quantit
analysi
contamin
protein
nephelometri
level
polym
fragment
gel
filtrat
chromatographi
superos
bind
affin
exogen
ligand
sudlow
site
warfarin
site
ii
dansylsarcosin
steadyst
spectrofluorimetri
reactiv
ellman
reagent
esteraselik
activ
use
pnitrophenyl
acet
substrat
spectrophotometri
result
pharmaceuticalgrad
product
show
puriti
rang
main
contamin
protein
prealbumin
transferrin
acid
glycoprotein
haptoglobulin
retinolbind
protein
conform
european
pharmacopeia
specif
warfarinbind
capac
albumin
prepar
studi
averag
bind
constant
x
n
found
presenc
stabilis
reduc
bind
dansylsarcosin
significantli
esteraselik
activ
toward
pnitrophenyl
acet
reactiv
differ
product
product
interest
absenc
free
recombin
albumin
conclus
signific
differ
observ
differ
human
albumin
prepar
recombin
confirm
presenc
stabilis
tryptophan
deriv
significantli
reduc
bind
capac
sudlow
site
ii
two
import
physiolog
properti
albumin
esteraselik
antioxid
activ
also
found
modifi
differ
extent
pharmaceuticalgrad
product
comparison
albumin
without
stabilis
benefit
albumin
administr
consid
care
take
account
differ
function
properti
albumin
aim
method
clinic
scenario
use
assess
current
knowledg
among
medic
staff
regard
iv
fluid
therapi
ladi
brought
e
semiconsci
temperatur
blood
pressur
mmhg
bm
mmoll
arteri
blood
gase
abg
room
air
ph
po
kpa
pco
kpa
hco
mmoll
satur
base
excess
medic
staff
ask
complet
questionnair
relat
case
supervis
condit
result
eightyseven
questionnair
complet
seven
sprconsult
hous
offic
finalyear
medic
student
abg
interpret
correct
could
calcul
anion
gap
list
fluid
caus
metabol
acidosi
eightythre
staff
knew
metabol
acidosi
caus
increas
respiratori
rate
normal
salin
firstchoic
fluid
resuscit
almost
case
chlorid
concentr
normal
salin
known
staff
serum
chlorid
concentr
known
staff
conclus
major
medic
staff
prescrib
normal
salin
firstchoic
intraven
fluid
mani
medic
staff
unawar
electrolyt
composit
normal
salin
phenomenon
hyperchloraem
metabol
acidosi
differenti
hyperchloraem
metabol
acidosi
lactic
acidosi
calcul
anion
gap
good
understand
fluid
therapi
import
medic
staff
introduct
postop
outcom
may
improv
cardiac
output
oxygen
deliveri
maintain
optim
level
trial
use
dopexamin
purpos
yield
inconsist
result
may
relat
use
high
dose
trial
metaanalysi
data
trial
may
therefor
identifi
benefit
lowdos
dopexamin
postop
mortal
length
stay
method
comprehens
literatur
review
perform
identifi
publish
randomis
trial
periop
dopexamin
infus
patient
undergo
major
surgeri
individu
patient
data
obtain
allow
metaregress
approach
explor
mortal
outcom
correct
age
dose
dopexamin
cox
proport
hazard
model
construct
examin
length
stay
result
five
studi
fulfil
inclus
criteria
lowdos
dopexamin
associ
reduct
mortal
vs
ci
p
length
postop
stay
also
reduc
lowdos
dopexamin
group
compar
control
median
vs
day
hr
ci
p
highdos
dopexamin
associ
differ
mortal
vs
ci
p
length
stay
median
vs
day
hr
ci
p
compar
control
conclus
periop
use
lowdos
dopexamin
decreas
mortal
durat
hospit
stay
patient
undergo
major
surgeri
blood
pressur
waveform
carri
inform
cardiac
contract
imped
characterist
vascular
bed
demonstr
start
isovolum
ventricular
contract
persist
reflect
inflect
point
pressur
wave
record
aortic
root
tpic
well
carotid
arteri
distens
waveform
tdic
travel
arteri
tree
group
six
patient
normal
pressur
gradient
across
aortic
valv
valv
replac
tpic
small
delay
respect
onset
isovolum
ventricular
contract
ms
group
n
young
presum
healthi
volunt
inflect
point
occur
persist
carotid
distens
waveform
record
mean
ultrasound
systol
foot
intersubject
delay
inflect
point
systol
foot
mean
sd
ms
intrasubject
sd
ms
retrograd
coronari
blood
flow
isovolum
ventricular
contract
may
origin
persist
enddiastol
pressur
distens
perturb
studi
show
durat
isovolum
contract
reliabl
extract
carotid
arteri
distens
waveform
introduct
follow
introduct
new
bariatr
surgic
servic
sheffield
aim
assess
impact
upon
critic
care
servic
examin
chang
servic
evolv
method
admiss
bariatr
surgeri
april
april
review
retrospect
procedur
perform
two
site
royal
hallamshir
hospit
rhh
thornburi
hospit
th
critic
care
admiss
length
hospit
stay
lo
review
result
total
patient
identifi
bariatr
surgeri
review
hospit
critic
care
admiss
data
total
identifi
complet
data
open
procedur
op
laparoscop
band
lb
laparoscop
gastric
bypass
lgb
age
rang
year
averag
hospit
lo
op
day
lgb
day
lb
day
surgic
procedur
hdu
admiss
increas
annual
respect
proport
open
procedur
declin
laparoscop
intervent
increas
lb
lgb
total
admiss
itu
patient
seven
undergon
initi
op
admiss
elect
eight
patient
requir
surgic
intervent
hdu
admiss
occur
site
patient
admit
hdu
th
rhh
th
three
patient
requir
level
care
discharg
within
hour
rhh
patient
requir
level
care
discharg
within
hour
discuss
requir
itu
admiss
surgic
group
remain
low
despit
signific
increas
bariatr
surgic
procedur
increas
predominantli
laparoscop
surgeri
hdu
activ
increas
servic
expand
howev
level
care
particularli
th
admiss
hdu
matter
polici
rather
clinic
necess
avail
level
facil
would
significantli
decreas
requir
hdu
provis
import
consider
introduc
new
bariatr
servic
avail
onlin
http
patient
method
ten
healthi
subject
seven
femal
three
male
age
year
investig
supin
posit
applic
continu
posit
airway
pressur
cpap
cmh
nasal
mask
studi
perform
use
sonograph
equip
multiprob
convex
mhz
sector
mhz
colordoppl
capabl
hitachi
h
ivc
visual
twodimension
echograph
sector
probe
mmode
use
measur
inspiratori
expiratori
diamet
origin
suprahepat
vein
hf
compos
portal
flow
pf
hepat
arteri
flow
haf
portal
veloc
assess
near
liver
hilum
use
measur
pf
left
intrahepat
branch
resist
index
ri
use
measur
haf
measur
repeat
twice
valu
intrathorac
pressur
two
differ
examin
mean
valu
given
statist
analysi
result
given
mean
sd
data
evalu
pair
test
p
taken
statist
signific
result
cpap
determin
reduct
portal
vein
veloc
cm
vs
cm
p
ivc
diamet
increas
cpap
inspiratori
diamet
cm
vs
cm
p
expiratori
diamet
cm
vs
cm
p
conclus
result
studi
demonstr
healthi
subject
variat
intrathorac
pressur
cpap
influenc
venou
return
hf
reduct
could
due
increas
ivc
pressur
display
bigger
diamet
measur
cpap
diaphragmat
descent
ultrasonographi
abl
detect
effect
could
use
complet
evalu
patient
haemodynam
statu
variou
clinic
set
introduct
critic
ill
patient
sever
sepsi
septic
shock
high
mortal
rate
aim
studi
investig
impact
intraabdomin
hypertens
iah
outcom
patient
without
sever
sepsissept
shock
method
two
hundr
fiftythre
mechan
ventil
patient
admit
gener
icu
tartu
univers
hospit
prospect
studi
patient
sever
sepsi
septic
shock
admiss
develop
first
week
stay
compar
patient
suffer
sever
sepsi
iah
defin
sustain
intraabdomin
pressur
equal
mmhg
develop
within
first
week
icu
result
sever
sepsi
septic
shock
observ
patient
icu
mortal
among
patient
compar
nonsept
patient
p
iah
develop
patient
incid
iah
higher
among
septic
patient
vs
p
septic
patient
develop
iah
mortal
rate
compar
septic
patient
without
iah
p
mortal
among
nonsept
patient
differ
patient
without
iah
vs
develop
iah
signific
risk
factor
death
septic
patient
ci
nonsept
patient
ci
conclus
develop
iah
significantli
increas
risk
death
patient
sever
sepsi
septic
shock
nonsept
patient
abdomin
pressurevolum
relat
describ
linear
relat
give
elast
e
pressur
zero
volum
p
goal
studi
measur
relat
larg
group
patient
differ
characterist
look
factor
influenc
explain
relat
believ
obes
person
higher
abdomin
pressur
unclear
whether
muscl
relax
lower
larg
group
patient
asa
class
ii
year
old
schedul
laparoscop
surgeri
includ
studi
approv
hospit
ethic
committe
anaesthesia
induc
propofol
mg
sufentanil
sevofluran
mac
n
patient
fulli
muscl
relax
nimbex
mg
other
patient
ask
empti
bladder
surgeri
stomach
empti
suction
gastric
tube
olympu
insuffl
initialis
abdomen
inflat
stepwis
flow
mmhg
pressur
reach
flow
stop
actual
pressur
volum
measur
give
four
data
point
e
p
calcul
fit
linear
relat
follow
record
determin
evalu
regress
analysi
effect
age
length
weight
bmi
sex
gravid
muscl
relax
p
increas
significantli
bodi
weight
decreas
significantli
muscl
relax
aim
studi
clarifi
japanes
citizen
interest
import
immedi
cardiopulmonari
resuscit
cpr
defibril
understand
import
japan
outofhospit
emerg
medic
servic
system
establish
ambul
servic
emerg
life
save
technician
elst
belong
fire
depart
patient
record
review
past
year
yokohama
peopl
pulmonari
arrest
cpa
patient
transfer
nearest
ed
select
hospit
adequ
abil
cpr
cerebr
resuscit
perform
ultrasound
chest
xray
blood
examin
includ
troponin
cpa
patient
cerebr
plane
ct
chest
ct
ct
perform
patient
clearli
known
aetiolog
treat
cpa
patient
past
year
cardiac
noncardiac
aetiolog
subarachnoid
haemorrhag
acut
aortic
dissect
restrict
cardiac
aetiolog
patient
show
ventricular
fibril
vf
first
monitor
rhythm
show
vf
resuscit
patient
vf
wit
wit
patient
wit
elst
transfer
layperson
patient
famili
patient
friend
fiftythre
per
cent
wit
patient
home
patient
privat
room
bathroom
lavatori
age
peopl
resid
hotel
restaur
offic
road
cpa
patient
underw
bystand
cpr
wit
cpa
patient
cpa
patient
underw
bystand
cpr
wit
patient
underw
bystand
cpr
patient
home
patient
famili
conclus
japan
cpa
patient
wit
mainli
home
famili
friend
aetiolog
cpa
patient
noncardiac
subarachnoid
haemorrhag
acut
aortic
dissect
etc
howev
cpa
patient
underw
bystand
cpr
wit
clinic
experiment
studi
demonstr
mark
activ
blood
coagul
fibrin
format
prolong
cardiopulmonari
resuscit
cpr
sever
experiment
studi
suggest
thrombolysi
therapi
act
directli
thrombi
emboli
also
enhanc
microcirculatori
reperfus
retrospect
studi
investig
extent
blood
coagul
fibrin
format
via
plasma
ddimer
level
indic
endogen
fibrinolyt
activ
patient
underw
inhospit
outofhospit
cardiac
arrest
nontraumat
caus
conclus
vasopressin
superior
epinephrin
patient
asystol
better
rosc
admiss
surviv
discharg
hospit
vasopressin
follow
epinephrin
effect
epinephrin
alon
treatment
refractori
cardiac
arrest
introduct
evalu
time
cours
relationship
proinflammatori
cytokin
procalcitonin
pct
serum
level
cardiopulmonari
resuscit
cpr
hypothes
increas
cytokin
level
would
preced
mark
increas
pct
level
pct
would
best
predictor
final
neurolog
outcom
method
data
prospect
collect
patient
blood
sampl
taken
admiss
hospit
hour
pct
level
measur
use
autom
assay
day
patient
divid
two
neurolog
outcom
group
accord
cerebr
perform
categori
cpc
bad
cpc
good
differ
group
evalu
use
test
roc
curv
comput
analyz
predict
valu
marker
bad
outcom
result
earli
signific
increas
admiss
hospit
ensu
hour
patient
bad
neurolog
outcom
initi
pct
level
indistinguish
group
howev
strike
increas
observ
patient
bad
neurolog
outcom
peak
hour
vs
p
pct
valu
hour
best
predictor
bad
neurolog
outcom
area
curv
cutoff
valu
sensit
specif
conclus
serum
level
significantli
elev
earli
phase
success
cpr
patient
bad
neurolog
outcom
pct
increas
subsequ
found
high
prognost
valu
neurolog
outcom
introduct
mortal
among
patient
surviv
discharg
follow
inhospit
cardiac
arrest
ihca
high
present
studi
assess
whether
might
explain
differ
patient
factor
factor
resuscit
method
analysi
ihca
data
collect
one
swedish
tertiari
hospit
five
finnish
secondari
hospit
period
studi
limit
patient
surviv
discharg
hospit
multipl
logist
regress
analysi
use
identifi
factor
associ
surviv
year
arrest
differ
initi
rhythm
delay
defibril
delay
return
spontan
circul
survivor
nonsurvivor
month
conclus
sever
patient
factor
mainli
age
function
statu
comorbid
diseas
influenc
longterm
surviv
follow
ihca
locat
arrest
also
influenc
surviv
initi
rhythm
delay
defibril
return
spontan
circul
introduct
mild
hypothermia
promis
new
therapi
patient
resuscit
cardiac
arrest
anim
studi
suggest
earli
fast
cool
crucial
benefici
effect
neurolog
outcom
induc
mild
hypothermia
immedi
success
restor
spontan
circul
rosc
outofhospit
set
remain
challeng
therefor
novel
coolingblanket
emcoolspad
independ
energi
sourc
use
develop
aim
studi
evalu
feasibl
safeti
outofhospit
surfac
cool
emcoolspad
patient
success
resuscit
cardiac
arrest
method
includ
patient
success
resuscit
outofhospit
cardiac
arrest
oesophag
temperatur
es
emcoolspad
consist
multipl
cool
unit
mm
thick
fill
mixtur
graphitewat
store
cool
box
ambul
car
cool
initi
soon
feasibl
first
treat
paramed
emerg
physician
continu
emerg
room
coolingblanket
remov
es
reach
target
temperatur
es
maintain
hour
data
present
median
interquartil
rang
result
septemb
decemb
patient
weigh
kg
includ
studi
cool
initi
minut
rosc
coolingblanket
decreas
es
start
cool
within
minut
target
temperatur
es
within
minut
result
cool
rate
hospit
admiss
minut
rosc
es
achiev
minut
admiss
eight
patient
precool
part
coolingblanket
appli
repeatedli
chest
abdomen
maintain
target
temperatur
es
hour
skin
lesion
observ
conclus
noninvas
surfac
cool
emcoolspad
immedi
resuscit
cardiac
arrest
outofhospit
set
shown
feasibl
safe
whether
earli
cool
compar
delay
cool
hospit
improv
neurolog
outcom
need
determin
prospect
random
trial
mild
hypothermia
induct
follow
cardiac
arrest
use
watercircul
cool
devic
use
mild
hypothermia
comatos
survivor
cardiac
arrest
endors
american
heart
associ
intern
liaison
committe
resuscit
unintent
overcool
common
techniqu
cool
intravascular
fluid
use
ice
pack
nowaday
mainten
hypothermia
facilit
new
technolog
avoid
unintent
overcool
method
male
histori
hypertens
previou
replac
aortic
valv
right
coronari
arteri
bypass
admit
icu
cardiac
arrest
suffer
collaps
walk
emerg
servic
arriv
within
minut
initi
cardiac
rhythm
ventricular
fibril
estim
time
return
spontan
circul
minut
patient
arriv
hospit
minut
collaps
immedi
admit
icu
thirti
minut
icu
admiss
unconsci
glasgow
coma
score
hypothermia
induc
artic
sun
cool
system
mediv
louisvil
co
usa
goal
temperatur
obtain
minut
induct
bodi
temperatur
monitor
continu
foley
cathet
hypothermia
maintain
hour
rewarm
target
temperatur
achiev
hour
electrolyt
imbal
coagulopathi
observ
overcool
observ
moment
patient
extub
day
admiss
discharg
icu
day
without
neurolog
sequela
conclus
care
monitor
temperatur
import
use
therapeut
hypothermia
unintent
overcool
may
place
patient
risk
seriou
complic
arrhythmia
infect
coagulopathi
cool
watercircul
cool
devic
fast
safe
clinician
work
institut
protocol
mild
hypothermia
treatment
patient
part
critic
care
treatment
introduct
induct
mild
hypothermia
mh
patient
resuscit
cardiac
arrest
improv
outcom
howev
benefit
risk
mh
induct
patient
remain
cardiogen
shock
return
spontan
circul
rosc
unclear
therefor
analys
group
cardiac
arrest
survivor
indic
mh
induct
coronari
care
unit
ccu
compar
outcom
patient
cardiogen
shock
syndrom
rosc
outcom
rel
haemodynam
stabl
method
perform
retrospect
analysi
consecut
cardiac
arrest
survivor
treat
mh
ccu
novemb
august
classifi
two
group
accord
whether
met
criteria
cardiogen
shock
rosc
mh
initi
primari
outcom
measur
inhospit
mortal
best
inhospit
discharg
neurolog
result
predict
mortal
evalu
apach
ii
score
neurolog
outcom
cerebr
perform
categori
score
mh
initi
soon
possibl
rosc
patient
cool
bodi
temperatur
hour
result
consecut
patient
fulfil
criteria
cardiogen
shock
mh
initi
group
rel
hemodynam
stabl
group
b
predict
mortal
group
group
b
p
real
inhospit
mortal
group
group
b
patient
p
best
inhospit
neurolog
outcom
found
favour
patient
group
group
b
p
favour
discharg
neurolog
outcom
reach
group
group
b
p
patient
group
differ
rate
complic
conclus
inhospit
mortal
cardiac
arrest
survivor
treat
mh
expect
higher
cardiogen
shock
stabl
patient
favour
neurolog
outcom
frequent
compar
group
patient
moreov
mh
applic
safe
group
therefor
induct
mh
consid
also
cardiac
arrest
survivor
cardiogen
shock
syndrom
rosc
chang
urinari
patient
global
brain
ischemia
undergo
brain
hypothermia
therapi
comparison
whole
bodi
select
head
cool
oxygen
free
radic
play
import
role
global
brain
ischemia
cardiac
arrest
brain
hypothermia
therapi
effect
suppress
free
radic
express
aim
studi
assess
free
radic
express
brain
hypothermia
compar
express
whole
bodi
select
head
cool
method
subject
patient
treat
mild
brain
hypothermia
resuscit
follow
cardiac
arrest
icu
five
patient
receiv
whole
bodi
cool
seven
patient
receiv
select
head
cool
examin
hemodynam
chang
urinari
concentr
determin
hplc
brain
hypothermia
therapi
furthermor
compar
prognosi
day
admiss
icu
induct
time
whole
bodi
cool
significantli
shorter
select
head
cool
rewarm
time
head
cool
significantli
shorter
whole
bodi
cool
mean
arteri
pressur
heart
rate
stabl
head
cool
group
urinari
concentr
decreas
significantli
group
data
significantli
lower
whole
bodi
cool
group
compar
select
head
cool
group
five
seven
patient
respect
exhibit
good
recoveri
day
admiss
whole
bodi
select
head
cool
group
conclus
mild
brain
hypothermia
therapi
suppress
product
free
radic
follow
global
brain
ischemia
whole
bodi
cool
stronger
effect
suppress
free
radic
compar
select
head
cool
consid
select
head
cool
exhibit
neuroprotect
similar
whole
bodi
cool
reduct
magnet
reson
spectroscopi
brain
temperatur
convect
head
cool
healthi
human
pilot
studi
assess
effect
forc
convect
head
neck
cool
brain
temperatur
measur
magnet
reson
spectroscopi
mr
five
healthi
adult
human
three
male
follow
baselin
subject
receiv
minut
head
cool
follow
minut
head
neck
cool
cool
devic
deliv
air
ms
hood
separ
neck
collar
made
doubl
layer
nylon
sheet
inner
layer
pierc
hole
subject
wore
windproof
waistcoat
tape
round
base
neck
wrap
blanket
base
neck
bilater
foot
warm
chemic
hot
pack
use
encourag
heat
loss
presenc
normothermia
mr
temperatur
data
collect
level
basal
ganglia
baselin
last
minut
cool
intervent
mr
detect
natur
occur
brain
metabolit
interpret
rel
frequenc
nacetyl
aspart
water
allow
estim
tissu
temperatur
cm
voxel
assess
region
cool
voxel
lie
within
region
form
join
tip
later
ventricl
defin
core
voxel
within
approxim
one
voxel
brain
surfac
defin
outer
voxel
defin
intermedi
oesophag
temperatur
measur
continu
fluoropt
thermomet
mean
baselinecorrect
mr
brain
temperatur
voxel
reduc
sd
p
ci
head
cool
sd
p
ci
head
neck
cool
head
cool
reduc
mean
baselinecorrect
mr
brain
temperatur
core
voxel
subject
formal
test
gradient
signific
p
ci
head
neck
cool
reduc
temperatur
core
voxel
three
subject
test
gradient
signific
p
ci
mean
baselinecorrect
oesophag
temperatur
reduct
last
minut
intervent
sd
head
cool
sd
head
neck
cool
forc
convect
head
cool
reduc
mr
brain
temperatur
equival
per
hour
healthi
subject
reduct
appar
across
brain
method
result
total
patient
examin
success
cpr
twentynin
patient
receiv
cold
infus
arriv
heart
cathet
laboratori
retrospect
data
patient
receiv
volum
substitut
mean
drip
ambient
temperatur
serv
control
group
admiss
icu
group
immedi
connect
extern
cool
devic
coolgard
thermo
wrap
cool
target
temperatur
bladder
temperatur
averag
temperatur
admiss
differ
group
vs
group
initi
cool
mean
cold
infus
signific
temperatur
decreas
could
reach
invas
coronari
diagnost
admiss
icu
averag
vs
p
middl
chill
durat
achiev
target
temperatur
admiss
significantli
shorter
combin
method
min
versu
min
p
period
achiev
target
temperatur
begin
extern
cool
devic
group
combin
method
significantli
shorter
min
versu
min
p
conclus
combin
method
initi
cool
cold
solut
show
sure
actual
prestationari
cool
procedur
introduct
realis
mild
hypothermia
offer
possibl
reach
purpos
temperatur
significantli
faster
preclin
introduct
mild
hypothermia
mean
cold
solut
could
benefici
criteria
futur
treatment
probabl
affect
outcom
patient
introduct
therapeut
hypothermia
th
follow
cardiac
arrest
associ
sever
complic
includ
symptomat
bradycardia
coagulopathi
pneumonia
furthermor
hyperthermia
associ
poor
outcom
follow
brain
injuri
incid
complic
may
increas
excess
temperatur
fluctuat
sought
compar
complic
two
techniqu
use
induc
th
surfac
cool
sc
use
ice
pack
endovascular
cool
ev
use
system
alsiu
corp
usa
method
retrospect
review
perform
cardiac
arrest
patient
undergo
th
surviv
hour
june
novemb
result
thirtyf
patient
underw
th
protocol
sc
group
ev
group
incid
overcool
sc
group
significantli
higher
ev
group
vs
p
whilst
trend
toward
episod
symptomat
bradycardia
sc
vs
ev
p
rebound
hyperthermia
sc
vs
ev
p
also
present
incid
pneumonia
sc
vs
ev
p
coagulopathybleed
sc
vs
ev
p
similar
group
conclus
sc
associ
significantli
higher
incid
overcool
ec
may
associ
increas
complic
symptomat
bradycardia
sc
may
also
associ
increas
rebound
hyperthermia
introduct
hypothermia
may
therapeut
benefici
stroke
victim
howev
provok
vigor
shiver
buspiron
partial
serotonin
antagonist
dexmedetomidin
agonist
linearli
reduc
shiver
threshold
trigger
core
temperatur
minim
sedat
respiratori
depress
test
hypothesi
buspiron
dexmedetomidin
synergist
reduc
shiver
threshold
without
produc
substanti
sedat
respiratori
depress
method
studi
four
healthi
male
volunt
day
control
drug
buspiron
mg
oral
dexmedetomidin
target
plasma
concentr
ngml
combin
buspiron
dexmedetomidin
dose
lactat
ringer
solut
infus
via
central
venou
cathet
decreas
tympan
membran
temperatur
mean
skin
temperatur
maintain
increas
oxygen
consumpt
baselin
identifi
shiver
threshold
sedat
evalu
use
observ
assess
sedationalert
scale
twoway
repeatedmeasur
analysi
varianc
use
identifi
interact
drug
data
present
mean
sd
p
statist
signific
shiver
threshold
control
day
p
control
buspiron
day
p
control
dexmedetomidin
day
p
control
combin
buspiron
dexmedetomidin
day
calcul
mean
differ
threshold
combin
control
day
measur
mean
differ
deriv
differ
combin
control
day
trivial
sedat
either
drug
alon
combin
respiratori
rate
endtid
pco
well
preserv
day
conclus
buspiron
dexmedetomidin
act
synergist
reduc
shiver
threshold
mild
sedat
respiratori
depress
combin
might
valid
treatment
prevent
shiver
stroke
patient
therapeut
hypothermia
bispectr
index
bi
calcul
frontotempor
electroencephalogram
eeg
suppress
ratio
sr
estim
percentag
eeg
suppress
monitor
bi
sr
therapeut
hypothermia
th
compar
neurolog
outcom
encephalopath
survivor
outofhospit
cardiac
arrest
ohca
method
thirtytwo
patient
anox
encephalopathi
ohca
receiv
hour
th
bi
monitor
initi
onset
th
neuromuscular
blockad
nmb
dose
respons
shiver
blind
bi
sr
data
record
first
dose
nmb
compar
cerebr
perform
categori
cpc
discharg
month
cpc
cpc
consid
good
outcom
go
result
fourteen
patient
surviv
go
five
remain
patient
die
neurolog
evalu
hour
one
patient
recov
neurolog
function
die
cardiogen
shock
survivor
recal
period
nmb
first
nmb
administ
median
hour
cardiac
arrest
minut
initi
th
patient
go
higher
first
postnmb
bi
vs
p
lower
sr
vs
p
cpc
initi
nmb
reduc
frontotempor
electromyogram
emg
power
db
p
patient
download
eeg
data
increas
emg
power
db
iqr
baselin
associ
clinic
detect
shiver
epileptiform
discharg
note
monitor
nmb
two
patient
seizur
activ
confirm
formal
eeg
conclus
cardiac
arrest
survivor
receiv
th
higher
postnmb
bi
score
lower
sr
earli
predictor
neurolog
outcom
potenti
benefit
monitor
bi
sr
well
emg
power
earli
recognit
shiver
continu
frontotempor
eeg
detect
seizur
warrant
studi
electroencephalogram
eeg
appropri
monitor
tool
intens
care
link
cerebr
metabol
sensit
ischaemiahypoxia
detect
neuron
dysfunct
revers
stage
best
method
detect
seizur
activ
scientif
data
prove
util
continu
eeg
monitor
intens
care
pauciti
data
relat
singl
record
eeg
especi
gener
icu
retrospect
chart
review
patient
bedsid
eeg
medicalsurg
icu
done
data
collect
focu
indic
request
eeg
technic
difficulti
studi
report
influenc
subsequ
clinic
manag
fortytwo
chart
review
indic
evalu
persist
comatos
state
n
diagnoseexclud
seizur
activ
nonconvuls
statu
epilepsi
n
adjunct
support
clinic
diagnosi
suspect
brain
death
prior
formal
test
n
movement
artifact
led
technic
difficulti
four
studi
eeg
confirm
moder
sever
nonspecif
brain
dysfunct
caus
persist
comatos
state
presenc
either
diffus
slow
thetadelta
activ
absenc
cerebr
activ
continu
rhythmic
semi
rhythmic
lateralizedbilater
epileptiform
discharg
burst
suppress
pattern
continu
bilater
slow
ushap
wave
anox
brain
damag
absenc
chang
electr
signal
follow
extern
applic
noxiou
stimuli
seizur
activ
epileptiform
discharg
twelv
report
state
use
sedat
interf
eeg
interpret
follow
clinic
decis
made
base
eeg
report
conjunct
clinic
find
initi
withdraw
life
support
donotresuscit
order
patient
diagnos
hypox
ischaem
encephalopathi
n
ad
escal
stop
antiseizur
drug
base
presenc
absenc
seizur
activ
n
continu
support
care
comatos
patient
diagnos
metabol
encephalopathyprolong
sedat
effect
caus
coma
n
base
result
conclud
despit
limit
motion
artifact
influenc
sedat
electr
signal
eeg
impact
clinic
decisionmak
process
critic
care
henc
benefici
widespread
use
would
improv
diagnost
potenti
introduct
aneurism
subarachnoid
hemorrhag
sah
extrem
sever
ill
associ
high
mortal
rate
perman
sever
neurolog
dysfunct
twothird
affect
patient
one
major
complic
sah
vasospasmassoci
cerebr
ischemia
clinic
experiment
data
suggest
vasospasm
link
inflammatori
respons
associ
sah
goal
studi
investig
express
prototyp
long
pentraxin
protein
induc
proinflammatori
signal
brain
sah
patient
test
hypothesi
sah
follow
upregul
establish
tempor
relationship
express
induct
vasospasm
also
attempt
establish
detect
cerebrospin
fluid
csf
method
studi
eight
sever
sah
patient
admit
neurosci
icu
median
world
feder
neurosurg
score
fisher
score
arteri
jugular
venou
blood
csf
sampl
routin
obtain
everi
hour
day
level
measur
elisa
plasma
csf
sampl
result
compar
plasma
level
normal
volunt
ngml
sah
induc
mark
increas
plasma
express
first
hour
follow
sah
acut
phase
arteri
jugular
venou
level
increas
ngml
ngml
respect
subsequ
decreas
concomitantli
reduct
inflamm
hour
subacut
phase
detect
csf
mean
csf
level
ngml
acut
phase
ngml
subacut
phase
test
p
compar
acut
phase
presenc
vasospasm
four
patient
detect
second
peak
ngml
csf
sampl
test
p
compar
subacut
phase
detect
plasma
conclus
sah
character
product
induct
vasospasm
associ
upregul
csf
detect
plasma
method
retrospect
analysi
prospect
gather
data
patient
sich
treat
icu
past
year
admiss
follow
data
regist
vascular
risk
factor
high
blood
pressur
diabet
mellitu
age
gender
apach
ii
score
gc
hemorrhag
characterist
locat
side
volum
mass
effect
surgic
procedur
mod
blood
pressur
systol
diastol
mean
puls
pressur
puls
rate
laboratori
paramet
hemoglobin
white
cell
platelet
count
inr
serum
valu
na
glucos
lactat
creatinin
bilirubin
also
regist
length
stay
lo
durat
mechan
ventil
mv
time
intub
tt
patient
outcom
haemodynam
instabl
defin
low
mean
blood
pressur
support
vasoact
inotrop
drug
statist
evalu
perform
use
univari
multivari
logist
regress
student
test
pearson
chisquar
test
fisher
exact
statist
use
patient
oper
higher
mortal
also
sever
ill
conclus
age
sever
ill
ich
score
hypoxemia
haemodynam
instabl
increas
temperatur
directli
relat
outcom
patient
sich
gender
lo
mv
tt
mod
influenc
mortal
introduct
recent
medic
treatment
acut
stroke
make
rapid
progress
especi
ischem
stroke
acut
stage
efficaci
thrombolysi
system
tpa
local
transarteri
urokinas
infus
prove
howev
effect
treatment
time
still
quit
limit
patient
must
brought
stroke
center
soon
possibl
analyz
reason
stroke
patient
delay
come
stroke
center
extract
problem
propos
solut
clinic
subject
consist
consecut
patient
ischem
stroke
acut
stage
hospit
hospit
april
septemb
investig
clinic
cours
especi
time
onset
physic
examin
radiolog
examin
ct
mri
mra
andor
cerebr
angiographi
mean
age
year
among
patient
classifi
atherothrombosi
cardiac
embol
lacunar
infarct
transient
ischem
attack
patient
underw
acut
thrombolyt
therapi
result
two
hundr
fortyon
patient
hospit
within
hour
onset
patient
within
hour
among
admit
ambul
found
follow
result
main
reason
delay
admiss
anoth
hospit
stroke
center
patient
deni
symptom
rare
patient
famili
often
hesit
request
emerg
car
conclus
signific
point
rapid
diagnosi
therapi
peopl
must
doubt
stroke
first
educ
citizen
warn
sign
stroke
also
necess
emerg
admiss
use
emerg
car
addit
justli
build
core
stroke
center
district
central
patient
intraaort
balloon
pump
shown
improv
cardiac
output
diastol
coronari
flow
aim
studi
determin
effect
intraaort
counterpuls
iabp
cerebr
blood
flow
veloc
measur
middl
cerebr
arteri
method
cardiac
surgeri
patient
receiv
iabp
postop
blood
flow
veloc
middl
cerebr
arteri
assess
transcrani
doppler
tcd
patient
measur
v
max
v
mean
v
min
perform
four
differ
pump
set
without
support
ws
pump
assist
puls
ratio
result
repeatedmeasur
analysi
varianc
p
consid
extrem
signific
variat
tcd
measur
among
iabp
set
compar
pair
v
max
v
mean
v
min
valu
found
v
max
especi
v
mean
significantli
greater
pump
set
set
also
found
end
diastol
veloc
v
min
signific
lower
pump
deflat
none
patient
signific
diastol
flow
veloc
revers
pump
deflat
conclus
left
ventricular
support
iabp
significantli
chang
flow
veloc
pattern
patient
pump
significantli
increas
v
max
v
mean
set
pump
inflat
diastol
suggest
veloc
chang
set
enddiastol
flow
veloc
reduc
everi
puls
accord
pump
deflat
background
patient
critic
ill
acquir
syndrom
weak
depend
mechan
ventil
link
peripher
nerv
muscl
injuri
aim
systemat
review
publish
data
diagnosi
risk
factor
outcom
patient
critic
ill
neuromuscular
abnorm
cinma
method
medlin
embas
cinahl
cochran
librari
search
studi
includ
report
icu
patient
year
old
evalu
cinma
clinic
electrophysiolog
contain
suffici
data
quantit
measur
associ
cinma
clinic
relev
exposur
andor
outcom
two
review
independ
extract
data
studi
methodolog
qualiti
method
diagnos
cinma
cinma
preval
risk
factor
outcom
result
icu
patient
evalu
studi
diagnos
cinma
enrol
patient
receiv
protract
mechan
ventil
sepsi
multipl
organ
failur
diagnost
criteria
cinma
heterogen
report
explicitli
differenti
polyneuropath
myopath
mix
type
cinma
cinma
link
sever
studi
hyperglycemia
system
inflammatori
respons
syndrom
sepsi
renal
replac
therapi
catecholamin
administr
contrast
across
studi
consist
relationship
cinma
patient
age
gender
sever
ill
multipl
organ
failur
use
glucocorticoid
neuromuscular
blocker
aminoglycosid
midazolam
mortal
increas
patient
cinma
mechan
ventil
icu
hospit
stay
prolong
conclus
risk
cinma
nearli
subset
icu
patient
sepsi
multiorgan
failur
protract
mechan
ventil
data
support
cinma
independ
predictor
death
impact
frequent
cite
risk
factor
uncertain
emerg
data
indic
glycem
control
decreas
cinma
risk
vulner
patient
gramneg
bacteremia
independ
predispos
factor
critic
ill
polyneuromyopathi
introduct
critic
ill
polyneuromyopathi
cipm
major
clinic
problem
icu
result
prolong
icu
stay
increas
morbid
mortal
object
investig
risk
factor
cipm
involv
gener
multidisciplinari
icu
patient
particip
four
hundr
seventyfour
femal
age
consecut
admit
patient
univers
multidisciplinari
icu
prospect
evalu
patient
assign
admiss
apach
ii
sofa
score
subsequ
evalu
newli
develop
neuromuscular
weak
examin
muscl
strength
accord
medic
research
council
scale
deep
tendon
reflex
sensori
function
muscl
wast
laboratori
valu
medic
therapi
record
daili
potenti
caus
newonset
gener
weak
icu
admiss
exclud
diagnosi
cipm
establish
patient
remain
icu
day
result
fortyfour
patient
develop
gener
weak
met
criteria
cipm
patient
cipm
higher
admiss
apach
ii
score
vs
p
sofa
score
vs
p
multivari
logist
regress
analysi
show
risk
factor
independ
associ
develop
cipm
sever
ill
time
admiss
icu
administr
aminoglycosid
antibiot
high
blood
glucos
level
analysi
accord
sever
ill
stratif
reveal
emerg
gramneg
bacteremia
import
independ
predispos
factor
cipm
develop
less
sever
ill
patient
conclus
cipm
high
incid
icu
set
studi
reveal
import
associ
gramneg
bacteremia
aminoglycosid
hyperglycemia
sever
ill
cipm
develop
examin
interhospit
cooper
critic
emerg
care
lifethreaten
cervicalthoracicabdomin
trauma
n
thoracoabdomin
emerg
diseas
n
treat
intens
care
ccec
abl
discharg
transfer
anoth
acut
treatment
hospit
trauma
patient
directli
transfer
center
transfer
affili
hospit
whose
medic
staff
dispatch
depart
univers
transfer
nonaffili
hospit
directli
discharg
center
emerg
diseas
patient
transfer
affili
hospit
transfer
hospit
directli
discharg
patient
stay
center
day
tend
transfer
affili
hospit
trauma
patient
indirectli
transfer
hospit
center
transfer
affili
nonaffili
hospit
directli
discharg
emerg
diseas
patient
valu
respect
patient
stay
center
day
tend
transfer
affili
hospit
discuss
conclus
result
thought
common
situat
typic
urban
citi
world
interhospit
cooper
citi
hospit
referr
hospit
function
well
poor
understand
retransf
previou
hospit
result
dysfunct
manag
critic
patient
local
medic
area
import
construct
new
interhospitalcooper
system
base
local
medic
area
object
determin
relationship
earli
hypothermia
multipl
organ
failur
mortal
sever
injur
trauma
patient
method
prospect
observ
studi
perform
seven
level
trauma
center
month
sever
injur
patient
hypoperfus
need
blood
transfus
earli
hospit
cours
follow
nearinfrar
spectroscopyderiv
tissu
oxygen
satur
sto
clinic
variabl
outcom
includ
multipl
organ
dysfunct
syndrom
mod
mortal
evalu
hypothermia
defin
temperatur
within
first
hour
result
hypothermia
common
hypotherm
patient
like
normotherm
patient
develop
mod
vs
p
increas
mortal
rate
vs
p
maximum
base
deficit
max
bd
hypotherm
patient
discrimin
develop
mod
meql
vs
meql
p
good
discrimin
mortal
hypotherm
normotherm
patient
signific
predictor
mod
use
multivari
analysi
includ
minimum
sto
p
hypothermia
p
max
bd
p
predictor
mortal
multivari
analysi
includ
minimum
sto
p
max
bd
p
hypothermia
p
hypothermia
remain
signific
risk
factor
mod
fluidblood
infus
volum
includ
multivari
model
conclus
hypothermia
common
sever
injur
trauma
patient
risk
factor
mod
mortal
minimum
sto
predict
mod
mortal
normotherm
hypotherm
patient
predict
effect
bd
mod
blunt
presenc
hypothermia
nonlact
gap
novel
predictor
organ
failur
mortal
follow
major
trauma
measur
admiss
deriv
calcul
ion
gap
use
simplifi
stewartfigg
equat
subtract
measur
serum
lactat
calcul
ion
gap
obtain
nonlact
gap
nlg
result
see
tabl
nlg
discrimin
survivor
nonsurvivor
p
analysi
varianc
nlg
mmoll
associ
increas
risk
mortal
p
fisher
exact
test
patient
nlg
less
mmoll
die
patient
nlg
mmoll
die
nlg
mmoll
also
correl
strongli
organ
failur
multipl
organ
dysfunct
syndrom
score
p
sequenti
organ
failur
assess
score
p
mannwhitney
u
test
describ
nlg
first
time
quantifi
use
simpl
bedsid
calcul
deriv
routin
blood
investig
nlg
excel
marker
organ
failur
death
follow
major
injuri
use
guid
trauma
resuscit
prehospit
hypotens
persist
arriv
emerg
depart
power
predictor
mortal
follow
major
trauma
object
outcom
follow
major
injuri
time
depend
earli
identif
highrisk
patient
allow
rapid
decisionmak
correct
lifethreaten
disord
complex
score
system
limit
valu
major
trauma
resuscit
aim
evalu
util
singl
blood
pressur
prehospit
phase
combin
blood
pressur
arriv
emerg
depart
method
data
collect
prospect
patient
admit
level
south
african
trauma
unit
period
patient
subdivid
two
group
accord
combin
prehospit
ph
emerg
depart
ed
blood
pressur
hypotens
defin
systol
blood
pressur
less
mmhg
mortal
defin
death
within
day
mortal
patient
n
normal
ph
ed
blood
pressur
mortal
patient
n
ph
ed
hypotens
significantli
higher
p
chisquar
test
tabl
combin
prehospit
emerg
depart
systol
blood
pressur
simpl
yet
extrem
power
predictor
mortal
follow
major
trauma
use
triag
tool
rapidli
identifi
highest
risk
patient
extravas
site
comput
tomographi
ct
studi
investig
site
extent
contrast
medium
extravas
ct
find
effect
treatment
predict
clinic
outcom
trauma
patient
method
fifti
patient
admit
emerg
depart
blunt
abdomin
trauma
show
contrast
medium
extravas
abdominalpelv
ct
scan
includ
studi
month
patient
prospect
collect
medic
record
review
analyz
retrospect
patient
clinic
laboratori
find
abdomin
sonograph
fast
find
ct
find
review
extravas
site
classifi
intraperiton
retroperiton
intrapelv
correl
posttreat
complic
mortal
morbid
rate
result
incid
extravas
site
intraperiton
case
retroperiton
case
intrapelv
four
case
frequenc
injur
vessel
show
extravas
hepat
vessel
nine
splenic
vessel
six
iliac
vessel
correl
extravas
site
icu
total
hospit
durat
p
sixteen
patient
intraperiton
extravas
requir
surgic
intervent
six
patient
underw
angiographi
embol
patient
retroperiton
extravas
nine
treat
conserv
two
embol
signific
differ
extravas
site
treatment
modal
intraperiton
group
highest
mortal
death
highest
earli
mortal
rate
first
hour
p
conclus
ct
find
patient
blunt
abdomin
trauma
show
signific
correl
contrast
medium
extravas
site
treatment
modal
icu
hospit
durat
final
result
howev
patient
intraperiton
extravas
requir
aggress
transfus
pack
red
cell
higher
mortal
rate
first
hour
techniqu
suggest
primari
survey
includ
xray
cspine
chest
pelvi
time
consum
radiat
intens
comparison
convent
multipl
radiograph
lodox
statscan
fullbodi
digit
radiolog
devic
perform
ap
later
wholebodi
examin
minut
onethird
irradi
without
necess
lift
patient
first
devic
instal
europ
method
paper
describ
experi
use
new
lowdos
xray
techniqu
part
modifi
atl
algorithm
singletot
aplater
bodi
radiograph
implement
adjunct
primari
survey
favour
sever
convent
xray
result
patient
male
femal
octob
decemb
age
rang
year
iss
rang
iss
patient
averag
time
obtain
lodox
radiograph
minut
rang
min
mean
time
resuscit
room
primari
secondari
survey
minut
new
techniqu
compar
minut
implement
lodox
median
time
min
min
patient
addit
full
bodi
ct
scan
perform
adjunct
secondari
survey
patient
addit
convent
xray
necessari
visual
skeleton
conclus
implement
modifi
atl
algorithm
use
lodox
allow
complet
ap
later
wholebodi
examin
without
signific
increas
time
taken
resuscit
sinc
begin
learn
curv
confid
futur
time
atl
primari
survey
markedli
reduc
ls
imag
system
seem
use
tool
rapid
screen
manag
trauma
patient
peripher
oxygen
extract
predict
organ
failur
mortal
follow
major
trauma
tabl
peripher
central
oxygen
extract
threshold
ml
oxygen
extract
per
litr
blood
distinguish
survivor
nonsurvivor
admiss
trauma
icu
low
peripher
oxygen
extract
ml
odd
ratio
risk
death
p
fisher
exact
test
associ
higher
organ
failur
score
p
mannwhitney
u
test
trend
increas
peripher
oxygen
extract
also
strong
predictor
mortal
p
mannwhitney
u
test
organ
failur
p
mannwhitney
u
test
conclus
arteri
venou
blood
sampl
simpl
equat
first
time
demonstr
absolut
serial
peripher
oxygen
extract
power
predictor
organ
failur
mortal
follow
major
injuri
manag
enabl
surgic
stabil
earli
phase
trauma
care
logist
organ
access
sever
therapeut
solut
influenc
physician
decis
regard
trauma
patient
aim
studi
investig
whether
time
surgeri
method
stabil
trauma
patient
femor
fractur
influenc
incid
pulmonari
complic
mof
length
stay
icu
method
retrospect
studi
perform
level
trauma
center
consid
adult
patient
major
trauma
iss
femor
shaft
fractur
admit
januari
juli
patient
separ
two
group
accord
manag
strategi
femor
fractur
group
surgeri
within
hour
primari
admiss
group
surgic
stabil
within
hour
dco
compar
two
group
consid
age
iss
rt
triss
sap
ii
gc
comorbid
associ
surgeri
paramet
evalu
mortal
icu
icu
length
stay
respiratori
failur
length
ventil
daili
sofa
collect
day
statist
determin
student
chisquar
test
p
consid
signific
identifi
patient
group
group
compar
regard
consid
paramet
except
gc
admiss
group
group
p
triss
group
group
p
observ
group
signific
decreas
mortal
vs
p
incid
aliard
vs
p
pneumonia
vs
p
decreas
sofa
score
mean
sofa
score
vs
p
maximum
sofa
score
vs
p
day
sofa
vs
p
observ
improv
respiratori
paramet
sofa
score
patient
treat
dco
furthermor
patient
wors
neurolog
condit
admiss
undergo
orthopaed
surgeri
could
worsen
cerebr
perfus
risk
relat
transfer
far
oper
room
physician
decis
therefor
patient
prognosi
experi
limit
access
optim
therapeut
solut
could
improv
clinic
cours
patient
head
trauma
risk
factor
earli
brain
death
experi
group
patient
evolv
brain
death
head
trauma
evalu
risk
factor
earli
brain
death
first
day
among
paramet
collect
prehospit
emerg
room
er
icu
stay
method
consecut
patient
admit
er
careggi
hospit
evolv
brain
death
head
trauma
period
januari
consid
n
follow
paramet
consid
studi
prehospit
phase
hypoxemia
sao
hypotens
sap
ii
mmhg
orotrach
intub
fluid
ml
gc
er
phase
atl
approach
hypoxemia
hypotens
orotrach
intub
fluid
gc
blood
lactat
pharyng
temperatur
iss
icu
stay
sap
ii
daili
sofa
score
blood
lactat
core
temperatur
glycaemia
scvo
basi
time
brain
death
patient
divid
two
group
group
n
brain
death
occur
first
day
group
n
brain
death
occur
day
statist
determin
student
chisquar
test
p
consid
signific
result
signific
differ
two
group
report
tabl
strict
relationship
exist
earli
brain
death
prehospit
treatment
icu
stay
low
level
scvo
high
level
glycaemia
relat
earli
brain
death
conclus
result
studi
confirm
prehospit
hypotens
main
risk
factor
earli
evolut
brain
death
head
trauma
also
patient
prolong
hypoperfus
neurohormon
imbal
postresuscit
phase
present
increas
risk
brain
death
sensit
specif
triag
score
dedic
trauma
patient
tertiarylevel
hospit
preliminari
result
craniotomi
traumat
brain
injuri
tbi
made
region
cerebr
blood
flow
cathet
rocbf
place
dura
tbi
intraabdomin
hemorrhag
made
pull
titch
ruptur
aorta
anim
assign
two
group
group
fluid
resuscit
group
b
hypotens
resuscit
anim
surviv
hour
hemorrhag
manag
surgic
check
hour
fluid
resuscit
result
see
tabl
rocbf
sjo
surgic
check
hemorrhag
conclus
group
b
complet
restor
cerebr
blood
flow
brain
oxygen
surgic
check
hemorrhag
hypotens
resuscit
caus
signific
reduct
mortal
patient
close
intraabdomin
trauma
coexist
head
injuri
without
put
cerebr
function
jeopardi
hyperoxemia
improv
cerebr
autoregul
sever
traumat
brain
injuri
intrins
autoregul
mechan
cerebr
vessel
normal
maintain
constant
cerebr
blood
flow
cbf
rel
independ
cerebr
perfus
pressur
variat
frequent
impair
sever
traumat
shown
hyperventil
restor
cerebr
autoregul
control
intracrani
pressur
much
less
attent
given
effect
hyperox
state
restor
cerebr
autoregul
purpos
studi
compar
autoregulatori
respons
hyperventil
vs
hyperoxia
sever
traumat
brain
injuri
avail
onlin
http
introduct
goal
studi
evalu
neurobehavior
effect
endogen
inhibitor
complement
contactkinin
pathway
follow
control
cortic
impact
cci
brain
injuri
mice
method
mice
anesthet
subject
cci
brain
injuri
minut
postinjuri
anim
randomli
receiv
intraven
infus
either
u
salin
equal
volum
second
group
mice
receiv
ident
anesthesia
surgeri
salin
serv
uninjur
control
neurobehavior
motor
outcom
evalu
weekli
week
perform
neuroscor
cognit
function
evalu
week
postinjuri
use
morri
water
maze
result
consist
braininjur
mice
receiv
show
attenu
neurolog
motor
deficit
period
compar
injur
mice
receiv
salin
figur
week
postinjuri
observ
trend
toward
better
cognit
perform
mice
receiv
compar
mice
receiv
salin
n
per
group
p
conclus
posttraumat
administr
endogen
complement
inhibitor
significantli
attenu
neurolog
motor
deficit
associ
traumat
brain
injuri
haemostat
activ
marker
brain
injuri
mortal
predict
comparison
blood
sampl
jugular
bulb
central
venou
line
introduct
norepinephrin
use
clinic
routin
increas
cerebr
perfus
follow
sever
traumat
brain
injuri
tbi
may
activ
adrenerg
receptor
platelet
therebi
possibl
promot
format
microthrombosi
induc
addit
brain
injuri
method
arteri
jugular
venou
platelet
isol
norepinephrinereceiv
tbi
patient
n
healthi
volunt
n
cubit
vein
stimul
vitro
increas
avail
onlin
http
chang
pselectin
express
isol
platelet
stimul
vitro
norepinephrin
trap
p
vs
lowdos
norepinephrin
p
vs
control
p
vs
first
week
norepinephrin
concentr
nm
thrombin
receptor
activ
peptid
trap
serv
posit
control
pselectin
express
determin
flow
cytometri
fac
result
follow
tbi
number
unstimul
pselectinposit
platelet
significantli
decreas
second
week
first
week
vitro
stimulatori
effect
significantli
reduc
second
week
howev
norepinephrinemedi
effect
exceed
chang
control
first
week
without
differ
arteri
jugular
venou
platelet
figur
largebor
cathet
mm
id
insert
right
superior
vena
cava
inject
preform
blood
clot
largebor
cathet
insert
inferior
vena
cava
via
femor
vein
aorta
via
femor
arteri
access
cpb
measur
mean
arteri
pressur
map
cardiac
output
co
blood
gase
pulmonari
arteri
pressur
measur
mpap
endtid
co
etco
blood
gase
ml
preform
blood
clot
inject
system
circul
ceas
systol
ap
mmhg
minut
interv
allow
start
cpb
flow
rate
lmin
heparin
ie
given
iv
rtpa
mg
aim
present
studi
examin
coagul
statu
patient
earli
postburn
period
method
coagul
fibrinolysi
paramet
antithrombin
iii
atiii
protein
c
prc
free
protein
pr
plasminogen
activ
inhibitor
tissu
plasminogen
activ
tpa
thrombin
antithrombin
complex
tat
antiplasmin
complex
pap
fibrin
degrad
product
measur
icu
admiss
daili
thereaft
postburn
day
result
fortyf
patient
screen
nine
nonsurvivor
survivor
patient
sever
defici
coagul
inhibitor
admiss
normal
level
survivor
observ
day
atiii
prc
day
pr
patient
elev
level
tat
investig
period
survivor
significantli
lower
level
day
postburn
vs
p
pap
level
within
physiolog
rang
group
day
remain
low
survivor
rais
significantli
nonsurvivor
day
vs
p
tpa
level
elev
perman
nonsurvivor
level
increas
day
group
return
normal
valu
day
survivor
degre
activ
significantli
higher
tpa
level
perman
elev
statist
signific
differ
group
logist
regress
analysi
reveal
atiii
pr
day
pr
c
day
tat
day
independ
predictor
icu
death
conclus
find
indic
earli
postburn
dysregul
hemostat
balanc
character
activ
procoagul
pathway
although
fibrinolysi
activ
inhibit
fibrinolysi
pronounc
time
coagul
inhibitor
tat
level
seem
earli
predictor
icu
mortal
teg
paramet
fibrinolysi
significantli
increas
cpb
frequenc
aprotinin
administr
teg
control
correl
posit
fibrinolysi
peroperativepostop
blood
loss
red
blood
cell
rbc
fresh
frozen
plasma
ffp
transfus
record
correl
aprotinin
administr
peroperativepostop
blood
loss
rbc
transfus
record
posit
correl
aprotinin
administr
ffp
transfus
record
conclus
fibrinolysi
usual
associ
seriou
bleed
posit
effect
aprotinin
reduc
bleed
transfus
therapi
fdp
ddimer
use
detect
fibrinolysi
cardiac
surgeri
intrinsicextrins
activ
fibtem
extem
inhibit
platelet
pentapharm
munich
germani
result
clot
format
time
cft
maximum
clot
firm
mcf
clot
time
ct
strongli
correl
fibrinogen
level
platelet
count
surgeri
significantli
decreas
rotem
haemostat
activ
normalis
patient
within
h
postoper
lowest
haemostat
activ
dramat
increas
ct
cft
decreas
mcf
seen
patient
condit
cardiopulmonari
bypass
cpb
connect
cpb
ct
cft
turn
recov
mcf
extem
remain
unchang
mcf
fibtem
declin
indic
continu
fibrinogen
consumpt
patient
postop
mcf
fibtem
reduc
mm
indic
need
fibrinogen
substitut
low
postop
activ
rotem
associ
high
postop
blood
loss
posit
predict
valu
specif
fibtem
clearli
superior
aptt
prothrombin
time
patient
increas
haemostat
activ
preoper
rotem
associ
high
crp
level
intraop
blood
loss
conclus
rotem
valuabl
tool
monitor
periop
haemostasi
decreas
haemostat
activ
postop
bleed
probabl
due
anticoagul
therapi
well
fibrinogen
platelet
consumpt
increas
preoper
haemostat
activ
probabl
due
acut
phase
reaction
associ
advanc
atherosclerosi
high
intraop
bleed
patient
might
due
atherosclerot
vessel
rather
due
insuffici
haemostasi
object
cardiac
surgeri
particular
done
cardiopulmonari
bypass
cpb
frequent
associ
excess
intraop
postop
bleed
employ
technothrombin
thrombin
gener
assay
tga
technoclon
monitor
chang
periop
haemostasi
method
one
hundr
fortyeight
patient
age
year
male
femal
elect
cardiac
surgeri
cpb
time
minut
mean
min
enrol
arteri
blood
sampl
obtain
preoper
postop
hour
postop
centrifug
within
minut
withdraw
minut
x
g
plasma
sampl
store
analysi
thrombin
gener
tg
induc
tga
rc
low
reagent
pm
tissu
factor
measur
multipl
use
fluostar
optima
fluoresc
reader
mwg
labtech
result
due
cardiac
surgeri
lagphas
timetopeak
tg
increas
respect
parallel
peak
thrombin
concentr
maximum
slope
decreas
respect
p
lagphas
timetopeak
return
basal
valu
within
hour
postop
peak
thrombin
maximum
slope
tg
rose
preoper
valu
p
onpump
time
posit
correl
lag
phase
time
peak
neg
correl
peak
thrombin
maximum
slope
tg
measur
hour
postop
correl
earli
postop
respect
classic
coagul
paramet
signific
correl
observ
tg
activ
partial
thromboplastin
time
preoper
hour
postop
tg
prothrombin
time
postop
p
hour
postop
signific
correl
tg
platelet
well
leukocyt
count
p
conclus
data
provid
clear
evid
mark
decreas
tg
cardiac
surgeri
follow
excess
restor
postop
phase
factor
releas
platelet
leukocyt
procoagul
microvesicl
might
contribut
enhanc
tg
observ
hour
postop
introduct
orgaran
danaparoid
sodium
lowmolecularweight
nonheparin
glycosaminoglycan
antithrombot
current
firstlin
treatment
heparininduc
thrombocytopenia
hit
conclus
find
high
incid
posit
heparin
antibodi
may
mainli
due
unfract
heparin
flush
use
heparin
flush
new
highqual
cathet
monitor
kit
question
sinc
low
dose
unfract
heparin
could
lead
product
antibodi
subsequ
hit
studi
examin
risktobenefit
ratio
use
unfract
heparin
flush
icu
set
introduct
transfusionrel
acut
lung
injuri
due
plasma
femal
donor
contain
antileucocyt
antibodi
may
common
contributor
develop
acut
lung
injuri
ali
critic
ill
juli
english
blood
servic
stop
use
femal
donor
plasma
manufactur
fresh
frozen
plasma
ffp
patient
undergo
repair
ruptur
abdomin
aortic
aneurysm
aaa
receiv
larg
amount
ffp
often
develop
ali
investig
whether
chang
maleonli
ffp
associ
chang
incid
ali
patient
undergo
emerg
aaa
repair
method
beforeandaft
observ
singlecentr
studi
subject
consecut
patient
undergo
open
repair
ruptur
aaa
primari
outcom
develop
ali
pao
fio
bilater
pulmonari
infiltr
chest
xray
first
hour
surgeri
secondari
outcom
time
extub
surviv
day
chest
xray
examin
independ
two
radiologist
blind
studi
hypothesi
result
one
hundr
twentynin
patient
oper
chang
ffp
procur
group
well
match
respect
age
sex
comorbid
sever
ill
receiv
similar
volum
iv
fluid
blood
product
admiss
hour
postop
mean
unit
ffp
p
maximum
tidal
volum
peep
cvp
similar
group
norepinephrin
given
patient
group
compar
p
otherwis
inotrop
use
similar
primari
outcom
significantli
less
ali
follow
chang
maleonli
ffp
vs
p
secondari
outcom
statist
differ
group
howev
patient
ali
either
group
poorer
surviv
vs
p
conclus
exclus
femaledonor
ffp
associ
statist
signific
reduct
incid
ali
patient
undergo
repair
ruptur
aaa
introduct
octaplex
new
prothrombin
complex
concentr
indic
treatment
periop
prophylaxi
bleed
patient
defici
prothrombin
complex
coagul
factor
defici
caus
treatment
vitamin
k
antagonist
liver
failur
rapid
correct
bleed
requir
studi
conduct
demonstr
prevent
bleed
achiev
haemostasi
acut
bleed
obtain
inform
safeti
administr
octaplex
conclus
result
support
evid
recombin
factor
vii
effect
haemostat
agent
use
patient
uncontrol
bleed
postcardiopulmonari
bypass
surgeri
despit
high
cost
advantag
term
effect
support
use
howev
potenti
thromboembol
risk
remain
concern
current
evid
may
restrict
use
rescu
therapi
follow
fail
convent
treatment
introduct
recombin
activ
factor
vii
rfviia
novoseven
novo
nordisk
denmark
develop
primarili
treatment
bleed
episod
hemophil
patient
littl
inform
avail
use
rfviia
situat
intract
postsurg
posttraumat
bleed
field
cardiac
surgeri
case
treatment
rfviia
describ
difficulti
perform
random
trial
set
inform
base
case
studi
valuabl
method
studi
consecut
patient
treat
rfviia
due
refractori
postop
bleed
rfviia
given
option
includ
revis
stop
bleed
fail
amount
bleed
number
transfus
unit
red
cell
platelet
blood
product
record
administr
rfviia
critic
care
march
vol
suppl
intern
symposium
intens
care
emerg
medicin
mean
hourli
drain
output
hour
pre
hour
post
novoseven
administr
clinic
databas
electron
medic
record
review
collect
data
element
need
assess
studi
object
one
hundr
twenti
patient
identifi
twentyseven
patient
exclud
lack
document
administr
treat
neurolog
indic
incomplet
medic
record
data
ninetythre
patient
analyz
effect
achiev
hemostasi
patient
intract
bleed
reduc
blood
product
transfus
within
hour
treatment
figur
find
suggest
differ
prbc
transfus
reduct
dose
observ
addit
reduct
prbc
transfus
patient
administ
dose
greater
figur
effect
surgic
reexplor
potenti
relat
advers
event
stroke
ami
vte
etc
forthcom
studi
like
other
evalu
indic
limit
retrospect
scope
random
trial
compar
dose
way
although
therapi
costli
minim
reduct
surgic
reexplor
may
offset
cost
therapi
provid
advers
event
increas
low
platelet
count
matern
mortal
report
high
two
classif
hellp
syndrom
wide
use
tennesse
mississippi
aim
studi
determin
mortal
hellp
syndrom
defin
classif
tri
assess
relev
patient
method
prospect
data
collect
part
aprimo
studi
assess
prognosi
risk
mortal
obstetr
includ
obstetr
patient
transfer
referr
center
highrisk
pregnanc
independ
multidisciplinari
icu
studi
period
januari
demograph
data
obstetr
histori
morbid
event
length
stay
lo
sever
ill
score
system
organ
dysfunct
score
day
admiss
collect
exclus
criteria
lo
hour
main
outcom
interest
surviv
statu
icu
discharg
two
group
compar
patient
hellp
syndrom
defin
altern
two
classif
group
patient
without
hepat
dysfunct
group
ii
result
express
mean
standard
deviat
p
consid
signific
discrimin
classif
assess
area
receiv
oper
characterist
curv
auroc
calibr
assess
hosmerlemeshow
hl
goodnessoffit
test
data
comput
spss
winxp
compat
result
discuss
differ
group
group
ii
statist
signific
concern
obstetr
hemorrhag
complic
p
incid
acut
renal
failur
p
mortal
p
lo
day
vs
day
p
sapsobst
score
vs
p
mississippi
classif
discrimin
well
calibr
badli
contrari
tennesse
classif
poor
discrimin
calibr
well
see
tabl
result
present
studi
complement
find
previou
studi
time
stroke
pregnanc
found
preeclampsiaeclampsia
intracrani
vascular
malform
major
caus
stroke
pregnanc
agre
find
studi
show
high
mortal
rate
indic
care
manag
atrisk
patient
first
postpartum
week
warrant
introduct
renal
dysfunct
associ
increas
morbid
mortal
intens
care
patient
aim
studi
investig
use
laboratori
marker
icu
especi
glomerular
filtrat
rate
gfr
marker
compar
two
gfr
marker
creatinin
cystatin
c
secondari
aim
assess
frequenc
reduc
gfr
patient
group
use
creatinin
cystatin
c
estim
gfr
sever
pharmaceut
prescrib
accord
renal
function
aim
studi
evalu
feu
followup
arf
due
preren
azotemia
order
predict
necess
renal
replac
therapi
rrt
prospect
studi
took
place
icu
stadtspit
waid
patient
admit
start
februari
evalu
arf
accord
rifl
classif
arf
due
preren
azotemia
defin
arf
combin
feu
less
equal
feu
calcul
urin
ureablood
urea
urin
creatinineplasma
creatinin
x
urin
specimen
taken
feu
calcul
daili
complet
partial
renal
recoveri
reach
criteria
rrt
met
goal
therapi
reconstitut
renal
function
treatment
underli
condit
rrt
initi
accord
usual
criteria
statist
determin
use
fisher
exact
test
avail
onlin
http
fraction
excret
urea
feu
followup
acut
renal
failur
arf
due
preren
azotemia
data
present
mean
sd
n
number
patient
decemb
patient
met
inclus
criteria
arf
due
preren
azotemia
nine
male
six
femal
mean
age
sd
year
male
patient
year
femal
patient
twelv
patient
respond
conserv
manag
complet
partial
renal
recoveri
three
patient
need
rrt
two
refus
rrt
die
cours
diseas
first
hour
initi
conserv
therapi
feu
remain
less
equal
three
patient
need
rrt
contrast
nine
patient
renal
function
recov
without
rrt
show
feu
within
first
hour
p
figur
patient
present
arf
due
preren
azotemia
increas
feu
within
first
hour
initi
conserv
therapi
arf
valuabl
paramet
predict
renal
recoveri
initi
conserv
therapi
measur
feu
valu
concern
discrimin
preren
azotemia
acut
tubular
necrosi
arf
hemodynam
goaldirect
intermitt
hemodialysi
major
concern
ih
septic
shock
patient
hemodynam
instabl
whether
stringent
hemodynam
monitor
maintain
preset
goal
would
reduc
instabl
deliv
optim
rrt
clear
undertook
prospect
studi
evalu
concept
method
preset
goal
keep
mean
arteri
pressur
map
mm
cardiac
output
co
lmin
cardiac
index
ci
lminm
throughout
session
attempt
achiev
stepwis
protocol
follow
fluid
bolus
increas
vasopressorinotrop
dose
adjust
ultrafiltr
rate
mlhour
adjust
blood
flow
rate
mlminut
hemodialysi
machin
dopamin
norepinephrin
vasopressin
dobutamin
use
alon
combin
achiev
goal
hemodynam
monitor
data
collect
done
datex
flotrac
vigileo
monitor
introduct
acut
renal
failur
arf
one
major
complic
cardiovascular
surgeri
investig
incid
prognosi
arf
cardiac
surgeri
perform
retrospect
studi
hypothesi
arf
common
patient
underw
surgeri
great
vessel
diseas
underw
coronari
valv
surgeri
method
enrol
patient
year
old
underw
cardiovascular
surgeri
enter
icu
background
diseas
classifi
two
group
great
vessel
diseas
coronaryvalv
diseas
determin
arf
serum
creatinin
increas
preoper
valu
renal
replac
therapi
newli
start
review
icu
chart
collect
data
admiss
icu
icu
stay
result
arf
occur
frequent
patient
great
vessel
diseas
coronaryvalv
diseas
vs
p
prognosi
patient
arf
poorer
without
arf
group
figur
patient
arf
show
longer
oper
time
larger
intraop
bleed
higher
level
blood
lactat
admiss
icu
without
arf
patient
arf
show
higher
incid
liver
dysfunct
need
longer
mechan
ventil
icu
stay
conclus
arf
common
cardiovascular
surgeri
especi
surgeri
great
vessel
diseas
arf
associ
postop
organ
disord
includ
retrospect
observ
studi
incid
postop
renal
dysfunct
compar
patient
given
aprotin
tranexam
acid
antifibrinolyt
agent
use
propensityadjust
multivari
logist
regress
analysi
perform
compar
patient
take
ace
inhibitor
preoper
take
ace
inhibitor
renal
dysfunct
defin
creatinin
higher
andor
renal
dialysi
patient
previou
histori
renal
dysfunct
exclud
studi
result
use
propensityadjust
multivari
logist
regress
cindex
use
aprotinin
patient
take
ace
inhibitor
associ
doubl
risk
acut
postop
renal
failur
patient
undergo
nonemerg
cardiac
surgeri
odd
ratio
confid
interv
tranexam
acid
also
associ
signific
increas
risk
renal
failur
odd
ratio
confid
interv
patient
take
ace
inhibitor
howev
studi
associ
either
aprotinin
odd
ratio
tranexam
acid
odd
ratio
postop
renal
failur
patient
take
ace
inhibitor
conclus
cardiac
surgeri
signific
associ
use
antifibrinolyt
drug
aprotinin
tranexam
avail
onlin
http
acid
occurr
acut
postop
renal
dysfunct
patient
take
ace
inhibitor
potenti
bloodsav
benefit
antifibrinolyt
drug
weigh
seriou
postop
complic
introduct
number
preoper
patientspecif
risk
factor
contribut
increas
periop
cardiovascular
risk
myocardi
infarct
heart
failur
death
patient
undergo
major
noncardiac
surgeri
renal
impair
one
predictor
creatinin
valu
poor
reflect
true
renal
function
measur
glomerular
filtrat
rate
provid
accur
measur
renal
function
true
preval
renal
impair
popul
may
significantli
higher
previous
appreci
aim
identifi
proport
elect
vascular
patient
undergo
abdomin
aortic
surgeri
ckd
assess
estim
glomerular
filtrat
rate
egfr
bodi
surfac
area
creatinin
method
retrospect
analysi
abc
studi
databas
undertaken
abc
studi
ongo
studi
look
preoper
risk
assess
use
cardiopulmonari
exercis
test
patient
undergo
elect
aortic
surgeri
result
sixtysix
patient
includ
analysi
patient
caucasian
male
patient
preexist
diagnosi
chronic
renal
impair
patient
stage
ckd
sever
reduc
kidney
function
egfr
moder
reduc
kidney
function
egfr
ckd
stage
seen
patient
mildli
reduc
kidney
function
egfr
ckd
stage
two
patient
normal
kidney
function
mean
total
cholesterol
cohort
mmoll
mmoll
see
tabl
major
vascular
patient
undergo
elect
aortic
surgeri
unit
impair
renal
function
accur
reflect
creatinin
valu
manag
patient
stage
ckd
primarili
cardiovascular
risk
assess
aggress
treatment
modifi
vascular
risk
factor
full
impact
risk
factor
modif
periop
outcom
vascular
patient
requir
detail
investig
introduct
gc
globulin
hepat
synthes
actin
bind
protein
known
decreas
acut
chronic
liver
diseas
low
level
associ
poor
prognosi
neutrophil
gelatinaseassoci
lipocalin
ngal
member
lipocalin
famili
protein
shown
earli
biomark
ischaem
renal
damag
prospect
investig
use
protein
marker
sever
ill
prognost
acut
acuteonchron
liver
failur
requir
intens
care
method
ngal
gc
globulin
measur
admiss
unit
use
sandwich
elisa
techniqu
antibodyshop
patient
acut
liver
failur
alf
patient
acuteonchron
liver
diseas
acld
biochem
physiolog
variabl
collect
prospect
enter
physiolog
databas
icar
measur
taken
day
admiss
result
express
median
interquartil
rang
result
mean
number
pdrspatient
three
mean
pdr
rang
two
patient
pdr
could
detect
due
hemodynam
instabl
pdr
predictor
valu
irrevers
liver
failur
p
nine
patient
pdr
nine
two
patient
recov
synthet
function
seven
patient
develop
irrevers
liver
failur
four
die
liver
failur
three
underw
liver
transplant
see
tabl
conclus
icgpdr
signific
predictor
irrevers
liver
failur
good
complement
score
decisionmak
introduct
desferrioxamin
dfx
clinic
approv
iron
chelat
use
treat
iron
overload
also
shown
benefici
effect
experiment
acut
liver
failur
alf
inhibit
oxid
damag
lung
dysfunct
commonli
complic
alf
ironmedi
process
shown
contribut
hypothes
inhibit
oxid
reaction
mean
iron
chelat
could
attenu
lung
injuri
ischem
alf
studi
aim
analys
incid
rel
adren
insuffici
rai
patient
identifi
factor
associ
rel
adren
insuffici
describ
adren
respons
affect
outcom
method
prospect
observ
multicent
studi
short
synacthen
test
sst
perform
within
day
admiss
hospit
patient
sever
acut
pancreat
sign
inform
consent
obtain
incid
rai
defin
increment
sst
less
primari
endpoint
studi
serum
cortisol
measur
baselin
minut
adrenocorticotrop
hormon
administr
median
baselin
cortisol
level
increas
minut
respect
rai
found
patient
patient
organ
dysfunct
patient
rai
sever
ill
higher
sofa
score
day
day
admiss
patient
rai
develop
pancreat
necrosi
need
surgic
intervent
mortal
significantli
higher
patient
rai
vs
p
patient
die
lower
increment
cortisol
level
sst
patient
surviv
conclus
rai
frequent
patient
sever
acut
pancreat
organ
dysfunct
occur
patient
sever
pancreat
associ
increas
mortal
rate
rel
sensit
serum
lipas
versu
amylas
radiolog
imageposit
pancreat
k
introduct
pulmonari
edema
common
consequ
hemorrhag
shock
resuscit
type
amount
fluid
use
resuscit
may
import
determin
amount
edema
form
ringer
lactat
rl
normal
salin
ns
remain
common
resuscit
fluid
experi
design
measur
extravascular
lung
water
evlw
resuscit
hemorrhag
shock
rl
vs
ns
determin
whether
fluid
type
result
differ
amount
evlw
determin
whether
exist
threshold
amount
fluid
result
develop
edema
method
random
control
trial
use
femal
yorkshir
crossbr
pig
anim
mechan
ventil
anesthesia
maintain
use
isofluoran
oxygen
continu
hemodynam
monitor
blood
sampl
determin
evlw
singl
indic
transpulmonari
dilut
done
use
picco
plu
monitor
pulsion
medic
system
munich
germani
anim
underw
midlin
celiotomi
suprapub
foley
cathet
placement
splenectomi
spleen
weigh
base
random
either
lr
ns
solut
infus
replac
three
time
spleen
weight
gram
follow
stabil
period
standard
grade
v
liver
injuri
injuri
central
hepat
vein
creat
use
special
clamp
follow
minut
uncontrol
hemorrhag
blindli
random
swine
receiv
either
ns
rl
resuscit
mlmin
resuscit
fluid
administ
achiev
maintain
baselin
mean
arteri
pressur
map
minut
post
injuri
result
anim
spontan
stop
bleed
within
minut
injuri
lose
approxim
blood
volum
differ
initi
blood
loss
two
group
estim
blood
loss
mean
standard
error
rl
incorpor
lipid
emuls
parenter
diet
requir
energi
essenti
fatti
acid
suppli
may
prevent
mani
metabol
disturb
associ
intraven
feed
amino
acid
glucos
alon
critic
ill
patient
differ
parenter
fat
emuls
signific
impact
immun
system
shown
studi
toxic
soybean
oilbas
emuls
oliv
oilbas
emuls
leukocyt
healthi
volunt
investig
method
twentyfour
volunt
recruit
blood
sampl
collect
infus
soybean
oilbas
emuls
oliv
oilbas
emuls
immedi
afterward
hour
later
cell
studi
immedi
isol
hour
hour
cultur
follow
determin
made
composit
concentr
fatti
acid
plasma
lymphocyt
neutrophil
lymphocyt
prolifer
toxic
determin
plasma
membran
integr
dna
fragment
phosphatidylserin
extern
mitochondri
depolar
product
reactiv
oxygen
speci
neutral
lipid
accumul
result
lipid
emuls
decreas
lymphocyt
prolifer
induc
cell
death
effect
soybean
oilbas
emuls
pronounc
soybean
oilbas
emuls
provok
apoptosi
necrosi
wherea
oliv
oilbas
emuls
caus
neutrophil
lymphocyt
necrosi
evid
present
lipid
emuls
less
toxic
neutrophil
lymphocyt
mechan
cell
death
induc
lipid
emuls
involv
mitochondri
membran
depolar
neutral
lipid
accumul
alter
product
reactiv
oxygen
speci
conclus
oliv
oilbas
emuls
altern
soybean
oilbas
emuls
avoid
leukocyt
death
suscept
patient
infect
avail
onlin
http
gdl
group
b
n
hb
level
gdl
group
c
n
hb
level
gdl
calcul
pearson
coeffici
sid
bicarbon
chlorid
bicarbon
three
group
patient
result
correl
strength
sid
hco
high
signific
even
hb
concentr
gdl
see
tabl
pearson
coeffici
chlorid
bicarbon
show
moder
signific
invers
correl
group
group
b
eventu
correl
complet
lost
group
c
immedi
incid
report
case
posttransfus
haemoglobin
averag
gdl
discuss
conclus
evolut
blood
transfus
remark
sinc
use
total
blood
acquisit
first
techniqu
separ
blood
compon
transfus
practic
tunisia
far
standard
result
obtain
make
possibl
transmit
clinician
failur
system
better
includ
prescrib
blood
product
follow
effect
possibl
side
effect
apprehend
impact
innov
biotechnolog
improv
qualiti
transfus
medicin
coher
secur
requir
person
answer
question
sedat
practic
use
sedat
score
system
withdraw
symptom
result
twentynin
total
possibl
hospit
answer
includ
answer
total
possibl
answer
ninetyseven
per
cent
physician
specialist
anaesthesiolog
eightyseven
per
cent
nurs
certifi
intens
care
nurs
fortyseven
per
cent
univers
hospit
twentysix
per
cent
sedat
protocol
physician
nurs
onethird
icu
protocol
sedat
sixtyeight
per
cent
protocol
use
alway
often
wherea
never
use
sixtyseven
per
cent
sedat
score
system
depart
score
system
use
ramsay
sedat
agit
score
local
made
score
system
twentytwo
per
cent
answer
score
system
alway
use
often
score
system
seldom
use
forti
per
sent
use
wakeup
call
test
physician
nurs
sixti
per
cent
answer
use
wakeup
call
test
physician
nurs
withdraw
symptom
experienc
three
time
frequent
nurs
compar
physician
vs
five
time
mani
experienc
withdraw
symptom
group
sedat
analgesia
protocol
vs
conclus
still
great
educ
potenti
improv
use
sedat
protocol
implement
sedat
score
system
wake
test
danish
icu
potenti
could
perhap
reduc
incid
withdraw
symptom
effort
also
place
implement
sedat
protocol
icu
illustr
differ
number
doctor
nurs
sedat
protocol
compar
efficaci
advers
event
recoveri
durat
etomid
propofol
use
procedur
sedat
emerg
depart
ed
random
nonblind
prospect
trial
adult
patient
undergo
procedur
sedat
pain
procedur
ed
made
patient
receiv
either
propofol
etomid
dose
vital
sign
nasal
endtid
co
etco
puls
oximetri
bispectr
electroencephalogram
analysi
score
record
subclin
respiratori
depress
defin
chang
etco
greater
mmhg
oxygen
satur
less
time
absent
etco
waveform
time
clinic
event
relat
respiratori
depress
includ
increas
supplement
oxygen
use
bagvalvemask
apparatu
airway
reposit
stimul
induc
breath
note
etomid
propofol
appear
equal
safe
ed
procedur
sedat
etomid
lower
rate
procedur
success
induc
myoclonu
patient
see
tabl
background
aim
studi
describ
matur
aspect
propofol
pharmacokinet
follow
singl
intraven
bolu
administr
childhood
method
seventi
propofol
bloodtim
profil
collect
nine
neonat
mean
weight
rang
kg
arteri
blood
sampl
hour
administr
singl
intraven
bolu
propofol
mgkg
elect
chest
tube
remov
concentrationtim
curv
obtain
everi
individu
neonat
interpret
twostag
analysi
twocompart
threecompart
open
model
newli
collect
observ
follow
intraven
bolu
administr
propofol
preterm
term
neonat
n
combin
individu
pharmacokinet
estim
toddler
n
young
children
n
data
report
median
rang
wilcoxon
test
linear
correl
use
analys
pharmacokinet
find
neonat
toddler
young
children
result
bloodconcentr
curv
obtain
everi
individu
patient
interpret
twostag
analysi
threecompart
open
model
cohort
patient
median
weight
rang
kg
median
postmenstru
age
rang
week
median
clearanc
rang
mlkgmin
median
appar
volum
distribut
steadi
state
v
ss
lkg
median
final
serum
elimin
halflif
rang
minut
median
clearanc
significantli
lower
neonat
compar
toddler
older
children
p
differ
remain
signific
allometr
scale
mlkg
signific
correl
v
ss
postmenstru
age
r
ci
p
observ
conclus
propofol
disposit
significantli
differ
neonat
compar
toddler
young
children
reflect
ontogeni
differ
bodi
composit
base
reduc
clearanc
propofol
accumul
repeat
administr
longer
recoveri
time
like
occur
neonat
background
acut
pain
common
cardiac
surgeri
keep
patient
particip
activ
prevent
postop
complic
especi
respiratori
complic
accur
assess
understand
pain
vital
provid
satisfactori
pain
control
optim
recoveri
studi
perform
find
locat
distribut
intens
pain
sampl
adult
cardiac
surgeri
patient
postop
icu
stay
method
prospect
studi
pain
locat
distribut
number
pain
area
per
patient
intens
numer
rate
scale
document
consecut
adult
patient
first
second
third
postop
day
pod
patient
characterist
age
sex
size
bodi
mass
index
analyz
impact
pain
intens
male
femal
patient
mean
sd
age
year
maxim
pain
intens
significantli
higher
pod
respect
lower
pod
order
overal
pain
score
among
activ
p
highest
lowest
cough
move
turn
bed
get
deep
breath
use
incent
spiromet
rest
chest
tube
discontinu
patient
lower
pain
level
rest
p
cough
p
age
sex
found
impact
pain
intens
patient
year
old
male
patient
higher
pain
intens
older
patient
pod
patient
ischem
coronari
arteri
diseas
sympathomimet
effect
ketamin
caus
myocardi
damag
howev
sisom
ketamin
may
variou
advantag
studi
cardiovascular
stabil
safeti
intraven
anesthesia
ketamin
coronari
arteri
bypass
graft
surgeri
cabg
method
approv
local
ethic
committe
written
inform
consent
patient
schedul
elect
onpump
cabg
enrol
studi
patient
randomli
alloc
three
anesthet
protocol
sufentanilsevofluoranepropofol
ssp
sufentanilpropofol
sp
ketaminemidazolampropofol
kmp
standard
invas
hemodynam
monitor
perform
use
pulmonari
arteri
cathet
hemodynam
variabl
report
measur
taken
induct
anesthesia
wean
cardiopulmonari
bypass
hour
postop
serial
plasma
troponin
level
taken
induct
anesthesia
surgeri
hour
postop
cardiovascular
advers
event
record
electrocardiograph
sign
ischemia
myocardi
infarct
mortal
factor
sex
age
trauma
nontrauma
whether
pmct
caus
death
final
diagnosi
especi
compar
two
group
pmct
pmct
abstract
outlin
use
simul
critic
care
telephon
call
educ
traine
hope
other
may
consid
centr
capit
health
region
provid
advanc
healthcar
million
peopl
spread
km
therefor
reli
heavili
transport
critic
ill
patient
singl
urban
centr
addit
geograph
climat
factor
bed
pressur
complic
triag
stabil
transport
receiv
patient
major
strategi
criticalcarelin
telephon
servic
teleconfer
capabl
contact
number
howev
experi
suggest
take
practic
becom
profici
use
given
import
optim
commun
arrang
simul
call
senior
traine
page
normal
workday
criticalcarelin
independ
practic
facilit
assum
role
refer
doctor
small
town
peerreview
case
use
includ
pertin
teach
point
applic
staff
teach
centr
brief
exercis
ask
act
normal
would
exampl
emerg
physician
internist
senior
nurs
administr
notifi
may
brought
call
depend
whether
traine
decid
involv
servic
exampl
hesh
decid
patient
requir
workup
decid
upon
icu
hesh
decid
bring
patient
emerg
icu
bed
current
avail
call
record
aid
debrief
method
allow
us
ascertain
traine
ask
focus
histori
offer
practic
advic
base
upon
variabl
skill
set
refer
physician
deal
complex
ethic
decis
exampl
famili
wish
overrid
patient
previou
wish
aggress
treat
termin
patient
prior
discuss
occur
allow
us
test
traine
knowledg
importantli
determin
well
knowledg
appli
everyday
practic
canada
royal
colleg
physician
surgeon
decre
traine
becom
medic
expert
also
profici
commun
collabor
manag
goal
laudabl
difficult
captur
without
novel
approach
one
outlin
simpl
costfre
addit
train
well
receiv
initi
success
mean
expand
throughout
acut
care
specialist
train
conclus
although
studi
small
two
observ
investig
clearli
show
signific
intraindividu
interindividu
variabl
classif
monitor
event
done
experienc
clinician
find
support
studi
imag
analysi
also
found
high
intraindividu
interindividu
variabl
high
interobserv
intraobserv
variabl
challeng
clinic
studi
new
alarm
algorithm
find
also
show
need
reliabl
classif
method
goal
program
develop
experiment
tool
abl
record
store
analys
data
issu
critic
care
patient
due
technic
limit
medic
constraint
inform
system
abl
manag
data
flow
difficult
deploy
method
data
record
done
laptop
connect
medic
devic
allow
analog
digit
signal
transmiss
highspe
network
sever
server
dedic
specialis
task
mass
storag
model
gener
artifici
intellig
ai
telecommun
secur
teraflop
supercomput
dedic
intens
comput
necessari
twenti
applic
dedic
elect
task
run
use
linux
oper
system
aiddiag
dataacquisit
softwar
standalon
applic
adapt
patient
data
record
biomed
devic
caregiv
input
friendli
design
userinterfac
touchscreen
bedsid
adapt
accord
caregiv
feedback
data
also
store
repositori
select
secondari
extract
possibl
onlin
offlin
analysi
ai
engin
allow
softwar
consid
time
specif
use
distribut
comput
achiev
high
workload
task
compli
french
legal
patient
data
manag
constraint
result
year
system
fulli
deploy
record
patienthour
period
signal
loss
less
tool
allow
record
digit
signal
eight
analog
signal
sampl
rate
khz
caregiv
comment
action
cpu
resourc
laptop
avail
supplement
ai
develop
data
acquisit
transfer
data
repositori
either
hotplugautom
process
delay
day
buffer
laptop
autom
artefact
clean
allow
timeseri
analysi
garch
method
extract
behaviour
model
intens
comput
ai
engin
use
medic
guidelin
implement
sever
brain
trauma
care
algorithm
later
comparison
caregiv
behaviour
remot
use
system
possibl
schedul
allow
research
team
work
data
limit
detect
intens
calcul
finetun
network
suppress
limit
conclus
isi
first
program
achiev
easytous
record
tool
abl
build
larg
medic
repositori
data
analysi
method
aicontrol
autom
complex
medic
guidelin
evalu
introduct
result
centralis
picu
servic
unit
kingdom
transfer
critic
ill
children
becom
common
past
decad
uncommon
receiv
multipl
retriev
request
simultan
thu
tool
prioritis
urgenc
would
benefici
aim
develop
tool
assess
interrat
repeat
method
tool
develop
three
senior
medic
staff
south
thame
retriev
servic
oper
picu
evelina
children
hospit
london
call
per
annum
district
gener
hospit
result
retriev
modifi
delphi
method
use
compris
iter
process
includ
literatur
review
knowledg
underli
condit
review
retriev
perform
servic
previou
year
n
interrat
agreement
assess
use
weight
kappa
statist
measur
variou
pair
junior
senior
medic
staff
n
combin
retriev
episod
final
tool
compris
five
categori
three
level
sever
allow
rang
score
figur
three
level
urgenc
defin
semiurg
score
urgent
score
immedi
score
overal
tool
show
good
good
strength
interrat
agreement
kappa
score
rang
figur
obviou
differ
level
staff
senior
score
show
accept
agreement
fullfil
first
step
valid
south
thame
retriev
servic
str
specialis
paediatr
intens
care
retriev
servic
integr
evelina
children
hospit
lead
centr
south
thame
region
london
last
year
number
initi
adopt
reduc
mobilis
time
time
retriev
accept
activ
departur
lead
centr
improv
servic
deliveri
surround
district
gener
hospit
dgh
aim
studi
evalu
whether
initi
led
reduct
mobilis
time
januari
decemb
method
str
cover
dgh
within
mile
rang
serv
popul
million
children
south
thame
region
greater
london
call
servic
log
detail
databas
retriev
request
potenti
picu
patient
triag
coordin
via
retrievalspecif
telephon
line
accept
onsit
retriev
team
mobilis
dispatch
via
dedic
ambul
dgh
mobilis
includ
assimil
check
prepack
equip
bag
ventil
drug
intub
kit
monitor
organis
team
least
one
retriev
nurs
doctor
ambul
driver
detail
retriev
request
str
includ
time
call
captur
databas
contain
patient
demograph
clinic
detail
interv
accept
patient
retriev
team
departur
unit
term
mobilis
time
minut
data
analys
two
time
period
n
retriev
n
coincid
dedic
ambul
driver
site
nonparametr
test
use
continu
data
kruskallw
test
mannwhitney
test
chisquar
test
categor
x
comparison
result
total
retriev
median
age
month
ventil
perform
includ
analysi
studi
period
exclud
miss
mobilis
time
n
elect
transfer
n
figur
show
process
introduc
improv
mobilis
time
dedic
onsit
ambul
servic
signific
reduct
avail
onlin
http
also
signific
increas
incid
mobilis
time
almost
doubl
avail
onsit
dedic
ambul
servic
p
conclus
signific
decreas
mobilis
time
str
last
year
although
presenc
onsit
ambul
servic
signific
impact
reduc
retriev
mobilis
time
number
factor
initi
contribut
steadili
reduc
mobilis
time
studi
period
ambul
transport
associ
higher
mortal
privat
transport
follow
major
penetr
trauma
semiurban
environ
aim
use
privat
transport
associ
improv
outcom
urban
trauma
patient
need
patient
stabil
scene
need
balanc
need
earli
oper
intervent
therefor
need
rapid
transport
hospit
aim
assess
relationship
mode
transport
hospit
outcom
semiurban
trauma
environ
method
data
collect
prospect
patient
admit
level
south
african
trauma
unit
period
revis
trauma
score
use
assess
injuri
sever
physiolog
derang
time
admiss
allow
comparison
group
mortal
defin
death
within
day
mortal
blunt
trauma
patient
n
higher
ambul
transport
group
statist
signific
howev
mortal
penetr
trauma
patient
n
significantli
higher
ambul
transport
group
p
chisquar
tabl
despit
similar
revis
trauma
score
tabl
use
ambul
transport
associ
increas
mortal
follow
penetr
injuri
may
relat
longer
time
field
result
delay
definit
care
hospit
southend
hospit
track
trigger
system
use
sinc
alert
nurs
abnorm
physiolog
paramet
order
trigger
urgent
medic
review
unwel
patient
recognis
respiratori
rate
particularli
use
predictor
signific
deterior
measur
everi
set
observ
audit
aim
assess
use
track
trigger
system
medic
ward
ensur
deterior
critic
ill
patient
promptli
review
method
patient
observ
chart
review
specifi
period
data
gather
frequenc
type
observ
taken
patient
met
criteria
trigger
review
data
abstract
natur
deterior
prompt
review
result
one
hundr
sixti
patientday
observ
evalu
seven
medic
ward
twentynin
patient
met
trigger
criteria
case
repres
deterior
doctor
call
two
case
observ
record
differ
frequenc
differ
ward
one
ward
manag
record
respiratori
rate
everi
set
observ
conclus
document
deterior
physiolog
observ
trigger
medic
review
may
commun
failur
failur
recognis
record
observ
abnorm
process
work
well
relev
observ
must
record
regularli
accur
respiratori
rate
consist
record
ward
frequenc
measur
observ
variabl
educ
train
need
improv
record
respiratori
rate
work
need
done
establish
doctor
call
appropri
concern
volum
work
gener
system
unfound
posit
predict
valu
accept
trigger
period
manag
median
retriev
mobilis
time
background
critic
care
outreach
servic
cco
introduc
unit
kingdom
aim
avert
ensur
time
admiss
critic
care
enabl
discharg
critic
care
share
skill
ward
staff
aim
assess
impact
introduct
cco
critic
care
unit
level
characteris
case
mix
outcom
activ
critic
care
unit
admiss
method
interrupt
timeseri
analysi
carri
use
data
unit
particip
case
mix
programm
complet
survey
cco
provis
individu
patientlevel
data
collaps
monthli
time
seri
unit
panel
data
populationaverag
paneldata
model
fit
use
generalis
estim
equat
approach
variou
outcom
reflect
state
aim
cco
consid
three
group
admiss
admiss
unit
admiss
ward
unit
survivor
discharg
ward
primari
exposur
variabl
presenc
formal
cco
secondari
exposur
cco
activ
coverag
staf
identifi
survey
data
unit
analysi
formal
cco
introduc
admiss
ward
presenc
cco
associ
signific
reduct
proport
admiss
receiv
cardiopulmonari
resuscit
hour
prior
admiss
odd
ratio
confid
interv
proport
admiss
mean
icnarc
physiolog
score
absolut
reduct
signific
effect
cco
outcom
includ
hospit
mortal
readmiss
critic
care
identifi
patient
discharg
ward
interpret
result
studi
mix
differ
characterist
patient
admit
critic
care
unit
found
associ
introduct
cco
evid
impact
outcom
patient
discharg
critic
care
possibl
identifi
clear
characterist
optim
cco
introduct
blood
group
may
relat
differ
inflammatori
respons
look
blood
group
risk
factor
icu
mortal
gener
patient
sepsi
method
data
retrospect
collect
patient
admit
medic
surgic
icu
result
icu
mortal
sap
ii
score
differ
blood
group
shown
tabl
p
valu
given
differ
blood
group
differ
found
age
gender
reason
admiss
influenc
rhesu
blood
group
type
seen
mortal
contribut
genom
variat
within
human
incid
outcom
sever
sepsi
multifunct
mediat
infect
inflamm
larg
explor
ex
vivo
studi
lack
fulli
repres
genet
anim
model
increas
import
analyz
impact
defensin
gene
polymorph
cours
infecti
inflammatori
diseas
sepsi
studi
design
investig
whether
genom
variat
associ
incid
outcom
sever
sepsi
six
report
polymorph
detect
patient
sever
sepsi
control
individu
use
divers
analyt
method
linkag
disequilibrium
ld
haplotyp
frequenc
statist
power
associ
studi
analyz
carri
genotyp
significantli
associ
incid
outcom
sever
sepsi
enough
statist
power
type
level
demonstr
signific
contribut
allel
sever
sepsi
allel
gg
genotyp
associ
suscept
sever
sepsi
carri
genotyp
influenc
outcom
sever
sepsi
snp
strong
ld
haplotyp
show
protect
role
sever
sepsi
wherea
haplotyp
serv
risk
factor
fatal
outcom
sever
sepsi
present
find
import
implic
understand
role
pathophysiolog
sever
sepsi
genom
variat
may
offer
new
mean
risk
stratif
patient
sever
sepsi
examin
associ
promot
singl
nucleotid
polymorph
haplotyp
gene
express
term
mrna
level
outcom
cohort
patient
sever
sepsi
method
sixtytwo
irish
caucasian
patient
present
sever
sepsi
enrol
blood
sampl
carri
day
day
mononuclear
cell
isol
mrna
quantifi
use
techniqu
quantit
realtim
polymeras
chain
reaction
qrtpcr
dna
extract
assay
four
promot
polymorph
haplotyp
infer
use
phase
softwar
result
twentyseven
patient
die
patient
carri
allel
posit
produc
mrna
day
c
homozygot
p
trend
patient
homozyg
g
allel
posit
produc
mrna
day
carri
allel
p
carrier
statu
haplotyp
posit
g
posit
associ
greater
mrna
level
day
p
carrier
statu
haplotyp
c
posit
posit
associ
nonsignific
decreas
mrna
level
day
p
directli
compar
haplotyp
associ
significantli
greater
level
mrna
haplotyp
day
p
patient
homozyg
allel
posit
like
succumb
sever
sepsi
carri
g
allel
p
conclus
result
contradict
previou
vitro
function
studi
allel
may
secondari
method
quantif
vivo
gene
express
qrtpcr
provid
accur
sensit
data
compar
prior
elisabas
assay
inde
extrapol
function
vitro
function
genet
test
lipopolysaccharid
stimul
may
question
valu
conclud
genotyp
analysi
place
risk
stratif
sepsi
genet
variant
posit
site
linkag
disequilibrium
variant
may
influenc
product
classic
respons
isol
endotoxin
challeng
entail
secret
purpos
studi
longitudin
character
cytokin
respons
sepsi
critic
ill
system
inflammatori
respons
syndrom
sir
patient
method
uninfect
critic
ill
trauma
patient
sir
evalu
daili
sepsi
patient
divid
two
group
presept
sir
patient
develop
sepsi
uninfect
sir
sir
patient
remain
uninfect
plasma
sampl
whole
blood
paxgen
obtain
studi
entri
daili
day
prior
sepsi
analyz
differenti
gene
express
group
affymetrix
plu
microarray
fals
discoveri
rate
p
quantit
plasma
protein
tnf
level
immunoassay
elev
sd
mean
normal
gene
express
data
median
fold
chang
group
presept
uninfect
result
gene
express
patient
protein
measur
patient
avail
protein
level
subtyp
tnf
elev
time
point
either
group
note
differenti
gene
express
hour
sepsi
differ
note
gene
express
differenti
gene
express
two
tnf
famili
member
note
howev
differenti
gene
express
tnf
receptor
receptor
antagonist
promin
tabl
background
myocardi
dysfunct
common
among
critic
ill
septic
patient
elev
level
cardiac
biomark
predictor
mortal
acut
coronari
syndrom
unselect
critic
ill
patient
aim
evalu
role
cardiac
marker
ntprobnp
troponin
tnt
myoglobin
predictor
inhospit
allcaus
mortal
patient
admit
gener
adult
icu
sever
sepsissept
shock
method
serial
plasma
sampl
taken
five
sequenti
day
patient
admit
sever
sepsissept
shock
sampl
analys
ntprobnp
tnt
myoglobin
result
sampl
analys
patient
elev
myoglobin
predictor
icu
mortal
age
myoglobin
ntprobnp
level
predict
hospit
mortal
predictor
mortal
age
peak
tnt
peak
myoglobin
peak
ntprobnp
level
apach
ii
score
predict
mortal
score
establish
depend
tnt
age
year
year
bnp
myoglobin
patient
place
tertil
score
produc
surviv
curv
figur
p
critic
ill
patient
sever
sepsissept
shock
score
base
age
increas
plasma
level
cardiac
biomark
help
riskstratifi
patient
predict
shortterm
month
outcom
calcul
ion
gap
novel
predictor
mortal
critic
ill
surgic
patient
evalu
anion
novel
marker
outcom
method
prospect
evalu
consecut
patient
admit
surgic
highdepend
unit
hdu
region
ethic
committe
approv
obtain
serum
electrolyt
albumin
phosphat
lactat
measur
admiss
day
deriv
calcul
ion
gap
cig
use
simplifi
modif
stewartfigg
equat
cig
day
predict
mortal
p
analysi
varianc
cig
mmoll
correl
strongli
mortal
mortal
patient
cig
mmoll
n
mortal
patient
cig
mmoll
n
p
chisquar
test
differ
cig
respect
mortal
admiss
day
p
respect
mean
hospit
stay
significantli
longer
patient
cig
mmoll
vs
day
p
test
tabl
conclus
describ
cig
first
time
critic
ill
surgic
patient
quantifi
use
simpl
bedsid
calcul
deriv
routin
blood
investig
failur
normalis
cig
day
admiss
hdu
excel
marker
mortal
length
hospit
stay
use
guid
resuscit
lung
nitroxid
stress
prognost
factor
ventil
septic
patient
introduct
sepsi
mechan
ventil
nitric
oxid
produc
lung
cell
studi
whether
pulmonari
product
prognost
factor
mechan
ventil
septic
patient
studi
patient
sepsi
within
first
hour
sepsi
oper
room
patient
serv
control
group
orcg
nitrit
nitrat
x
plasma
bronchoalveolar
lavag
fluid
balf
analyz
griessvanadium
chlorid
method
elisa
respect
result
express
median
interquartil
rang
receiv
oper
curv
construct
compar
predict
valu
x
valu
balf
admiss
variabl
kaplanmei
analysi
use
compar
surviv
high
low
balf
x
level
admiss
p
valu
less
consid
signific
result
studi
admiss
sepsi
group
nonsurvivor
higher
level
balf
introduct
myocyt
stretch
main
stimulu
brain
natriuret
peptid
bnp
synthesi
releas
septic
shock
import
variat
volemia
occur
correl
describ
cardiac
index
bnp
level
howev
relat
echocardiograph
left
ventricul
area
bnp
level
never
describ
aim
studi
evalu
bnp
left
ventricul
area
variat
acut
fluid
load
septic
shock
method
mechan
ventil
patient
septic
shock
without
anterior
cardiac
diseas
includ
studi
fluid
challeng
perform
colloid
ml
minut
bnp
blood
sampl
drawn
hour
fluid
load
primari
endpoint
bnp
variat
fluid
challeng
median
valu
percentil
compar
wilcoxon
test
p
enddiastol
left
ventricul
area
record
hour
fluid
challeng
linear
regress
bnp
variat
left
ventricular
area
variat
determin
r
calcul
result
eight
patient
median
age
year
six
malestwo
femal
sofa
score
enrol
studi
initi
bnp
level
median
increas
fluid
load
p
figur
find
statist
signific
relationship
bnp
variat
left
ventricul
area
variat
fluid
challeng
p
figur
conclus
increas
bnp
level
patient
septic
shock
fluid
challeng
knowledg
preliminari
studi
first
evalu
relationship
bnp
left
ventricul
area
variat
patient
septic
shock
although
statist
signific
left
ventricul
area
variat
bnp
variat
fluid
challeng
trend
correl
two
paramet
patient
includ
confirm
result
nomin
variabl
analyz
chisquar
test
risk
ratio
rr
confid
interv
perform
intragroup
ordin
variabl
analyz
wilcoxon
test
w
intergroup
ordin
variabl
analyz
mannwhitney
test
mw
receiv
oper
characterist
test
use
discrimin
bnp
cutoff
valu
sensibl
specif
respect
group
group
b
p
taken
statist
signific
result
wean
failur
group
occur
patient
vs
group
b
patient
p
chisquar
test
rr
bnp
valu
differ
group
signific
step
pgml
step
pgml
step
pgml
bnp
valu
differ
group
b
statist
signific
w
step
pgml
step
pgml
p
vs
step
step
pgml
p
vs
step
p
vs
step
statist
signific
differ
group
group
b
everi
step
p
mw
bnp
cutoff
valu
discrimin
group
group
b
pgml
sensibl
specif
conclus
risk
wean
failur
increas
four
time
patient
hd
bnp
valu
group
b
patient
higher
normal
peopl
probabl
heart
icu
patient
submit
differ
kind
stress
therefor
bnp
cutoff
valu
consid
discrimin
patient
hd
patient
without
hd
icu
higher
bnp
product
icu
patient
good
perform
heart
right
protect
respons
stress
perform
therapi
adopt
icu
stay
respons
absent
patient
hd
heart
alreadi
work
safeti
mode
combin
variou
sever
ill
score
system
improv
outcom
predict
pilot
experi
critic
ill
obstetr
popul
z
haddad
c
kaddour
l
skandrani
nagi
chaaoua
r
souissi
chi
stcloud
franc
nation
institut
neurolog
tuni
tunisia
critic
care
suppl
doi
introduct
perfect
sever
score
exist
predict
icu
mortal
thu
search
new
system
still
preoccup
hypothesi
use
mani
sever
ill
score
simultan
improv
mortal
predict
open
prospect
observ
studi
part
aprimo
project
studi
period
januari
inclus
criteria
critic
ill
obstetr
patient
icu
length
stay
hour
exclus
criteria
use
score
main
outcom
interest
surviv
statu
icu
discharg
databas
divid
two
sampl
develop
valid
dataset
develop
databas
patient
chosen
randomli
n
remain
patient
compos
valid
dataset
n
multivari
logist
regress
model
develop
predict
mortal
associ
acut
physiolog
chronic
health
evalu
ii
score
simplifi
acut
physiolog
score
ii
admiss
mortal
predict
model
day
mortal
predict
model
discrimin
calibr
assess
goodnessoffit
chat
statist
area
roc
curv
develop
model
test
valid
dataset
good
discrimin
retain
chat
statist
p
good
calibr
area
roc
curv
six
hundr
fortythre
patient
enrol
overal
mortal
rate
new
model
predict
accur
survivor
nonsurvivor
conclus
multiscor
model
seem
refin
prognosi
partli
due
mix
new
evalu
paramet
test
latest
develop
gener
score
also
organ
dysfunct
system
could
interest
valid
logist
organ
dysfunct
score
predict
compar
apach
ii
score
predict
hospit
outcom
thai
patient
conduct
prospect
observ
review
consecut
patient
admit
icu
collect
data
relat
daili
maximum
organ
dysfunct
score
outcom
defin
term
length
icu
stay
icu
mortal
includ
patient
male
mean
age
year
admiss
elect
surgic
emerg
surgic
medic
median
sequenti
organ
failur
assess
sofa
score
admiss
iqr
median
maximum
sofa
score
iqr
median
length
icu
stay
day
iqr
overal
icu
mortal
rate
patient
maximum
sofa
score
mortal
vs
whose
maximum
sofa
score
p
sixtyfour
per
cent
patient
score
maximum
sofa
score
admiss
patient
whose
sofa
score
increas
admiss
mortal
logist
regress
analysi
show
maximum
sofa
score
bore
stronger
correl
mortal
admiss
sofa
score
see
figur
conclus
maximum
admiss
sofa
score
prognost
valu
intens
care
set
allow
patient
increas
risk
mortal
prolong
stay
identifi
like
india
associ
signific
mortal
outcom
malari
mod
predict
variou
studi
extrem
variabl
depend
mani
patient
paramet
object
prospect
evalu
correl
apach
ii
score
parasit
index
procalcitonin
pct
level
number
organ
dysfunctionsfailur
sequenti
organ
failur
assess
sofa
score
outcom
sever
malaria
method
eleven
patient
acut
sever
malaria
mod
treat
icu
last
month
patient
treat
artesun
andor
quinin
per
antimalari
treatment
schedul
along
standard
icu
care
apach
ii
sofa
score
calcul
admiss
pct
level
measur
semiquantit
admiss
parasit
index
confirm
two
pathologist
result
nine
patient
surviv
without
residu
organ
damag
remain
two
die
due
mod
figur
patient
five
organ
dysfunct
admiss
sofa
score
respect
low
parasit
index
pct
level
semiquantit
method
respect
apach
ii
score
conclus
pretreat
apach
ii
score
parasit
index
pct
level
number
organ
involv
variabl
correl
mortal
consist
predictor
outcom
higher
sofa
score
admiss
reliabl
predictor
mortal
malari
mod
model
calibr
discriminatori
abil
comparison
four
deriv
variabl
sofa
score
sap
ii
introduct
sought
compar
four
deriv
variabl
sofa
score
sap
ii
icu
patient
term
discriminatori
abil
model
calibr
patient
method
four
hundr
fourteen
patient
includ
evalu
admiss
everi
hour
thereaft
icu
discharg
death
readmiss
patient
icu
stay
shorter
hour
exclud
tm
score
calcul
sum
worst
score
organ
system
organ
failur
defin
sofa
score
median
length
icu
stay
patient
admiss
sofa
score
vs
whose
admiss
sofa
score
p
defin
tm
minu
admiss
sofa
sofai
maximum
sofa
defin
worst
sofa
valu
icu
stay
logist
regress
model
techniqu
use
describ
associ
deriv
sofa
variabl
sap
ii
mortal
roc
curv
use
assess
model
discriminatori
abil
examin
model
calibr
use
hosmerlemeshow
goodnessoffit
test
p
consid
signific
result
diagnost
categori
trauma
postop
medic
global
mortal
survivor
lower
averag
sap
ii
p
sofai
score
p
sofamax
score
p
p
domax
p
tm
p
differ
statist
signific
result
regard
model
calibr
discriminatori
abil
present
figur
conclus
sofamax
score
best
model
calibr
could
use
compar
differ
patient
popul
term
mortal
introduct
sepsi
associ
progress
organ
failur
sought
describ
sequenti
organ
failur
assess
sofa
score
daili
trend
septic
patient
tri
correl
trend
surviv
method
patient
sever
sepsi
septic
shock
admit
least
day
sevenb
medicosurg
icu
brazilian
univers
hospit
studi
daili
sofa
score
patient
calcul
first
day
admiss
relev
data
prospect
acquir
march
may
latter
retriev
electron
databas
icu
survivor
compar
nonsurvivor
use
mannwhitney
u
test
daytoday
chang
verifi
within
group
use
friedman
test
p
elect
signific
limit
median
interquartil
rang
iqr
use
describ
sampl
one
hundr
seventysix
patient
studi
male
median
age
iqr
year
sever
sepsi
median
length
icu
stay
day
iqr
median
admiss
sofa
iqr
median
apach
ii
score
iqr
icu
mortal
patient
sofa
score
compon
score
along
five
admiss
day
distinguish
survivor
nonsurvivor
consid
sofa
score
respiratori
neurolog
circulatori
compon
survivor
present
lower
score
day
pass
p
mortal
increasingli
higher
patient
persist
sofa
score
day
pass
conclus
sampl
studi
persist
elev
sofa
score
compon
first
day
admiss
predict
higher
mortal
surviv
appear
relat
earli
organ
dysfunct
recoveri
sofa
score
sofarel
variabl
daytoday
chang
popul
septic
patient
may
import
prognost
implic
pattern
daili
evolut
may
distinguish
patient
omin
outcom
cumul
lactat
load
correl
cumul
sequenti
organ
failur
assess
score
surviv
intens
care
unit
patient
background
chang
lactat
level
use
prognost
marker
critic
ill
patient
howev
relat
time
cours
arteri
blood
lactat
clearanc
import
outcom
paramet
icu
length
stay
lo
incid
organ
failur
surviv
rate
establish
method
case
record
icu
patient
admit
retrospect
identifi
icu
databas
sequenti
organ
failur
assess
sofa
score
calcul
daili
assess
time
cours
organ
failur
lactat
level
extract
total
cumul
lactat
load
area
curv
upper
normal
level
mmoll
cumlact
total
cumul
sofa
score
cumsofa
calcul
relat
icu
lo
final
hospit
surviv
valu
median
interquartil
rang
result
observ
icu
admiss
analyz
age
year
cumlact
cumsofa
cumsofa
higher
patient
hyperlactatemia
cumlact
icu
stay
n
without
p
cumsofa
correl
cumlact
icu
lo
cumlact
correl
icu
lo
p
patient
die
hospit
n
cumlact
cumsofa
higher
hospit
survivor
n
p
emerg
admiss
cumlact
cumsofa
higher
plan
admiss
p
respect
conclus
icu
patient
cumul
area
lactat
curv
correl
icu
lo
cumul
sofa
score
inhospit
mortal
prognost
valu
cumlact
requir
prospect
evalu
avail
onlin
http
classifi
predict
mortal
domax
maximum
number
organ
failur
icu
stay
p
p
mortal
patient
readmit
total
patient
die
bigger
mortal
patient
readmit
total
patient
die
p
length
stay
nonsurviv
readmit
patient
depart
readmiss
higher
length
stay
survivor
mean
day
vs
mean
day
conclus
sex
age
older
year
patient
readmit
icu
readmiss
hour
length
stay
depart
readmiss
could
use
simpl
predict
mortal
patient
readmit
icu
amount
singl
patient
readmiss
icu
use
predictor
death
patient
readmit
icu
introduct
aim
studi
assess
role
absolut
risk
reduct
arr
measur
icu
perform
altern
standard
mortal
ratio
smr
method
retrospect
studi
involv
patient
admit
three
icu
singl
tertiari
medic
center
januari
decemb
first
icu
admiss
patient
includ
studi
icu
staf
similarli
abstract
data
apach
iii
databas
icu
smr
arr
confid
interv
ci
calcul
icu
perform
categor
shown
tabl
compar
icu
ci
smr
arr
overlap
unit
perform
consid
similar
overlap
differ
perform
consid
statist
signific
result
studi
period
patient
admit
three
icu
medic
icu
mix
icu
surgic
icu
predict
mortal
rate
observ
mortal
rate
medic
mix
surgic
icu
respect
smr
arr
mortal
icu
present
tabl
conclus
icu
mortal
perform
assess
smr
arr
give
differ
result
arr
may
better
metric
compar
icu
differ
case
mix
multipl
linear
regress
support
vector
regress
linear
nonlinear
rbf
kernel
function
perform
select
relev
data
compon
model
paramet
perform
predict
model
unseen
dataset
analyz
fivefold
crossvalid
wilcoxon
signedrank
analysi
perform
examin
differ
perform
predict
model
analyz
differ
real
predict
tacrolimu
blood
concentr
mean
absolut
differ
measur
tacrolimu
blood
concentr
predict
regress
model
ngml
sd
linear
svm
rbf
svm
predict
model
mean
absolut
differ
measur
tacrolimu
blood
concentr
respect
ngml
sd
ngml
sd
differ
within
accept
clinic
rang
statist
analysi
demonstr
signific
better
perform
linear
p
nonlinear
p
svm
figur
comparison
linear
regress
moreov
nonlinear
rbf
svm
requir
seven
data
compon
perform
predict
compar
avail
onlin
http
increas
apach
ii
score
delay
icu
readmiss
need
mechan
ventil
three
organ
dysfunct
significantli
associ
mortal
conclus
admiss
icu
common
lung
transplant
recipi
associ
high
mortal
sepsi
main
caus
icu
readmiss
frequent
caus
death
lung
transplant
recipi
higher
apach
ii
score
three
organ
dysfunct
present
higher
mortal
delay
icu
readmiss
also
associ
higher
mortal
readmiss
icu
hospit
associ
signific
morbid
mortal
result
longer
length
stay
higher
cost
therefor
grow
interest
identifi
reliabl
predictor
readmiss
aim
studi
assess
incid
icu
readmiss
identifi
predictor
icu
readmiss
determin
patient
outcom
method
perform
retrospect
casecontrol
studi
studi
popul
consist
patient
discharg
aliv
surgic
thoracicsurg
medic
icu
univers
teach
hospit
period
case
defin
patient
readmit
icu
within
hour
discharg
case
three
control
patient
randomli
select
studi
popul
follow
inform
collect
demograph
paramet
apach
ii
score
paramet
hemodynam
respiratori
renal
function
length
icu
stay
durat
invas
ventilatori
support
ventil
time
time
extub
discharg
determin
predict
model
covari
select
done
twosampl
test
mannwhitney
test
univari
logist
regress
signific
p
plausibl
clinic
relev
variabl
predict
model
gener
use
multivari
logist
regress
result
period
patient
admit
icu
patient
risk
readmiss
readmiss
occur
patient
nine
readmit
patient
die
hospit
overal
icu
mortal
import
reason
readmiss
case
respiratori
deterior
univari
analysi
age
ventil
time
first
admiss
time
extub
icu
discharg
signific
predictor
readmiss
multivari
analysi
age
ci
p
ventil
time
first
admiss
ci
p
signific
predictor
correct
patient
characterist
furthermor
patient
readmit
signific
longer
durat
total
first
second
admiss
ventil
time
vs
hour
p
total
icu
stay
vs
hour
p
conclus
patient
readmit
icu
signific
longer
overal
ventil
time
icu
stay
higher
icu
mortal
ventil
time
first
admiss
especi
beyond
hour
import
predictor
readmiss
time
take
get
patient
readi
discharg
extub
also
differ
significantli
data
suggest
elderli
patient
ventil
long
period
particular
risk
readmiss
receiv
addit
care
discharg
icu
patientcent
familycent
qualiti
care
literatur
examin
patient
famili
satisfact
sdu
limit
method
administ
modifi
version
previous
valid
famili
satisfact
icu
care
survey
patient
famili
patient
care
sdu
bed
four
separ
unit
tertiari
region
referr
center
obtain
selfreport
level
patient
famili
satisfact
aspect
care
relat
sdu
experi
commun
decisionmak
respons
convert
item
score
reflect
poor
excel
satisfact
care
result
total
patient
survey
respons
famili
survey
respons
complet
patient
mean
sdu
length
stay
day
apach
ii
score
sdu
mortal
highest
level
satisfact
care
mean
standard
deviat
item
score
present
aspect
care
patient
famili
p
valu
overal
care
aggreg
score
ns
concern
care
receiv
sdu
staff
ns
nurs
skill
compet
ns
lowest
level
satisfact
frequenc
commun
physician
p
decisionmak
aggreg
score
ns
decisionmak
process
proport
respond
felt
includ
patient
famili
p
valu
ns
support
ns
control
p
patient
famili
least
satisfi
frequenc
commun
physician
particip
decisionmak
patient
famili
similar
assess
except
frequenc
commun
physician
control
care
deliv
conclus
patient
famili
member
satisfi
care
receiv
data
identifi
opportun
improv
specif
attent
must
paid
commun
decisionmak
process
sdu
investig
patient
manag
plan
ascertain
total
number
made
type
plan
prioriti
personnel
respons
expect
time
frame
proport
complet
caus
consequ
fail
plan
patient
famili
critic
care
servic
method
seven
consecut
day
detail
consult
determin
manag
plan
record
dedic
nurs
auditor
plan
defin
identifi
doabl
shortterm
action
data
type
arbitrari
prioriti
involv
personnel
time
frame
note
auditor
later
return
end
shift
determin
whether
plan
complet
appropri
time
frame
success
plan
unsuccess
plan
unsuccess
plan
nurs
senior
nurs
senior
hous
offic
fellow
consult
independ
quizz
caus
consequ
patient
famili
servic
predetermin
list
possibl
plan
success
three
plan
data
miss
plan
unsuccess
unsuccess
plan
complet
late
never
complet
nine
miss
data
thirtysix
per
cent
arbitrarili
defin
highprior
mediumprior
lowprior
plan
unsuccess
plan
action
nurs
senior
hous
offic
unsuccess
respect
unsuccess
plan
success
plan
record
computeris
note
vs
data
staff
opinion
percept
caus
consequ
gather
patient
consequ
fail
plan
includ
increas
icu
stay
increas
morbid
risk
inadequ
nutrit
delay
definit
treatment
delay
wean
increas
risk
infect
impact
patient
consequ
famili
includ
impact
misinform
given
delay
patient
access
delay
commun
servic
consequ
bed
blockingincreas
workload
delay
admiss
anoth
patient
cancel
elect
oper
loss
unit
capac
cohes
conclus
fail
achiev
success
plan
small
number
failur
gather
staff
opinion
caus
consequ
fail
plan
limit
pilot
studi
document
electron
note
improv
complet
plan
process
effici
care
impact
least
aspect
morbid
length
stay
deserv
studi
conclus
octogenarian
admit
icu
ohca
hospit
mortal
higher
younger
group
still
import
proport
surviv
nonoctogenarian
surviv
often
predict
apach
ii
despit
higher
mortal
icu
treatment
hospit
resuscit
octogenarian
seem
worthwhil
cost
intens
care
introduct
countri
good
estim
cost
intens
care
ic
although
known
icu
major
inpati
cost
driver
aim
studi
estim
real
cost
ic
two
hospit
netherland
use
microcost
methodolog
method
cost
studi
undertaken
two
hospit
netherland
conduct
retrospect
cost
analysi
consecut
patient
admit
mix
adult
icu
academ
hospit
two
period
may
june
comparison
collect
detail
data
gener
hospit
bedadult
gener
icu
period
juli
cost
adjust
use
gener
price
index
time
appli
microcost
approach
impli
relev
resourc
identifi
valu
detail
level
data
resourc
use
diagnost
drug
fluid
materi
admiss
discharg
acquir
computer
patient
data
manag
system
hospit
hotel
nutrit
cost
collect
respect
financi
depart
cost
divid
annual
number
patientday
calcul
cost
per
day
nem
tiss
score
academ
gener
hospit
respect
use
estim
nurs
time
per
patient
per
day
cost
medic
specialist
base
labour
cost
number
icu
day
per
year
academ
hospit
time
consult
medic
staff
attribut
individu
patientday
prospect
collect
use
patient
record
form
cost
assum
compar
gener
hospit
absenc
detail
data
unit
cost
diagnost
consum
deriv
financi
hospit
databas
labour
cost
base
standardis
cost
per
minut
equal
norm
incom
divid
number
workabl
minut
per
year
estim
cost
inpatientday
nonpatientrel
care
base
annual
account
hospit
nonpatientrel
care
capit
overhead
appoint
patient
use
margin
markup
percentag
academ
hospit
averag
total
cost
per
icu
day
amount
compar
gener
hospit
distribut
cost
cost
compon
vari
overal
cost
per
day
ic
academ
hospit
slightli
higher
cost
icu
day
gener
hospit
deriv
cost
fit
nice
offici
refer
cost
icu
day
netherland
base
global
topdown
approach
introduct
progress
intens
care
led
increas
number
patient
surviv
sever
brain
injuri
therefor
number
patient
impair
conscious
avail
onlin
http
histor
patient
regard
poor
prognosi
admit
icu
decid
compar
icu
hospit
mortal
patient
patient
similar
age
sever
acut
ill
method
twentyfour
patient
admit
icu
august
august
haematolog
malign
casematch
use
sex
age
year
apach
ii
score
admiss
diagnosi
patient
admit
icu
without
diagnosi
haematolog
malign
eighteen
patient
match
one
case
control
howev
six
patient
two
match
found
imposs
differenti
case
ground
diagnosi
age
apach
ii
score
includ
compar
icu
hospit
mortal
two
group
result
patient
haematolog
malign
icu
mortal
hospit
mortal
control
patient
icu
mortal
hospit
mortal
statist
nonsignific
length
time
admiss
two
group
significantli
longer
haematolog
group
day
compar
day
control
patient
p
level
organ
support
two
cohort
conclus
demonstr
unit
statist
signific
differ
hospit
icu
mortal
two
group
fact
group
haematolog
malign
lower
mortal
control
group
presenc
haematolog
malign
appear
increas
mortal
risk
compar
popul
patient
without
haematolog
malign
similar
age
apach
ii
score
admiss
diagnosi
day
respect
compar
nicugp
patient
icugp
like
develop
postop
arrhythmia
vs
p
older
higher
asa
statu
like
diabet
coronari
arteri
diseas
hypertens
higher
cancer
stage
receiv
intraop
blood
product
patient
origin
sent
icu
subsequ
admit
icu
patient
higher
apach
iii
score
like
aspir
document
although
mortal
higher
direct
icu
admiss
conclus
esophagectomi
overal
mortal
low
mani
patient
requir
icu
admiss
postop
arrhythmia
aspir
pneumon
especi
problemat
data
complet
defin
ratio
avail
requir
data
icu
admiss
level
evalu
dataset
select
signific
admiss
scheme
variabl
includ
complet
ratio
calcul
major
data
collect
manual
system
remain
integr
softwar
mean
admiss
data
complet
ratio
cr
increas
p
icu
mean
cr
vari
p
mean
cr
data
collect
ivt
manual
system
p
rate
complet
record
per
patient
increas
conclus
data
complet
ficqc
improv
studi
period
although
still
signific
variat
icu
improv
data
complet
decreas
proport
miss
data
like
due
increasingli
common
use
ci
autom
data
collect
conclud
measuringreport
amount
miss
data
mandatori
data
collect
data
manag
procedur
benchmark
develop
number
heartbeat
donor
netherland
decreas
decreas
partial
compens
increas
nonheartb
donat
result
increas
shortag
donor
organ
especi
donor
heart
lung
compar
number
patient
wait
donor
heart
increas
lung
donat
increas
one
approach
reduc
shortag
maxim
number
organ
per
donor
optimis
donor
treatment
icu
method
investig
possibl
improv
donor
manag
icu
retrospect
studi
heartbeat
organ
donor
hospitalis
icu
protocol
treatment
organ
donor
institut
heart
donat
patient
lung
donat
possibl
eight
donor
heart
lung
reject
transplant
valid
reason
patient
room
improv
two
three
case
hemodynam
instabl
imped
heart
lung
donat
one
die
subarachnoid
bleed
one
ischem
cerebr
infarct
hemodynam
instabl
close
associ
moment
cerebr
death
three
patient
heart
donat
carri
wall
movement
abnorm
electrocardiogram
abnorm
none
avail
onlin
http
introduct
critic
care
research
involv
data
mani
countri
critic
care
resourc
countri
unknown
hypothes
larg
differ
critic
care
resourc
countri
method
identifi
origin
research
articl
critic
care
three
high
impact
factor
journal
n
engl
j
med
jama
lancet
publish
list
countri
data
collect
occur
extract
eight
countri
contribut
studi
collabor
countri
ask
provid
baselin
critic
care
inform
countri
close
date
possibl
result
sixtytwo
studi
involv
data
countri
identifi
eight
countri
contribut
data
studi
time
period
usa
studi
franc
unit
kingdom
canada
belgium
germani
netherland
spain
relev
data
baselin
hospit
critic
care
resourc
eight
countri
identifi
present
figur
data
canada
avail
adult
icu
bed
rang
popul
unit
kingdom
germani
repres
rang
acut
care
hospit
bed
unit
kingdom
bed
usa
conclus
mani
countri
contribut
substanti
critic
care
research
howev
underli
critic
care
resourc
vari
dramat
among
countri
avail
onlin
http
baselin
critic
care
resourc
eight
countri
extrapol
survey
data
full
nation
data
